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A B S T R A C T
Background
A glioblastoma is a fatal type of brain tumour for which the standard of care is maximum surgical resection followed by chemoradiotherapy,
when possible. Age is an important consideration in this disease, as older age is associated with shorter survival and a higher risk of
treatment-related toxicity.
Objectives
To determine the most e$ective and best-tolerated approaches for the treatment of elderly people with newly diagnosed glioblastoma. To
summarise current evidence for the incremental resource use, utilities, costs and cost-e$ectiveness associated with these approaches.
Search methods
We searched electronic databases including the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE and Embase to 3 April
2019, and the NHS Economic Evaluation Database (EED) up to database closure. We handsearched clinical trial registries and selected
neuro-oncology society conference proceedings from the past five years.
Selection criteria
Randomised trials (RCTs) of treatments for glioblastoma in elderly people. We defined ‘elderly' as 70+ years but included studies defining
‘elderly' as over 65+ years if so reported.
Data collection and analysis
We used standard Cochrane methods for study selection and data extraction. Where su$icient data were available, treatment options were
compared in a network meta-analysis (NMA) using Stata soMware (version 15.1). For outcomes with insu$icient data for NMA, pairwise
meta-analysis were conducted in RevMan. The GRADE approach was used to grade the evidence.
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Main results
We included 12 RCTs involving approximately 1818 participants. Six were conducted exclusively among elderly people (either defined as
65 years or older or 70 years or older) with newly diagnosed glioblastoma, the other six reported data for an elderly subgroup among a
broader age range of participants. Most participants were capable of self-care. Study quality was commonly undermined by lack of outcome
assessor blinding and attrition. NMA was only possible for overall survival; other analyses were pair-wise meta-analyses or narrative
syntheses.
Seven trials contributed to the  NMA for overall survival, with interventions including supportive care only (one trial arm);
hypofractionated radiotherapy (RT40; four trial arms); standard radiotherapy (RT60; five trial arms); temozolomide (TMZ; three trial
arms); chemoradiotherapy (CRT; three trial arms); bevacizumab with chemoradiotherapy (BEV_CRT; one trial arm); and bevacizumab with
radiotherapy (BEV_RT). Compared with supportive care only, NMA evidence suggested that all treatments apart from BEV_RT prolonged
survival to some extent.
Overall survival
High-certainty evidence shows that CRT prolongs overall survival (OS) compared with RT40 (hazard ratio (HR) 0.67, 95% confidence interval
(CI) 0.56 to 0.80) and low-certainty evidence suggests that CRT may prolong overall survival compared with TMZ (TMZ versus CRT: HR 1.42,
95% CI 1.01 to 1.98). Low-certainty evidence also suggests that adding BEV to CRT may make little or no di$erence (BEV_CRT versus CRT:
HR 0.83, 95% CrI 0.48 to 1.44). We could not compare the survival e$ects of CRT with di$erent radiotherapy fractionation schedules (60
Gy/30 fractions and 40 Gy/15 fractions) due to a lack of data. When treatments were ranked according to their e$ects on OS, CRT ranked
higher than TMZ, RT and supportive care only, with the latter ranked last. BEV plus RT was the only treatment for which there was no clear
benefit in OS over supportive care only. 
One trial comparing tumour treating fields (TTF) plus adjuvant chemotherapy (TTF_AC) with adjuvant chemotherapy alone could not be
included in the NMA as participants were randomised aMer receiving concomitant chemoradiotherapy, not before. Findings from the trial
suggest that the intervention probably improves overall survival in this selected patient population.
We were unable to perform NMA for other outcomes due to insu$icient data. Pairwise analyses were conducted for the following.
Quality of life
Moderate-certainty narrative evidence suggests that overall, there may be little di$erence in QoL between TMZ and RT, except for
discomfort from communication deficits, which are probably more common with RT (1 study, 306 participants, P = 0.002). Data on QoL for
other comparisons were sparse, partly due to high dropout rates, and the certainty of the evidence tended to be low or very low.
Progression-free survival
High-certainty evidence shows that CRT increases time to disease progression compared with RT40 (HR 0.50, 95% CI 0.41 to 0.61);
moderate-certainty evidence suggests that RT60 probably increases time to disease progression compared with supportive care only (HR
0.28, 95% CI 0.17 to 0.46), and that BEV_RT probably increases time to disease progression compared with RT40 alone (HR 0.46, 95% CI
0.27 to 0.78). Evidence for other treatment comparisons was of low- or very low-certainty.
Severe adverse events
Moderate-certainty evidence suggests that TMZ probably increases the risk of grade 3+ thromboembolic events compared with RT60
(risk ratio (RR) 2.74, 95% CI 1.26 to 5.94; participants = 373; studies = 1) and also the risk of grade 3+ neutropenia, lymphopenia, and
thrombocytopenia. Moderate-certainty evidence also suggests that CRT probably increases the risk of grade 3+ neutropenia, leucopenia
and thrombocytopenia compared with hypofractionated RT alone. Adding BEV to CRT probably increases the risk of thromboembolism
(RR 16.63, 95% CI 1.00 to 275.42; moderate-certainty evidence).
Economic evidence
There is a paucity of economic evidence regarding the management of newly diagnosed glioblastoma in the elderly. Only one economic
evaluation on two short course radiotherapy regimen (25 Gy versus 40 Gy) was identified and its findings were considered unreliable.
Authors' conclusions
For elderly people with glioblastoma who are self-caring, evidence suggests that CRT prolongs survival compared with RT and may
prolong overall survival compared with TMZ alone. For those undergoing RT or TMZ therapy, there is probably little di$erence in QoL
overall. Systemic anti-cancer treatments TMZ and BEV carry a higher risk of severe haematological and thromboembolic events and CRT is
probably associated with a higher risk of these events. Current evidence provides little justification for using BEV in elderly patients outside
a clinical trial setting. Whilst the novel TTF device appears promising, evidence on QoL and tolerability is needed in an elderly population.
QoL and economic assessments of CRT versus TMZ and RT are needed. More high-quality economic evaluations are needed, in which a
broader scope of costs (both direct and indirect) and outcomes should be included.
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P L A I N   L A N G U A G E   S U M M A R Y
Treatment options for newly diagnosed glioblastoma in older people
What is the issue?
Glioblastoma is a fatal type of brain tumour. The standard treatment of newly diagnosed glioblastoma is to remove as much of the tumour
as possible by operation, and then to give chemotherapy (an anti-cancer medicine called temozolomide (TMZ)) and radiotherapy. TMZ is
usually given at the same time as radiotherapy (concomitant chemotherapy), and also for about six months aMer radiotherapy (adjuvant
chemotherapy). Together, these treatments can be called chemoradiotherapy (CRT). However, not all people, particularly the elderly, are
fit enough to receive CRT, which can have serious side-e$ects. In this review we evaluated evidence on di$erent treatments that have been
looked at in older people with newly diagnosed glioblastoma, to find out which treatments may help.
How we conducted the review
We searched for trials that compared di$erent treatments in elderly people with newly diagnosed glioblastoma and also for studies on
cost-e$ectiveness. We defined 'the elderly' as 70+ years, but also included data from patients 65+ years old if studies did not give results for
the 70+ age group. We used standard Cochrane methods to assess studies and collect data. We compared treatments in a network meta-
analysis (NMA), which allowed us to rank di$erent treatments options.
What we found
We found 12 studies evaluating di$erent options including radiotherapy, chemotherapy, supportive (palliative) care, combinations of
treatments, and a medical device that is worn on the head and emits an electric field (known as tumour treating fields). Most people
enrolled in these studies did not have serious disabilities. In the NMA, we compared the e$ects of seven treatments on patients overall
survival. All treatments tested in the NMA apart from one, in which an agent called bevacizumab (BEV) was combined with radiotherapy,
clearly prolonged survival compared with supportive care only. The strongest evidence we found showed that CRT leads to a longer survival
time than short-course radiotherapy only; but weaker evidence suggested that CRT also prolongs survival compared with TMZ only. When
we ranked all treatments according to their e$ectiveness in prolonging survival time, CRT ranked higher than TMZ, RT and supportive care
only, with the latter ranked last.
A study of tumour treating fields could not be included in the NMA because it was conducted among fitter elderly patients who had already
received part of their CRT. Evidence from this study suggested that adding tumour treating fields aMer radiotherapy probably improves
survival in this fitter group of patients.
With regard to quality of life, evidence suggested that the impact of TMZ and radiotherapy-only treatments is probably not very di$erent,
except for greater discomfort from communication deficits with radiotherapy. Quality of life evidence was hard to interpret for other
treatment options because it tended to be limited by high dropout rates, as people with glioblastoma do not live very long and may not
feel like filling out questionnaires when they feel unwell.
With regard to other outcomes, high-certainty evidence showed that CRT delays disease progression compared with radiotherapy only.
Evidence also suggested that adding BEV to short-course radiotherapy probably delays disease progression, but may not improve overall
survival. TMZ and BEV are more toxic to blood cells than radiotherapy and are associated with an increased risk of blood clots and blood
vessel blockages (thromboembolism).
Our conclusions
For reasonably fit elderly people with glioblastoma, evidence suggests that CRT prolongs survival compared with radiotherapy or TMZ
alone, and that any of these three treatment options may prolong survival compared with supportive care only. Serious adverse events
a$ecting blood components are more common with anti-cancer medicines TMZ and BEV. There is not enough evidence on BEV to support
its use in elderly people with glioblastoma outside of a research setting. More evidence is needed on how di$erent treatments impact
quality of life and health costs. Age alone is unlikely to be the best determinant of optimal treatment of older people with glioblastoma.
Treatment of newly diagnosed glioblastoma in the elderly: a network meta-analysis (Review)
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S U M M A R Y   O F   F I N D I N G S
 
Summary of findings for the main comparison.   Summary of findings on overall survival comparing treatments to
supportive care only
Estimates of effects, certainty assessment and rankings of different treatment options compared with supportive care only
on overall survival in elderly people with glioblastoma
Patient or population: elderly people with newly diagnosed glioblastoma
Interventions: radiotherapy with 40 Gy in 15 fractions (RT40); radiotherapy with 60 Gy in 30 fractions (RT60); chemoradiother-
apy (CRT); chemoradiotherapy plus bevacizumab (BEV_CRT); radiotherapy plus bevacizumab (BEV_RT); temozolomide (TMZ)
Comparison: supportive care only
Outcome: overall survival
All intervention options












(1 RCT, 81 participants)




(5 RCTs; 713 participants)






(1 RCT; 75 participants)




(4 RCTs; 930 participants)






(3 RCTs, 538 participants)






(2 RCTs; 635 participants)




(1 RCT; 73 participants)
HR 0.25 (0.11 to 0.54) 30 per 100
(15 to 54)
Not graded2 1.4
NMA-'Summary of findings' table definitions
Estimates are reported as HR: hazard ratio, CI: confidence interval,NMA: network meta-analysis.
* This refers to the number of studies in the network evaluating the given intervention and the number of participants involved in
these studies.
** All NMA effect estimates in this 'Summary of findings' table are derived 100% from indirect evidence, except for the comparison of
RT60 versus supportive care, which was directly compared in one study. Where there was no common comparator for the comparison
we did not grade the certainty of the evidence.
*** The assumed effect of supportive care is based on Keime-Guibert 2007 data, which may be slightly overestimated because a high
proportion of patients underwent biopsy only.
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¥These rankings do not take into account the certainty of the evidence and should be interpreted with caution. The estimates of un-
graded evidence are very uncertain.
GRADE Working Group grades of evidence
High certainty: we are very confident that the true effect lies close to that of the estimate of the effect.
Moderate certainty: we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the ef-
fect, but there is a possibility that it is substantially different.
Low certainty: our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the
effect.
Very low certainty: we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the
estimate of effect.
1 Downgraded -1 as the evidence was derived from a single small study.
2 There was no common comparator for the comparison (i.e. the intervention was not connected in a loop in the evidence network),
therefore we did not grade the certainty of the evidence.
3 Contributing direct evidence was of moderate or low certainty.
Abbreviations
BEV_CRT; chemoradiotherapy plus bevacizumab; CI: confidence interval; CRT; chemoradiotherapy; HR: hazard ratio: RT40; radiotherapy
(40 Gy in 15 fractions); RT60; radiotherapy (60 Gy in 30 fractions); SC; supportive care; TMZ; temozolomide; TTF_AC; tumour treating fields
plus adjuvant chemotherapy) aMer concomitant CRT)
 
 
Summary of findings 2.   Summary of findings on overall survival comparing treatments to hypofractionated
radiotherapy
Estimates of effects and certainty assessments compared with hypofractionated radiotherapy (40 Gy/15 fractions) on overall
survival in elderly people with newly diagnosed glioblastoma
Patient or population: elderly people with newly diagnosed glioblastoma
Interventions: chemoradiotherapy (CRT); chemoradiotherapy plus bevacizumab (BEV_CRT); radiotherapy plus bevacizumab
(BEV_RT); temozolomide (TMZ)
Comparison: hypofractionated radiotherapy (RT 40)
Outcome: overall survival
All intervention options
(7 RCTs; 1540 participants in total)*










(4 RCTs; 930 participants)
Reference comparator 78 per 100*** Reference com-
parator
BEV_RT
(1 RCT; 75 participants)





(3 RCTs, 538 participants)





(2 RCTs; 635 participants)




BEV_CRT HR 0.56 (0.31 to 0.99) 57 per 100 ⊕⊕⊕⊝
Moderate2
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(1 RCT; 73 participants) (37 to 78)
For the comparison with standard radiotherapy (60 Gy/30 fractions) see Summary of findings 3.
NMA-'Summary of findings' table definitions
Estimates are reported as HR: hazard ratio. CI: confidence interval.
***The assumed absolute effect of RT40 is based on Perry 2017 data.
NMA: network meta-analysis
GRADE Working Group grades of evidence
High certainty: we are very confident that the true effect lies close to that of the estimate of the effect.
Moderate certainty: we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the ef-
fect, but there is a possibility that it is substantially different.
Low certainty: our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the
effect.
Very low certainty: we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the
estimate of effect.
1Contributing direct evidence was of low certainty (study design limitations and imprecision).
2Contributing direct evidence was of high or moderate certainty.
 
 
Summary of findings 3.   Summary of findings on overall survival comparing treatments to standard radiotherapy
Estimates of effects and certainty assessment compared with standard radiotherapy (60 Gy/30 fractions) on overall survival
in elderly people with newly diagnosed glioblastoma
Patient or population: elderly people with newly diagnosed glioblastoma
Interventions: radiotherapy with 40 Gy in 15 fractions (RT 40); chemoradiotherapy (CRT); chemoradiotherapy plus beva-
cizumab (BEV_CRT); radiotherapy plus bevacizumab (BEV_RT); temozolomide (TMZ);
Comparison: standard radiotherapy (RT 60)
Outcome: overall survival
All intervention options
(7 RCTs; 1540 participants in total)*
Relative effect (network estimate) **
(95% CI)




(5 RCTs; 713 participants)
Reference comparator Reference comparator
RT 40
(4 RCTs; 930 participants)
HR 0.94 (0.72 to 1.23) ⊕⊕⊝⊝
Low1
BEV_RT
(1 RCT; 75 participants)
HR 1.01 (0.58 to 1.79) ⊕⊝⊝⊝
Very low1,2
TMZ
(3 RCTs, 538 participants)
HR 0.89 (0.71 to 1.11) ⊕⊝⊝⊝
Very low3
CRT HR 0.63 (0.46 to 0.87) ⊕⊕⊝⊝
Low
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(2 RCTs; 635 participants)
BEV_CRT
(1 RCT; 73 participants)
HR 0.52 (0.28 to 0.98) Not graded
NMA-'Summary of findings' table definitions
Estimates are reported as HR: hazard ratio. CI: confidence interval. For assumed median survival times and absolute effect esti-
mates, please refer to Summary of findings for the main comparison.
NMA: network meta-analysis
GRADE Working Group grades of evidence
High certainty: we are very confident that the true effect lies close to that of the estimate of the effect.
Moderate certainty: we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the ef-
fect, but there is a possibility that it is substantially different.
Low certainty: our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the
effect.
Very low certainty: we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the
estimate of effect.
1 Contributing direct evidence was of low certainty (study design limitations and imprecision).
2 Downgraded for imprecision.
3 Contributing direct evidence of very low certainty (imprecision, study design limitations and inconsistency).
 
 
Summary of findings 4.   Summary of findings on quality of life
The effect of different treatment comparisons for newly diagnosed glioblastoma in the elderly on quality of life
Patient or population: elderly people with newly diagnosed glioblastoma
Interventions: one treatment option
Comparison: an alternative treatment option
Compari-
son



























The study reported that global assessments of de-
terioration over time also did not differ significant-
ly between the two groups.
The dropout rate was high and unbalanced so find-








There may be little difference in
HRQoL scores between hypofrac-
tionated
and standard fractionation sched-








One study compared a 25 Gy schedule with a 40
Gy schedule; the other compared a 40 Gy schedule
with a standard 60 Gy schedule.
Treatment of newly diagnosed glioblastoma in the elderly: a network meta-analysis (Review)















TMZ vs RT No significant differences in global
QoL scores at 3, 6, or 12 month mea-
surements. However, there was a
significant difference in discomfort
from communication deficits, which
were greatest for those receiving
RT who died at between 6 and 12







Evidence was not downgraded for attrition be-
cause data were reported for 82% of participants in
each group for this outcome.
CRT vs RT Authors reported that quality of life











Investigators noted that attrition impacted the
quantity of data. They conducted analyses using
time to deterioration (with deterioration defined
as a 10-point decrease in the score on the function
domain or a 10-point increase in the score on the
symptom domain) and plotted QoL scores over
time. They reported that "There were no other clin-
ically important differences between trial groups,
which supports our observation that quality of life
was similar in the two treatment groups."
BEV_CRT
vs CRT
This was reported for the overall







The authors reported significantly delayed deterio-
ration in HRQoL scores in favour of BEV_CRT across
five main HRQoL domains (global health, commu-
nication, social functioning, motor function, physi-
cal functioning). When progression of disease was
removed as a deterioration event, the time to clin-
ically significant deterioration or death remained
statistically significant for communication, social
functioning and global health.
BEV_RT
vs RT
Investigators reported that "before
progression, no differences were de-
tected for individual scales in a gen-
eralized linear mixed model, except
for less favourable values in arm A







In the publication, global health was reported in
a forest plot along with individual HRQoL items,
such as cognitive functioning, emotional function-
ing and pain, measured with EORTC QLQ-C30/BN20




This was reported for overall trial







Investigators reported no significant differences




This was reported for overall trial







There was no significant difference in HRQoL re-
ported between the trial arms, except for itchy skin
which was more prominent in the TTFields arm
at 3,6 and 9 months (P = 0.005, P = 0008, P = 0.04).
There was no significant difference at 12 months.
IRI_BEV_RT
vs CRT
This was reported for overall trial







There was no significant difference between the
treatment arms.
GRADE Working Group grades of evidence
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High certainty: we are very confident that the true effect lies close to that of the estimate of the effect.
Moderate certainty: we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the ef-
fect, but there is a possibility that it is substantially different.
Low certainty: our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the
effect.
Very low certainty: we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the
estimate of effect.
1Sparse data from single studies [-1]
2 Serious risk of bias from attrition [-1]
3 Downgraded because data were presented graphically and e$ects could not be estimated.
4 In this trial (Stupp 2017a) TTF_AC was compared with adjuvant chemotherapy (TMZ) only, aMer both arms had received concomitant CRT.
Abbreviations: BEV_CRT: chemoradiotherapy plus bevacizumab; BEV_RT: radiotherapy plus bevacizumab; CI: confidence interval; CRT:
chemoradiotherapy; HR: hazard ratio; IRI: irinotecan; RT: radiotherapy; TMZ: temozolomide; TTF_AC: tumour treating fields with adjuvant
chemotherapy (aMer concomitant CRT) (TTF_AC); RIN_CRT: rindopepimut aMer CRT.
 
 
Summary of findings 5.   Summary of findings on progression-free survival
The effect of different treatment comparisons for newly diagnosed glioblastoma in the elderly on progression-free survival
Patient or population: elderly people with newly diagnosed glioblastoma
Interventions: one treatment option
























Median time to progression was 3.5 months in the RT arm vs













This study (Roa 2015) reported that median progression-free
survival showed no statistically significant difference be-
tween arms (4.2 v 4.2 months in arms 1 and 2, respectively; P
= 0.716).
TMZ vs RT HR 1.15 (0.92
to 1.44)




















In this study (AVAglio 2014), BEV_CRT did not increase overall
survival either relative to CRT alone for elderly patients.
BEV_RT vs RT HR 0.46 (0.27
to 0.78)





Despite delaying disease progression in this study (ARTE
2018), BEV_RT did not increase overall survival.
RIN_CRT vs
CRT
Not reported separately for elderly subgroup.
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TTF_AC vs CRT Not reported separately for elderly subgroup.
IRI_BEV_RT vs
CRT
Not reported separately for elderly subgroup.
GRADE Working Group grades of evidence
High certainty: we are very confident that the true effect lies close to that of the estimate of the effect.
Moderate certainty: we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the ef-
fect, but there is a possibility that it is substantially different.
Low certainty: our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the
effect.
Very low certainty: we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the
estimate of effect.
1Sparse data from single studies [-1]
2 Serious risk of bias from attrition [-1]
3 Serious imprecision
Abbreviations:BEV_CRT: chemoradiotherapy plus bevacizumab; BEV_RT: radiotherapy plus bevacizumab; CI: Confidence interval; HR:
hazard ratio;IRI: irinotecan; RT: radiotherapy; CRT: chemoradiotherapy; TMZ: temozolomide; TTF_AC: tumour treating fields with
adjuvant chemotherapy (aMer concomitant CRT) (TTF_AC); RIN_CRT: rindopepimut aMer CRT.
 
 
Summary of findings 6.   Summary of findings on severe adverse events
The effect of different treatments for newly diagnosed glioblastoma on severe adverse events
Patient or population: elderly people with newly diagnosed glioblastoma
Settings: any
Intervention: one treatment option



























This outcome was on-
ly reported in one small
study and there were no








TMZ vs RT TMZ probably increases
the risk of thromboembol-







Thrombocytopenia occurred in 24 TMZ vs 8 RT participants
(RR 2.74, 95% CI 1.26 to 5.94) and lymphocytopenia occurred
in 16 TMZ vs 2 RT participants (RR 7.30, 95% CI 1.70 to 31.31).
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CRT vs RT CRT probably increases







Neutropenia occurred in 22 CRT vs 2 RT participants (RR 10.30;
95% CI 2.45 to 43.34); throbocytopenia occurred in 30 CRT vs
1 RT participants (RR 28.56, 95% 3.92 to 207.86); lymphocy-
topenia occurred in 73 CRT vs 26 RT participants (RR 2.65, 95%
CI 1.75 to 4.01); leucopenia occurred in 19 CRT vs 1 RT partici-
pant (RR 18.16, 96% CI 2.45 to 124.64); and anaemia occurred












Other adverse events data were not available for elderly sub-
group specifically. For the larger study sample, Grade 3+ cere-
bral bleeding events (2.0% versus 0.9%) and wound healing
events (3.3% vs 1.6%) were higher in the BEV plus CRT arm
versus CRT alone. There were also higher rates of Grade 3+
thrombocytopenia (15% vs 9.8%) and infection rates (12.8%
versus 7.8%) in the BEV_CRT arm.
BEV_RT
vs RT
There was little or no dif-
ference in thromboem-
bolic, haematological,
and other severe adverse






An example of these non-statistically significant findings for
thrombocytopenia are that this SAE occurred in 8 BEV_RT vs
2 RT participants (RR 2.00, 95% CI 0.46 vs 8.73). Haematologi-
cal SAEs occurred in 2 vs 0 participants, respectively (RR 2.55,
95% CI 0.13 vs 51.17).
RIN_CRT
vs CRT
This was reported for over-







The most common severe adverse events for the experimental
(rindopepimut) versus control arm of the trial were: thrombo-
cytopenia (9% vs 6%), fatigue (2% vs 5%), brain oedema (2%
vs 3%), seizure (2% vs 2%) and headache (2% vs 3%). There
was one death, secondary to pulmonary embolism, that was




This was reported for over-







Overall, it was reported that there was no significant increase
in rates of severe adverse events when TTF were added to ad-
juvant chemotherapy (48% vs 44%, P = 0.58).
IRI_BEV_RT
vs CRT
This was reported for over-







Overall, rates of severe adverse events were 72% in the experi-
mental arm and 84% in the CRT arm. In the experimental arm,
severe vascular events were most common (11.8%) and two
cerebral haemorrhages occurred (one fatal). For patients in
the CRT arm, severe haematological toxicity was most com-
mon (18.2%).
GRADE Working Group grades of evidence
High certainty: we are very confident that the true effect lies close to that of the estimate of the effect.
Moderate certainty: we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the ef-
fect, but there is a possibility that it is substantially different.
Low certainty: our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the
effect.
Very low certainty: we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the
estimate of effect.
1 Downgraded -2 for sparse data from small single study and imprecision
Abbreviations: BEV_CRT: chemoradiotherapy plus bevacizumab; BEV_RT: radiotherapy plus bevacizumab; CI: confidence interval; HR:
hazard ratio; RT: radiotherapy; CRT: chemoradiotherapy; IRI: irinotecan; NA: not applicable; TMZ: temozolomide; TTF_AC: tumour treating
fields with adjuvant chemotherapy (aMer concomitant CRT) (TTF_AC); RIN_CRT: rindopepimut aMer CRT.
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B A C K G R O U N D
Description of the condition
Glioblastoma multiforme is a high-grade, aggressive primary
tumour of the central nervous system with a poor prognosis. The
incidence of glioblastoma is increasing and this rise is most rapid in
the elderly (Ferguson 2014). Use of the term 'the elderly' in relation
to glioblastoma commonly refers to people 70 years and older
(NCCN 2018). Age is an important consideration in the treatment of
glioblastoma as it is a negative prognostic indicator (Lorimer 2017).
A Surveillance Epidemiology and End Results (SEER) population
analysis reported that for every year increase in patient age, there
was a statistically significant decrease in survival (Thumma 2012).
Median survival drops from about 12 to 18 months for younger
people with glioblastoma, to three to six months for older age
cohorts (Brodbelt 2015).
The molecular status of glioblastoma is also an important
prognostic factor and several molecular subtypes of glioblastoma
have been recognised (Lara-Velazquez 2017). One of the
most important molecular signatures is O6-methylguanine-DNA-
methyltransferase (MGMT) promoter methylation, which has been
shown to confer predictive and prognostic benefit (Malmstrom
2012; Yin 2014). Treatment for glioblastoma is not curative and
the natural history of the disease is that patients will relapse
aMer treatment and it will ultimately be a fatal condition (Louis
2016). Retrospective studies have shown that older people are
less likely to get aggressive, multi-modality treatment (Iwamoto
2008; Lorimer 2017; Paszat 2001), but people with glioblastoma
across all age groups who do get active treatment live longer
(Brodbelt 2015). Direct healthcare costs for the management of
malignant gliomas (malignant glioma encompasses anaplastic
glioma, i.e. World Health Organization (WHO) grade 3 and 4) have
been estimated at USD 32,764 per patient (2011 data; Raizer 2015).
Description of the intervention
The ‘standard of care' of treatment for patients aged under 70
years of age with glioblastoma consists of surgery followed by
radiotherapy (60 Gy in 30 fractions) with concomitant and adjuvant
temozolomide (TMZ) chemotherapy (NCCN 2018; Stupp 2005). This
management plan is less oMen used in the elderly for the following
reasons.
• People over 70 years old were not included in the landmark trial
(Stupp 2005), and a subsequent communication of the results
of an exploratory subgroup analysis revealed that the survival
benefit in this trial was not statistically significant for a subgroup
of people aged 66 to 70 years (Laperriere 2013).
• Shorter radiotherapy courses or chemotherapy alone can lead
to better outcomes for the elderly than the standard course
of radiotherapy. Patients rarely live long enough to develop
late complications from radiation therapy, therefore larger
fraction size may be justified to allow for a shortened course of
treatment.
• Both chemotherapy and radiotherapy treatment toxicities are
oMen greater in the elderly (Lawrence 2011; Sijben 2008).
• The shorter predicted survival time for older people with
glioblastoma means that they might spend much of this time
recovering from the six-week course of radiotherapy.
Small prospective (Vuorinen 2003), and retrospective studies
(Chaichana 2011a; Chaichana 2011b), have shown that, for people
aged 65 and over with glioblastoma, maximal debulking (resection)
is associated with better survival and a trend to longer time
remaining independent versus biopsy alone. Therefore maximal
resection, if feasible, is the recommended primary approach to
glioblastoma in the elderly (NCCN 2018). Depending on a person's
performance status, radiotherapy or chemotherapy, or both, can
then be added. As it remains unclear which treatment is best for
glioblastoma in the elderly, participation in clinical trials is strongly
encouraged (NCCN 2018). There is little evidence to guide treatment
of recurrent glioblastoma in the elderly and approaches are based
on retrospective studies (Socha 2016).
Treatment with either radiotherapy or chemotherapy
A randomised trial of radiotherapy (50 Gy delivered over a period
of five to six weeks) versus best supportive care showed that
radiotherapy conferred a 12-week survival benefit in older people
with malignant glioma (Keime-Guibert 2007). Another randomised
trial found that radiotherapy (60 Gy over a period of six to
seven weeks) was as e$ective as intensive ("dose-dense") TMZ
chemotherapy alone (Wick 2012). There is increasing interest in
using hypofractionated radiotherapy (radiotherapy delivered over
shorter period of time, e.g. 40 Gy in 15 fractions over three weeks
and 34 Gy in 10 fractions over two weeks) for older people with
glioblastoma, as these have been found to have similar survival
benefits compared to the standard regimen of 60 Gy in 30 fractions
over a period of six weeks (Malmstrom 2012; Roa 2004).
Combination treatment
A randomised trial has shown that adding TMZ to hypofractionated
radiotherapy for older people with glioblastoma confers a survival
advantage compared to hypofractionated radiotherapy alone
(Minniti 2012; Perry 2017), but not necessarily for those people with
MGMT unmethylated tumours.
How the intervention might work
Surgery is an important step in the treatment of glioblastoma.
Also, there is evidence that surgery improves one- and two-year
survival rates compared to biopsy alone (Brown 2016). The extent
of surgery can be divided into three main categories which have
di$erent definitions in the literature: ‘maximal' debulking or gross
total resection (GTR), subtotal resection (STR), and biopsy. The role
of maximal debulking surgery is to minimise the tumour volume
that remains to optimise the impact of subsequent treatment
modalities, which are likely to be more e$ective against small
volume tumours (Lara-Velazquez 2017).
Radiotherapy is delivered to the primary tumour or the surgical
cavity with a margin to account for microscopic spread, patient
movement, and set-up error (Niyazi 2016). One of the most
important mechanisms of action of radiation therapy is the
promotion of double strand breaks in DNA which, if leM unrepaired,
will result in cell death (Baskar 2014). DNA damage is more likely to
occur in rapidly dividing cells, such as glioblastoma tumour cells,
rather than normal brain which has a slower rate of cellular turn
over. This provides the therapeutic index between the tumour and
normal surrounding tissue.
Systemic chemotherapy can enhance the therapeutic e$ect of
radiotherapy but is also an e$ective treatment on its own.
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The most widely used chemotherapy agent for newly diagnosed
glioblastoma is TMZ, which acts as a DNA alkylating agent (Zhang
2012). Those tumours with MGMT-promoter methylation lack the
MGMT enzyme which repairs the cytotoxic damage caused by TMZ,
thereby making tumour cells more chemosensitive.
Why it is important to do this review
Previous research has demonstrated that increasing age has an
important e$ect on overall survival and tolerability of treatment
for patients with a diagnosis of glioblastoma (Thumma 2012).
Increasing age, regardless of performance status, has an important
influence on treatment decisions made by clinicians (Palmer 2018),
however there is still a lack of consensus on the optimal treatment
options for the elderly subgroup of patients with glioblastoma.
It is recognised that treating older people with glioblastoma
presents unique challenges and that the standard approach is not
always appropriate. There have been several randomised trials in
recent years that have tested therapeutic strategies specifically for
older people with glioblastoma (e.g. Malmstrom 2012; Perry 2017
Roa 2004; Wick 2012). Other trials including younger people have
also performed subgroup analysis to test if therapeutic benefit is
maintained in older people. Due to the variation in age thresholds
to define the ‘elderly', performance status, treatment regimens,
and molecular subtypes, it has been di$icult to translate these
individual studies into clinical practice. This is also because the
focus of many intervention trials is on survival, which might not be
the most important outcome to elderly people with glioblastoma;
rather, the quality of the remainder of their life might be their most
important consideration. As the median age of diagnosis is around
64 years of age (Ostrom 2015), a significant proportion of newly
diagnosed patients fall into the 'elderly' category.
There is been some evidence to suggest that total direct costs
of care associated with glioblastoma have been increasing over
recent years with the increased use of costly systemic anti-cancer
treatments (Henaine 2016; Ray 2014). Selecting the appropriate
management strategy for an elderly patient group is important
from a quality of life perspective and also has significant resource
implications (Raizer 2015). It has been estimated the average cost
for a regimen of TMZ to treat a person with newly diagnosed
glioblastoma is USD 46,693 (USD in 2018 converted from NZD 2005)
(Hamilton 2005). It is therefore important to understand the costs
and benefits to avoid implementing costly and potentially toxic
treatment for little clinical benefit.
Currently there is no clear consensus on how to apply the available
evidence to guide treatment of the individual person seen in
clinic. A systematic review and network meta-analysis (NMA) of
randomised trials would help to inform the best approach to the
treatment of older individuals with newly diagnosed glioblastoma
and help to identify research gaps.
O B J E C T I V E S
To determine the most e$ective and best-tolerated approaches
for the treatment of elderly people with newly diagnosed
glioblastoma. To summarise current evidence for the incremental
resource use, utilities, costs and cost-e$ectiveness associated with
these approaches.
M E T H O D S
Criteria for considering studies for this review
Types of studies
• Randomised controlled trials (RCTs) for evidence on
e$ectiveness and safety.
• Full economic evaluations (cost-e$ectiveness analyses, cost-
utility analyses, and cost-benefit analyses) conducted alongside
any study design and any model-based economic evaluations
for economic evidence.
Types of participants
Elderly people undergoing treatment for histologically confirmed
newly diagnosed glioblastoma. For the purpose of this Cochrane
Review, we defined ‘elderly' as 70 years and older; however, where
investigators defined the ‘elderly' as over 65 years of age, we
included these studies. We included studies of people of all ages
that reported subgroup findings for elderly people (over 65 or 70
years of age) provided the participants in the subgroup numbered
more than 20. We also included the mixed data if it was clear that
80% or more of participants in the study were over the age of 65
years. Similarly, where the study population included both grade 3
or 4 gliomas (anaplastic astrocytomas or glioblastoma), we tried to
obtain separate data for participants with glioblastoma; if this was
not possible, we considered including the study if more than half
the study population had glioblastoma.
Types of interventions
Interventions evaluated alone or in combination with each other
versus any of the other interventions included the following.
• Radiotherapy (standard, hypofractionated, and other
techniques).
• Chemotherapy (temozolomide (TMZ) and other types).
We included all available regimens of radiotherapy and
chemotherapy that were evaluated in randomised trials. If we
identified interventions in the included studies of which we were
not aware, we considered including them aMer we assessed their
comparability with those interventions named above. We excluded
phase 1 and 2 studies of novel interventions that have been shown
to be detrimental and have not been developed further.
It was not possible to create separate networks according to the
type of surgical procedure (gross total resection (GTR), subtotal
resection (STR), and biopsy only). Within each network we assumed
that any participants within the network could be randomised to
any of the interventions e.g. an elderly person with histologically
confirmed glioblastoma could be equally likely to be randomised to
standard radiotherapy, chemotherapy, any combination of these or
supportive care.
Types of outcome measures
Primary outcomes
• Overall survival (time from randomisation to death from any
cause).
• Quality of life (QoL), as measured using a standardised
questionnaire, e.g. the European Organisation for Research and
Treatment of Cancer (EORTC) QLQ-C30 or QLQ-BN20 (specific for
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brain cancer), or the Functional Assessment of Cancer Therapy
scale (FACT-G (general) or FACT-Br (specific for brain cancer)).
Secondary outcomes
• Progression-free survival (time from randomisation to disease
progression or death from any cause).
• Severe adverse events, according to standardised scales, e.g.
Common Terminology Criteria for Adverse Events (CTCAE).
• Cognitive impairment (objective or subjective), as measured by
an overall cognitive function score, as a change-over-time score,
or reported as individual cognitive function domains, e.g. verbal
fluency, processing speed, memory, attention, and executive
functioning, using a standardised measurement tool, e.g. Mini
Mental State Exam (MMSE), EORTC, FACT.
• Functional impairment or disability, as measured by an overall
ability score and/or as a change of ability over time score using
a standardised measurement tool, e.g. Karnofsky Performance
Status Scale, Neurological Functions Score, EORTC, FACT; or as
a categorical outcome as defined by investigators.
• Fatigue, according to CTCAE, EORTC, or as defined by
investigators.
• Economic outcomes:
* resource use for health care;
* health state utilities;
* costs of health care;
* incremental cost-e$ectiveness.
Search methods for identification of studies
Electronic searches
For studies on the e$ects of the interventions, we searched the
following databases to 3 April 2019:
• The Cochrane Central Register of Controlled Trials (CENTRAL;
2019, Issue 4), in the Cochrane Library;
• MEDLINE via Ovid (1946 to March week 4 2019);
• Embase via Ovid (1980 to 2019 week 13).
For economic evidence we searched the following databases:
• MEDLINE via Ovid (January 2015 to March week 4 2019);
• Embase via Ovid (January 2015 to 2019 week 13);
• NHS Economic Evaluation Database (EED) to December 2014.
The NHS EED database was searched up to the end of December
2014 (when the last records were added to that database) and
MEDLINE and Embase from 1 January 2015, as the NHS EED
already included comprehensive searches of these databases prior
to 2015. We also considered relevant grey literature (such as
health technology assessments, reports, and working papers) for
inclusion.
Please refer to Appendix 1 for the CENTRAL, MEDLINE, and Embase
search strategies.
We did not apply language restrictions to any literature searches.
Searching other resources
We searched the following for ongoing trials.
• ClinicalTrials.gov (clinicaltrials.gov/)
• WHO International Clinical Trials Registry Platform (ICTRP)
(apps.who.int/trialsearch/)
If ongoing trials that have not been published were identified
through these searches, we approached the principal investigators
to ask for an update on the trial status and any relevant
unpublished data, if available.
We used the related articles feature of PubMed and handsearched
the reference lists of included studies to identify newly published
articles and additional studies of relevance. We also handsearched
conference proceedings from 2014 to 2018 (five years) of the
British Neuro-Oncology Society, the Society of Neuro-Oncology, the
European Association of Neuro-Oncology and the World Federation
of Neuro-Oncology Societies conferences for relevant ongoing or
unpublished studies.
Data collection and analysis
Selection of studies
For the results of search 1 (trials of e$ects of interventions), the
Information Specialist at the Cochrane Gynaecological, Neuro-
oncology and Orphan Cancer Group (CGNOC) downloaded all
titles and abstracts retrieved by electronic searching to EndNote
X8 and removed duplicates. Two review authors (TAL, CH, or
ER) independently screened the remaining records and excluded
studies that clearly did not meet the eligibility criteria. For
potentially eligible records, copies of the full texts were obtained
and three review authors (TAL,CH and ER) independently assessed
them for eligibility. The respective review authors resolved any
disagreements through discussion and, if necessary, consulted at
least one other review author. We used Covidence to facilitate this
study selection process and documented the reasons for exclusion
of studies accordingly.
To inform the economic outcomes, full economic evaluations
(cost-e$ectiveness analyses, cost-utility analyses, and cost-benefit
analyses), we considered cost analyses and comparative resource-
utilisation studies. Studies carried out alongside relevant RCTs and
model-based studies were considered for inclusion. Two review
authors (TR and AK) independently screened for eligible studies.
Data extraction and management
Two review authors (TAL, CH, or ER) independently extracted data
from included studies using a pre-designed data extraction form
(Higgins 2011). We extracted the following data.
• Author contact details.
• Country.
• Setting.
• Dates of participant accrual.
• Funding source.
• Inclusion and exclusion criteria.
• Study design.
• Study population and baseline characteristics:
* number of participants enrolled;
* number of participants analysed;
* age;
* gender.
Treatment of newly diagnosed glioblastoma in the elderly: a network meta-analysis (Review)









Cochrane Database of Systematic Reviews
• Potential e$ect modifiers:
* molecular type of glioblastoma;
* performance status.
• Intervention details:
* type of intervention, dose, timing, and other regimen details;
* Type of comparator.
• Risk of bias assessment (see below).
• Duration of follow-up.
• Primary outcome(s) of the study.
• Review outcomes:
* For time-to-event outcomes (overall and progression-free
survival) we extracted the hazard ratio (HR) with its 95%
confidence interval (CI) for time points as reported by the
study authors. We noted the definition of and procedure used
to identify progression. Where reported, we also extracted
dichotomous data for these outcomes at author-specified
time points.
* For dichotomous outcomes (e.g. serious adverse events), we
extracted the number of participants in each treatment arm
that experienced the outcome of interest and the number of
participants assessed.
* For continuous outcomes (e.g. QoL scores), we extracted the
value and standard deviation of the outcome of interest and
the number of participants assessed at the relevant time
point in each group. We also extracted change-from-baseline
score data where reported and noted the type of scale used.
* We extracted adjusted statistics where reported.
* Where possible, all data extracted were those relevant to
an intention-to-treat analysis, in which participants were
analysed in the groups to which they were assigned.
* We resolved di$erences between review authors by
discussion or by appeal to a third review author when
necessary.
Assessment of risk of bias in included studies
We assessed the risk of bias using Cochrane's ‘Risk of bias' tool
and the criteria specified in the Cochrane Handbook for Systematic
Reviews of Interventions (Higgins 2011). This included assessment
of the following.
• Random sequence generation.
• Allocation concealment.
• Blinding of participants and healthcare providers.
• Blinding of outcome assessors.
• Incomplete outcome data (more than 20% missing data
considered high risk).
• Selective reporting of outcomes.
• Other possible sources of bias, e.g. lack of a power calculation,
baseline di$erences in group characteristics.
Two review authors (ER and CH) independently assessed risk of
bias and resolved any di$erences in opinion by discussion or by
consulting a third review author (TAL). We summarised judgements
in ‘Risk of bias' tables along with the characteristics of the included
studies and interpreted the results of meta-analyses in light of the
overall ‘Risk of bias' assessment. For more details about the ‘Risk of
bias' assessment see Appendix 2.
We assessed economic evaluation studies for bias in two stages.
The first stage involved assessing risk of bias from the sources
of the e$ectiveness data. In economic evaluations carried out
alongside clinical trials, we assessed these using the Cochrane
‘Risk of bias' tool, as described above. If the economic evaluation
was model-based, we used the ROBIS tool to assess bias in the
e$ectiveness studies (Whiting 2016). The second stage involved
assessing the risk of bias of the economic evidence (i.e. assessing
the overall methodological quality). This was done using the
Consolidated health Economic Evaluation Reporting Standards
(CHEERS) checklist (Husereau 2013).
Measures of treatment e7ect
Eectiveness data
• For time-to-event outcomes (e.g. overall survival), we extracted
the hazard ratio (HR) with its 95% confidence interval (CI).
• For continuous outcomes (e.g. QoL scores) we assumed
that study authors would use di$erent measurement scales,
therefore, we planned to estimate the standardised mean
di$erence (SMD) and its 95% CI using the pooled data. However,
if the same measurement scale was used, we estimated
the mean di$erence (MD) and its 95% CI. If studies did
not report total values but, instead, reported change-from-
baseline outcomes, we combined these change values with
total measurement outcomes by using the (unstandardised) MD
method in Review Manager 5 (RevMan 5) (RevMan 2014). We
used subgroups to distinguish between MDs of change scores
and MDs of final values, and pooled the subgroups in an overall
analysis (Higgins 2011).
• For dichotomous outcomes, we calculated the e$ect size as a
risk ratio (RR) with its 95% CI.
Economic data
Two review authors (AK and TR) independently extracted data from
relevant economic studies and summarised this information in
tables. We extracted data on the following.
• Type of evaluations.
• Sources of e$ectiveness data.
• Cost data.
• Sources of cost data.
• Sources of outcome valuations.
• Analytical approach.
Unit of analysis issues
Two review authors (TAL and ER) assessed unit of analysis issues
according to Higgins 2011, and resolved any di$erences in opinion
by discussion. These included reports where there are multiple
observations for the same outcome (e.g. repeated measurements
with di$erent scales or at di$erent time points, recurring events).
If meta-analysis was not feasible or meaningful, we extracted data
from all scales or time points and attempted to describe them
narratively.
Multi-arm trials
We included multi-arm trials in this review. We treated multi-arm
studies as multiple independent comparisons in pairwise meta-
analyses and did not combine data from di$erent arms. In the
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network meta-analysis (NMA) we accounted for the correlation
between the e$ect sizes derived from the same study (White 2015).
Dealing with missing data
We did not impute missing data. In the event of missing data, we
wrote to study authors to request the data on primary outcomes
and describe in the ‘Characteristics of included studies' tables how
any missing data were obtained.
Assessment of heterogeneity
Assessment of clinical and methodological heterogeneity
We assessed clinical heterogeneity between studies by comparing
characteristics of included participants, and interventions in each
meta-analysis of each comparison, by visual inspection of forest
plots, by estimation of the percentage heterogeneity between trials
which cannot be ascribed to sampling variation (Higgins 2003),
by a formal statistical test of the significance of the heterogeneity
(Deeks 2001), and, where possible, by subgroup analyses. If there
was evidence of substantial heterogeneity, we investigated and
reported the possible reasons for this.
Assessment of consistency across treatment comparisons
We examined the assumption of consistency by assessing the
distribution of potential e$ect modifiers across the pairwise
comparisons (Cipriani 2013; Jansen 2013; Salanti 2012). The
assumption would hold if the following were true.
• The common treatment used to compare di$erent interventions
indirectly was similar when it appeared in di$erent trials.
• All pairwise comparisons did not di$er with respect to the
distribution of e$ect modifiers.
Assessment of statistical heterogeneity and inconsistency
Assumptions when estimating the heterogeneity
In standard pairwise meta-analyses, we estimated di$erent
heterogeneity variances for each pairwise comparison. In the NMA,
we assumed a common estimate for the heterogeneity variance
across the di$erent comparisons (White 2015).
Measures and tests for heterogeneity
We assessed the presence of statistical heterogeneity within the
pairwise comparisons using the I2 statistic, which is the percentage
of variability that cannot be attributed to random error (Higgins
2003).
Assessment of statistical inconsistency
We were not able to assess statistically the global agreement
between the various sources of evidence in a network of
interventions (consistency). However, we were able to apply a local
approach using a node-splitting method (Dias 2010).
Assessment of reporting biases
In pairwise comparisons, if there were 10 or more studies included
in meta-analyses, we had planned to investigate reporting biases
(such as publication bias) using funnel plots. However, in none of
the analyses were 10 or more studies included.
Data synthesis
Methods for direct treatment comparisons
Initially we performed standard pairwise meta-analyses for each
comparison using the random-e$ects model in Stata statistical
soMware version 15.1 (STATA) and Review Manager soMware
(RevMan 2014).
Methods for indirect and mixed comparisons
We conducted network meta-analyses within a frequentist
framework using multivariate meta-analysis (White 2015), if
we considered participants, comparisons, and outcomes to be
su$iciently similar to ensure an answer that was clinically
meaningful. We also used STATA commands for visualising and
reporting NMA results (Chaimani 2015). If meta-analysis was
not possible but limited data were available, we attempted to
synthesise narrative summaries according to guidance in the
Cochrane Handbook.
We summarised characteristics and results of included economic
evaluations using additional tables, supplemented by a narrative
summary that compared and evaluated methods used and
principal results between studies. Unit cost data were also
tabulated, when available. We reported the currency and price
year applicable to measures of costs in each original study
alongside measures of costs, incremental costs, and incremental
cost-e$ectiveness by study. Where details of currency and price
year were available in original studies, we converted measures
of costs, incremental costs, and cost-e$ectiveness to (latest year)
international dollars value using implicit price deflators for gross
domestic product (GDP) and GDP Purchasing Power Parities
(EPPI Centre Cost Converter 2016). Details of the methodological
characteristics of individual included health economics studies
was summarised in Characteristics of included studies tables.
All elements of the economics component of this review were
conducted according to current guidance on the use of economics
methods in the preparation and maintenance of Cochrane Reviews
(Higgins 2011; Shemilt 2018; Wijnen 2016).
‘Summary of findings' tables and results reporting
E7ectiveness summary of findings
We presented the primary outcomes in the 'Summary of findings'
tables. Evidence for pairwise comparisons was assessed based on
GRADEpro Guideline Development Tool (GDT) methods (GRADEpro
2015) (i.e. we assessed risk of bias, inconsistency, imprecision,
indirectness and publication bias), whereas network evidence
was assessed using the approach suggested by Puhan 2014
and advanced by Brignardello-Petersen 2018. Narrative evidence
summaries were prepared if data could not be synthesised and
assessed according to the GRADE approach suggested by Murad
2017. The certainty of pairwise and network evidence for each
outcome was rated as ‘high’, ‘moderate’, ‘low’ or ‘very low’ as
defined according to the GRADE approach.
• High certainty: we are very confident that the true e$ect lies
close to that of the estimate of the e$ect.
• Moderate certainty: we are moderately confident in the e$ect
estimate; the true e$ect is likely to be close to the estimate of the
e$ect, but there is a possibility that it is substantially di$erent.
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• Low certainty: our confidence in the e$ect estimate is limited;
The true e$ect may be substantially di$erent from the estimate
of the e$ect.
• Very low certainty: We have very little confidence in the e$ect
estimate; the true e$ect is likely to be substantially di$erent
from the estimate of e$ect.
To assess the network evidence, we assessed the certainty of the
direct evidence (if any), the indirect evidence (if estimable) and
the network evidence in this order. Direct evidence was assessed
using the standard (pairwise) GRADE approach, but without
assessing imprecision (i.e. we assessed risk of bias, inconsistency,
indirectness and publication bias). Indirect evidence ratings, based
on the certainty rating of the lower of the two arms forming the
loop in the network diagram, were assessed when they contributed
more than the direct evidence to the network estimates. The final
step was to assess the certainty of the network e$ect estimate
based on whether intransitivity was present (i.e. whether there
were di$erences in study characteristics that may modify the e$ect
in the direct comparisons that form the basis for the indirect
estimate; Puhan 2014). The network estimate was assessed in the
first instance as being equivalent to the higher of the direct and
indirect estimates, and incoherence and imprecision were then
considered, with downgrading by one level accordingly if serious.
Where no direct evidence was available and when the treatments
did not have a common comparator, we presented the network
estimate but did not rate the certainty of the evidence. Where
possible, we estimated the absolute e$ects of treatments relative
to the e$ect of a given reference comparator based on an assumed
risk, the source of which was stated. For median survival times, we
based illustrative absolute e$ects on hazard ratios (HRs).
'Summary of findings' tables were designed following the approach
suggested by Schunemann 2009 and by Yepes-Nuñez 2019. In
the 'Summary of findings' tables we provided justification for
each assessment about the confidence in the estimates of e$ect
(e.g. reasons for downgrading the certainty of the evidence),
with confidence assessed as 95% credible intervals (CrI). Two
review authors (TAL and ER) independently assessed the certainty
of the evidence. We resolved any di$erences of opinion by
discussion. We interpreted the graded evidence based on the
Cochrane E$ective Practice and Organisation of Care (EPOC)
Group's guidance (Cochrane EPOC 2015) and, for time-to-event
evidence, on suggestions in Barraclough 2011.
Relative treatment ranking
We computed ranking of probabilities for all included treatments
and obtained a treatment hierarchy using the surface under the
cumulative ranking curve (SUCRA). For primary outcomes, we
assessed the robustness of these findings in sensitivity analysis.
Economic evaluation summary of findings
For the economic evaluation studies, we presented the following
findings in a table.
• Method of economic evaluation
• Costs
• Outcomes
• Incremental cost-e$ectiveness ratio
Subgroup analysis and investigation of heterogeneity
For pairwise comparisons we assessed heterogeneity using the I2
statistic that measures the percentage of variability that cannot
be attributed to random error (Higgins 2003). We considered
clinical heterogeneity and risk of bias in the interpretation of any
heterogeneity. The certainty of the evidence was downgraded for
heterogeneity where I2 ≥ 60%.
Due to sparse structure of the network, we assumed no
substantial statistical heterogeneity and fitted a fixed-e$ect model.
However, we performed sensitivity analyses to examine the
impact of our original assumptions by applying an alternative
classification of radiotherapy with 50 Gy in one study (Keime-
Guibert 2007); removing one of the arms from three-arm trial
(hypofractionated radiotherapy Malmstrom 2012), and splitting
the chemoradiotherapy node according to the radiation dose
(hypofractionated radiotherapy and 60 Gy).
For primary outcomes, we had planned to assess findings by the
di$erent age thresholds used by investigators to define the elderly
and by MGMT methylation status; however, data were insu$icient
for these subgroup analyses.
Sensitivity analysis
We performed sensitivity analyses to investigate assumptions that
we made to facilitate a connected network, including:
• pooling data from a study utilising a radiotherapy dose of 50Gy
with studies utilising 60 Gy or 40 Gy dose schedules;
• pooling data from study arms utilising combined
chemoradiation, where studies utilised 60 Gy or 40 Gy
radiotherapy dose schedules.
We based these assumptions on calculations of the equivalent
doses (EQD2) and biologically e$ective doses (BED) of the di$erent
radiotherapy schedules utilised in included studies (Table 1). Note
that data from trials using 34 Gy/10 fractions were pooled with
those of 40 Gy/15 schedules in our NMA, as we considered the BEDs
of these schedules to be su$iciently similar.
We also conducted sensitivity analysis to investigate the impact of
a single three-arm study forming the only loop in the network and
to justify the lack of assessment of inconsistency (see above).
R E S U L T S
Description of studies
Results of the search
Intervention studies
Searches conducted on the 13 June 2018 and the 3 April 2019
led to the identification of 12 included studies (with 31 associated
records) and two potentially eligible ongoing studies (with three
associated records). We identified the following numbers of records
through the first electronic database search.
• MEDLINE: 1946 to May week 5 2018 – 930 records
• Embase: 1980 to 2018 week 24 – 848 records
• CENTRAL: Issue 5 2018 – 1571 records
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The results of this initial search are summarised in Figure 1.
Following de-duplication across the databases, the combined total
yield was 2493 records. The Information Specialist at the Cochrane
Gynaecological, Neuro-oncology and Orphan Cancer (CGNOC)
Group ran these records through the Cochrane RCT 'Classifier’,
which uses machine learning to identify records that are likely to be
randomised controlled trials (RCTs). Following classification, 1462
records were identified as having more than a 10% likelihood of
being RCTs, whilst 1031 references had less than a 10% likelihood
of being RCTs. The Information Specialist then de-duplicated the
remaining 1462 records and siMed out the clearly irrelevant records
(e.g. those that related to other types of cancers). Two study
authors (CH, TAL) independently screened the remaining yield of
990 records. Out of these, 12 studies (ARTE 2018; AVAglio 2014;
GLARIUS 2016; Green 1983; Keime-Guibert 2007; Malmstrom 2012;
Perry 2017; Roa 2004; Roa 2015; Stupp 2017a; Weller 2017; Wick
2012) with 31 associated records were finally included (Figure 1).
Additionally, one ongoing study was identified (NCT01602588).
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Figure 1.   Study flow diagram (search date 13 June 2018)
 
The top-up search on 3 April 2019 yielded 125 additional records
to be screened on title and abstract. AMer de-duplication and
screening on title and abstract, six full-text papers were retrieved.
Three of these papers were additional publications related to two
already included studies (AVAglio 2014; GLARIUS 2016), the other
three were excluded with reasons. Additionally, searches of clinical
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trial registries and of relevant society conference proceedings from
2014 to 2018 identified one ongoing trial (NUTMEG 2018) and four
potentially eligible records, respectively. The ongoing trial was
added to the Ongoing studies section, including one conference
abstract (NUTMEG 2018). The other three conference abstracts were
classified as excluded studies. The results of the top-up search are
summarised in Figure 2.
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Figure 2.   Study flow diagram (search date 3 April 2019).
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Figure 2.   (Continued)
 
Economic studies
For economic studies, we identified the following numbers of
records through electronic database searches conducted on 13
June 2018.
• MEDLINE: 1946 to May week 5 2018 – 113 records
• Embase: 1980 to 2018 week 24 – 151 records
Following de-duplication across these databases, the total yield
to be siMed was 101 records. The top-up search conducted on
the 3 April 2019 yielded an additional 22 records. Five titles and
abstracts were identified for full-text screening (Ghosh 2018, Jiang
2017; Moroney 2017; Roussakou 2017; Waschke 2018), one of which
(Ghosh 2018) was included.
Included studies
We included 12 RCTs, six were conducted exclusively among elderly
people (either defined as 65 years or older or 70 years or older) with
newly diagnosed glioblastoma (ARTE 2018; Keime-Guibert 2007;
Perry 2017; Roa 2004; Roa 2015; Wick 2012). The other six RCTs
included patients from a broader age range and reported some data
separately for their elderly subgroup (AVAglio 2014; GLARIUS 2016;
Green 1983; Malmstrom 2012; Stupp 2017a; Weller 2017), which we
extracted for this review.
Numbers recruited and analysed
Altogether, approximately 1818 elderly participants involved in the
included studies contributed data to the review. In seven studies,
the elderly participants analysed numbered less than 100. In five
studies (Green 1983; Malmstrom 2012; Perry 2017; Stupp 2017a;
Wick 2012); the number analysed was more than 100, equalling to
107, 123, 562, 134, and 373 participants, respectively.
Location of studies
Six studies were conducted in the following individual countries:
Canada (Roa 2004), France (Keime-Guibert 2007), Germany
(Wick 2012; GLARIUS 2016), the USA (Green 1983); Switzerland
(ARTE 2018); the rest were multi-country studies (AVAglio 2014;
Malmstrom 2012; Perry 2017;Roa 2015; Stupp 2017a; Weller 2017).
Dates of recruitment
Accrual occurred before 1980 in one study (Green 1983) and
between 1996 and 2001 in another (Roa 2004). In all other studies,
accrual occurred from 2000 onwards.
Funding
Seven studies were funded by pharmaceutical companies
(ARTE 2018: Roche Pharmaceuticals; AVAglio 2014: Ho$mann-La
Roche; GLARIUS 2016: Roche Pharmaceuticals; Malmstrom 2012:
Merck; Perry 2017: Schering-Plough/Merck; Weller 2017: Celldex
Therapeutics; Wick 2012: Merck, Sharp & Dohme; two of these
(Malmstrom 2012; Perry 2017) also received grants from national
cancer research funds. One study (Stupp 2017a) received funding
from a medical device company, Novocure Ltd). The rest were
funded by research grants from national cancer research funds or
charities.
Characteristics of study participants
Also see Table 2.
Age
Eight studies defined older patients using an age threshold of 65
years, two studies (AVAglio 2014; Keime-Guibert 2007) used an
age threshold of 70 years, and two studies recruited participants
from 60 years of age (Malmstrom 2012; Roa 2004). One of the
latter studies defined an older subgroup using a threshold of 70
(Malmstrom 2012), whereas the other did not define an older
subgroup and presented all data together (Roa 2004). As the mean
age of participants in the latter study was about 72 years with a
standard deviation of about five years, the majority of participants
in this study would have been over 65 years of age, but the exact
proportion of the sample that this represents was unclear (see Risk
of bias in included studies).
Gender
Most studies had participant gender ratios of about 3 to 2 in favour
of male participants; however, in two studies, the proportion of
men and women was roughly equal (Roa 2015; Wick 2012).
Performance status
Most studies required that participants had a certain performance
status prior to enrolment and did not recruit participants who were
not self-caring. Thus, participants of six studies specified Karnofsky
performance scores (KPS) of 60 or more (ARTE 2018; Wick 2012), or
70 or more (GLARIUS 2016; Green 1983; Keime-Guibert 2007; Stupp
2017a). Two studies specified an Eastern Cooperative Oncology
Group (ECOG) performance status of 0 to 2 (Perry 2017; Weller 2017),
and two specified a World Health Organization (WHO) performance
status of 0 to 2 (AVAglio 2014; Malmstrom 2012). Two studies,
however, recruited participants with poorer performance status
(minimum KPS of 50) (Roa 2004; Roa 2015), patients with a KPS of 50
require considerable assistance and frequent medical care (Table
3).
O6-methylguanine DNA methyltransferase (MGMT)-methylation status
Eight studies reported the MGMT-methylation status of their
participants (ARTE 2018; AVAglio 2014; GLARIUS 2016; Malmstrom
2012; Perry 2017; Stupp 2017a; Weller 2017;Wick 2012). In the
overall samples, the MGMT-methlyated status was represented by
at least 21% of participants with these test results: in ARTE 2018
26%, in AVAglio 2014 47%, in Malmstrom 2012 46.6%, in Perry
2017 37%, in Stupp 2017a 34%, in Weller 2017, and 20% in Wick
2012. In GLARIUS 2016, all participants had MGMT-unmethylated
glioblastomas. For two studies in which the elderly were a subgroup
(Malmstrom 2012; Weller 2017), MGMT-methylation status was
reported for the broader sample and might not necessarily have
reflected the MGMT-methylation status of the elderly subgroup
relevant to this review.
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Interventions and comparisons
Most studies (10) randomised participants to two treatment arms
but one trial (Malmstrom 2012) had three treatment arms and
one had four treatment arms (Green 1983). The majority of
treatments o$ered to patients were either radiotherapy alone,
systemic anti-cancer treatment (SACT) alone, or a combination of
both. One trial (Keime-Guibert 2007) had a standard management
arm of supportive care, and one RCT used a medical device,
known as tumour treating fields (TTF), in combination with
radiotherapy and TMZ (Stupp 2017a) in its experimental arm.
All studies randomised participants aMer diagnosis and before
radiotherapy and/or chemotherapy with the exception of Stupp
2017a and Weller 2017, both of which randomised participants aMer
chemoradiotherapy and before commencement on adjuvant TMZ.
In the trials that included elderly patients only (ARTE 2018; Keime-
Guibert 2007; Perry 2017; Roa 2004; Roa 2015; Wick 2012), the
reference treatment arms were radiotherapy alone (60 Gy in 30
fractions (Roa 2004; Wick 2012), or 40 Gy in 15 fractions (ARTE
2018; Perry 2017; Roa 2015)), or supportive care (Keime-Guibert
2007). The experimental arms in these trials were hypofractionated
radiotherapy treatment alone (40 Gy in 15 fractions (Roa 2004),
or 25 Gy in five fractions (Roa 2015), radiotherapy (40 Gy in 15
fractions combined with a systematic anti-cancer treatment TMZ
(Perry 2017) or bevacizumab (ARTE 2018), radiotherapy (50 Gy in 28
fractions with supportive care (Keime-Guibert 2007), or TMZ alone
(Wick 2012).
In the six trials (AVAglio 2014; GLARIUS 2016; Green 1983;
Malmstrom 2012; Stupp 2017a; Weller 2017) that included patients
of all ages, with the elderly as a subgroup, the radiotherapy
fractionation in the reference treatment was exclusively 60 Gy in 30
fractions. In the reference arms of the trials, this was used alone
(Malmstrom 2012), in combination with concomitant and adjuvant
TMZ +/- placebo (AVAglio 2014; GLARIUS 2016; Stupp 2017a; Weller
2017), or in combination with intravenous carmustine (BCNU)
(Green 1983). The experimental arms in these trials were mostly 60
Gy of radiotherapy in 30 fractions in combination with additional
or alternative SACTs (AVAglio 2014; GLARIUS 2016; Green 1983;
Weller 2017). Malmstrom 2012 was the only trial that included an
experimental treatment arm with TMZ alone and hypofractionated
radiotherapy alone (34 Gy in six fractions over two weeks). Stupp
2017a was the only trial to include a medical device (TTF) and they
used this device in their experimental arm in combination with
adjuvant TMZ following chemoradiotherapy (60 Gy of radiotherapy
plus TMZ).
Radiotherapy fractionation and delivery
All of the included RCTs, except one (Green 1983) used megavoltage
(MV) photon radiotherapy to the tumour or tumour bed with a 2
cm to 3 cm margin. Green 1983 used whole brain radiotherapy
(WBRT), which is likely a reflection of the more limited technological
capabilities to deliver conformal radiotherapy in the 1970s when
this trial was open to recruitment. A comparison of the biologically
e$ective dose (BED) and E2D2 of radiotherapy fractionation
schedules used across all trials is outlined in Table 1.
Systemic anti-cancer treatment
TMZ was the most frequently used SACT. When combined with 60 Gy
in 30 fractions, it was used as per the "Stupp" regimen (Stupp 2005).
This comprises 75 mg/m2 of TMZ given concomitantly with six
weeks of radiotherapy, followed by adjuvant treatment delivered
over five days each month at a dose of 150 mg/m2 to 200 mg/
m2. In the original Stupp regimen (Stupp 2005), adjuvant treatment
was continued for a total of six cycles. AVAglio 2014; GLARIUS 2016;
Stupp 2017a all followed this regimen. Weller 2017 specified that
adjuvant TMZ could be continued for six to 12 cycles or longer, and
Perry 2017 specified that up to 12 adjuvant cycles of TMZ could be
delivered. When TMZ was used alone (Wick 2012, Malmstrom 2012),
this was given orally using a week-on/week-o$ schedule of 100 mg/
m2/day for up to six months of treatment (Wick 2012) or 200 mg/m2
on days one to five of every 28 days for up to six cycles (Malmstrom
2012).
Bevacizumab was used in the experimental arm of three trials
(ARTE 2018, AVAglio 2014, GLARIUS 2016) and was delivered
intravenously at a dose of 10 mg/kg every two weeks in all of these
trials. Irinotecan was used in combination with bevacizumab and
radiotherapy in the GLARIUS 2016 trial and delivered intravenously
at a dose of 125 mg/m2 every two weeks.
Green 1983 combined WBRT with intravenous BCNU (80 mg/
m2/day on three successive days every eight weeks) in their
reference arm. In the first experimental arm of this trial, BCNU
was replaced by high-dose oral methylprednisolone (400 mg/m2/
day in three divided doses for seven days) in four weekly cycles,
and their second experimental arm combined BCNU and high-dose
methylprednisolone. The last experimental arm in the trial by Green
1983, combined WBRT with procarbazine which was given orally at
a total dose of 150 mg/m2/day in three or four divided doses for 28
consecutive days every eight weeks.
Finally, Weller 2017 used rindopepimut (500 ug) admixed with 150
ug granulocyte-macrophage colony-stimulating factor (GM-CSF),
given via monthly intradermal injection in their experimental arm
and 100 ug keyhole limpet haemocyanin in their control arm, both
in combination with standard oral TMZ (150 mg/m2 to 200 mg/
m2 for 5 of 28 days) for six to 12 months or longer. In this trial,
all patients had completed standard chemoradiation with 60 Gy of
radiotherapy and concomitant TMZ prior to commencing treatment
in either the experimental or control treatment arm.
Other treatments
Carmustine wafers
Although not randomised between arms, Stupp 2017a was the
only trial that specified that treatment with implanted carmustine
wafers was permitted for patients on either arm of their trial. The
proportion of patients receiving carmustine wafers in each arm was
not reported.
Medical devices
Stupp 2017a was the only trial to use a medical device. Tumour
treating fields (TTF) comprise an external medical device that is
worn by the patient. It consists of four transducer arrays which
are connected to a portable device. These arrays are applied
to the patients’ shaved scalp via nine electrodes and emit low-
intensity, intermediate frequency (200kHz) alternating electric
fields to the brain. The patient carries the device in a backpack
and is encouraged to wear the device for at least 18 hours per day.
Determining the layouts of the transducer is performed using a TTF
mapping soMware system. Patients and their families are trained
on how to use the device and how to trouble shoot problems with
the device by nursing sta$ and a device technician. The patients
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must replace the transducer arrays twice weekly and the treatment
is delivered on an outpatient basis. Participants in the Stupp 2017a
trial were randomised aMer the completion of chemoradiation and,
therefore, the TTF treatment was given in the adjuvant setting
only in combination with TMZ, and not given concomitantly with
radiotherapy. TTF treatment was to be initiated at least four weeks
but not more than seven weeks from the last day of radiotherapy.
Supportive care
Keime-Guibert 2007 was the only trial to include supportive care
as a management option. This was used alone in the reference
arm and in combination with radiotherapy (50 Gy in 28 fractions)
in the experimental arm. Supportive care was defined as any
mixture of treatment with corticosteroids and anti-epileptics, as
well as physical and psychological support and management by
a palliative care team. There was no information on the timing of
when referral to the palliative care team was made.
Outcomes and follow-up
Table 4 outlines both the primary and secondary outcomes from
each of the included trials that were of interest for the purposes
of this review, along with the evaluation tools used to assess
each outcome. All of the included trials, except Green 1983,
reported overall survival outcomes using time-to-event analysis
and provided median overall survival for either all participants
(ARTE 2018; Keime-Guibert 2007; Malmstrom 2012; Perry 2017;
Roa 2004; Wick 2012), or for a subgroup of patients if the trial
was not restricted to recruiting elderly patients (AVAglio 2014;
GLARIUS 2016; Roa 2015; Stupp 2017a; Weller 2017). Although
reporting median survival, several trials did not provide a hazard
ratio to show the di$erence between survival for elderly patients
in di$erent treatment arms (ARTE 2018; GLARIUS 2016; Roa 2015).
Median survival data, where reported, are tabulated in Table 5.
The proportion of patients alive at six months (Roa 2004, Wick
2012), 12 months (ARTE 2018; Malmstrom 2012; Perry 2017; Wick
2012), 18 months (Perry 2017) and 24 months (Perry 2017) was
also used to report survival outcomes. Stupp 2017a and Green 1983
reported the proportion of patients who had died by the end of the
study period.
The second main outcome of interest was health-related quality of
life (HRQoL). The most common tools used to collect HRQoL data
were patient-completed questionnaires, specifically the European
Organisation for the Research and Treatment of Cancer (EORTC)
QLQ-C30 and QLQ-BN20 questionnaires. The results of HRQoL
outcomes for elderly patients using these questionnaires were
reported for five trials (ARTE 2018; Keime-Guibert 2007; Malmstrom
2012; Perry 2017; Wick 2012). Roa 2004 was the only trial to
use the Functional Assessment of Cancer Therapy-Brain (FACT-Br)
questionnaire but the results of using this tool were not reported
due to a low completion rate. Several of the studies that included
both younger and elderly patients did record HRQoL, but did
not report results of these assessments for elderly subgroups
separately (AVAglio 2014, GLARIUS 2016, Green 1983, Stupp 2017a,
Weller 2017).
Follow-up times were varied and were oMen not documented in
the trial publications. For those trials that did specify their follow-
up time, AVAglio 2014 had follow-up for at least 17 months (with
the end of study at 64 months aMer opening) and Stupp 2017a
specified a median follow-up of 40 months (interquartile range, 34
to 66 months) with a minimum follow-up of 24 months. Only two
patients in the over-65 age group were alive at 60 months of follow-
up. Wick 2012 had a minimum follow-up of 12 months (median 25.2
months (range 20.0 to not reached)). Roa 2015 specified that all
patients were followed up until death.
Excluded studies
In selecting studies for evaluation of treatment e$ectiveness,
excluded studies numbered 145 records. Studies were excluded
mainly for the following reasons.
Ineligible study design, e.g. non-randomised trial; editorial: Bent
2009; Blumenthal 2018; Boisen 2018; Boxerman 2013; Catterall
1980; Chamberlain 2005; Chong 2018; Cohen 2005; Corn 1994; Das
2017; Dherijha 2018; Espana 1978; Halperin 1993; Jeremic 1999; Koc
2008; Lamers 2008; Lorimer 2016; McCarthy 2017; Napolitano 1999;
Pinzi 2017; Reyes-Botero 2018; So$ietti 2017; Solth 2018; Stupp
2002; Vellayappan 2017 (25 studies)
Ineligible study population, e.g. not elderly participants; not newly
diagnosed glioblastoma: Ali 2018; Armstrong 2013; Athanassiou
2005; Balana 2016; Bampoe 2000; Batchelor 2013; Beije 2015;
Bhandari 2013; Bhandari 2017; Bleehen 1981; Bleehen 1991;
Blumenthal 2015; Bogdahn 2011; Boiardi 1992; Bower 1997;
Brandes 2016; Brisman 1976; Brown 2016; Buckner 2001; Buckner
2006; Carpentier 2017; Castro 1997; Chang 1983; Chau$er 2014;
Cianfriglia 1980; Clarke 2009; Combs 2008; Curran 1992; Deutsch
1989; Dinapoli 1993; Du 2018; Duncan 1986; Elinzano 2018; Eljamel
2008; Elliott 1997; Eyre 1983; Farkkila 1994; Field 2015; Field
2017; Fischer 1985; Fulton 1984; Gaber 2013; Gilbert 2013; Glinski
1993; Grossman 2003; Halperin 1996; Harada 1996; Hatlevoll 1985;
Henriksson 2006; Hiesiger 1995; Hildebrand 1994; Hitchon 1999;
Hofland 2014; Imbesi 2006; Iwadate 1993; Karacetin 2011; Kim
2011; Knerich 1990; Kocher 2008; Kochii 2000; Kong 2017; Lanzetta
2003; Lee 2015; Lenartz 2000; Levin 1979; Levin 2000; Levin 2006;
Lissoni 1993; Ludgate 1988; Mallick 2018; Mao 2015; Marshall 2006;
Montemor 2008; MRC 1983; Nabors 2015; Nelson 1988; Payne 1982;
Peszynski 1988; Phillips 2003; Prados 2001; Reagan 1976; Shapiro
1976; Shapiro 1989; Shapiro 1992; Sharma 2003; Simpson 1976;
Sneed 1998; Socha 2016; Solero 1979; Solomon 2013; Souhami
2004; Stadler 1984; Stupp 2005; Stupp 2009; Stupp 2014; Stupp
2015; Szczepanek 2013; Takakura 1986; Taphoorn 2005; Urtasun
1982; Ushio 1985; Wakabayashi 2018; Wang 2008; Weller 2003;
Werner-Wasik 1996; Westphal 2003; Westphal 2006; Westphal 2015;
Wick 2009; Wick 2016; Yang 2018; Zhu 2017 (112 studies).
Other reasons were insu$icient information (three studies:
Felzmann 2013; Felzmann 2014; Muragaki 2017) and a di$erent
study objective (five studies:Stragliotto 2013; Stummer 2006;
Stummer 2011; Stummer 2017; Westphal 2013).
Risk of bias in included studies
All included studies were RCTs and the trial quality was generally
high, with most studies assessed as having a low risk of bias overall
Figure 3. For the individual study risk of bias explanations, please
refer to the Characteristics of included studies tables.
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Figure 3.   'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study.
 
Allocation
The method of randomisation was described for all of the studies;
therefore, all studies were at low risk of bias for the sequence
generation criterion. Regarding concealment allocation at the
participant selection stage, sixr studies were assessed as being
at low risk of bias for this criterion (Green 1983; Keime-Guibert
2007; Roa 2004; Stupp 2017a; Weller 2017; Wick 2012). However,
allocation concealment was not clearly described in the other
studies, which were assessed as having unclear risk of bias for this
criterion.
Blinding
Most studies were open-label studies, therefore, were potentially at
a high risk of bias for blinding, and most did not describe assessor
blinding. However, two studies was double-blinded (AVAglio 2014;
Weller 2017) and, therefore, were assessed as having a low risk of
bias for this criterion.
Incomplete outcome data
For the primary outcome, most included studies had good follow-
up with low dropout rates. One study (Wick 2012) that compared
radiotherapy with temozolomide had relatively higher dropout
rates in the radiotherapy arm (14% versus 5%), which might have
influenced the findings. This study was assessed as having an
unclear risk of bias for this domain.” Weller 2017 had unclear risk
for this domain.
For studies that measured quality of life in an elderly population
(Perry 2017; Roa 2004; Roa 2015), attrition was a problem that
had a major impact on the quality of these findings. We therefore
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considered these studies to be at high risk of attrition bias for
quality of life findings.
Selective reporting
All studies reported pre-specified outcomes and were considered
to be at a low risk of bias for this criterion.
Other potential sources of bias
In the context of the review evidence, Stupp 2017a represented
a high risk of bias due to the timing of randomisation in this
trial. Randomisation was performed for a select group of patients
who had completed concomitant chemoradiotherapy without
progressive disease as those who died during chemoradiotherapy
or who had severe early toxicities would have dropped out by the
time of randomisation. Consequently, we decided not to include
this trial in the quantitative synthesis due to concern over networks
transitivity. .
Similarly, Weller 2017 randomised participants aMer concomitant
chemoradiotherapy and its findings would have downgraded for
indirectness; however, this trial contributed no data to meta-
analyses. All patients in the GLARIUS 2016 trial had MGMT
unmethylated glioblastoma , which is associated with a shorter
survival time than MGMT-methylated tumours. Whilst this could
bias the findings of review meta-analyses, this trial contributed no
data to pooled analyses. REview authors had no other serious risk
of bias concerns, although in some studies the risk of bias due to
protocol deviations was assessed as unclear.
Quality of economic studies
The quality of the trial on which Ghosh 2018 is based has been
discussed in the previous section (Roa 2015). The study was found
to have a low risk of bias (with the exception of the blinding,
which is open-label). The Consolidated health Economic Evaluation
Reporting Standards (CHEERs) checklist (Husereau 2013) and the
Consensus on Health Economic Criteria (CHEC (checklist (Evers
2005) were applied to the study to assess the quality of economic
evaluation as recommended but the current guidelines (Shemilt
2018). The results can be found in Table 6 and Table 7. The results of
the CHEERS reporting checklist show that a number of parameters
are not reported (e.g. sources of costs, time horizon, perspective).
The results of the CHEC checklist show that there a number of
issues with the methodological quality of the study, including
inappropriate costing and analysis methods.
E7ects of interventions
See: Summary of findings for the main comparison Summary
of findings on overall survival comparing treatments to supportive
care only; Summary of findings 2 Summary of findings on overall
survival comparing treatments to hypofractionated radiotherapy;
Summary of findings 3 Summary of findings on overall survival
comparing treatments to standard radiotherapy; Summary of
findings 4 Summary of findings on quality of life; Summary
of findings 5 Summary of findings on progression-free survival;
Summary of findings 6 Summary of findings on severe adverse
events
Results of network meta-analysis (NMA)
Network meta-analysis could only be performed for the primary
outcome of overall survival.
Overall Survival
Seven trials contributed data to this time-to-event outcome and,
across all studies included in the NMA, the following treatments
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• Four trial arms of hypofractionated radiotherapy (40 Gy/15
fractions) (RT 40)
• Five trial arms of standard radiotherapy (60 Gy/30 fractions),
including one trial utilising a 50 Gy/28 fractions (RT 60)
• One trial arm of supportive care only (SuppCare)
• Three trial arms of temozolomide (TMZ)
• Two trial arms of chemoradiotherapy, including one trial
utilising 40 Gy in 15 fractions and one utilising 60 Gy in 30
fractions (CRT)
• One trial arm of bevacizumab plus chemoradiotherapy (BEV
CRT)
• One trial arm of bevacizumab plus radiotherapy (BEV RT)
The forest plot is presented in Figure 5 and e$ect estimates and
certainty ratings for the overall survival network can be found in
Table 8. Evidence derived from the network only (i.e. where there
were no common comparators) was not graded. Pooled network
estimates suggested that, compared with supportive care only, any
of the treatments except for bevacizumab plus radiotherapy lead
to better overall survival. However, only three treatments (RT40,
RT60 and TMZ) could be compared either directly or indirectly
with supportive care through a common comparator. The graded
evidence related to the three comparisons with direct and/or
indirect evidence can be interpreted as follows.
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Figure 5.   Forest plot of all treatment comparisons for overall survival
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Figure 5.   (Continued)
 
• RT60 probably improves overall survival time compared with
supportive care only (HR 0.47, 95% CI 0.29 to 0.76; moderate-
certainty evidence)
• RT40 may improve overall survival time compared with
supportive care only (HR 0.44, 95% CI 0.25 to 0.77; low-certainty
evidence)
• TMZ may improve overall survival time compared with
supportive care only (HR 0.42, 95% CI 0.25 to 0.71; low-certainty
evidence)
• E$ect estimates of other treatment options compared with
supportive care were not graded for the reasons given in the
Summary of findings for the main comparison.
Similarly, pooled network estimates for four treatments
(CRT, BEV_CRT, TMZ, and BEV-RT ) could be compared
with hypofractionated radiotherapy (RT40) through a common
comparator, and graded evidence can be interpreted as follows.
• CRT improves overall survival time compared with RT40 (HR
0.67, 95%CI 0.56 to 0.80; high-certainty evidence). On average,
this equates to a 33% lower risk of death over the course of the
disease and a 49% increase in survival time.
• BEV_CRT probably improves overall survival time compared
with RT40 (HR 0.56, 95% CI 0.31 to 0.99; moderate-certainty
evidence)
• There may be little or no di$erence in overall survival time
between TMZ and RT40 (HR 0.95, 95% CI 0.71 to 1.26; low-
certainty evidence)
• There may be little or no di$erence in overall survival time
between BEV_RT and RT40 (HR 1.08, 95% CI 0.66 to 1.78; low-
certainty evidence)
Based on these findings, the average absolute e$ects on risk of
death and median survival time of treatments relative to supportive
care have been illustrated in Summary of findings 2.
Pooled network estimates for four treatments (RT40, BEV_RT, TMZ
and CRT) could be compared with 'standard' radiotherapy (60 Gy in
30 fractions) through a common comparator. The graded evidence
related to these comparisons can be interpreted as follows.
• There may be little or no di$erence in overall survival time
between RT40 and RT60 (HR 0.94, 95% CI 0.72 to 1.23; low-
certainty evidence)
• CRT may improve survival time compared with RT60 (HR 0.63,
95% CI 0.46 to 0.87; low-certainty evidence)
• The evidence on e$ects of TMZ and BEV_RT compared with RT60
was graded very low-certainty.
Based on these findings, the average absolute e$ects on risk of
death and median survival time of treatments relative to RT40 have
been illustrated in Summary of findings 3.
Interpretation of other graded network estimates are as follows.
• BEV_RT may be associated with shorter overall survival time
compared with CRT, however, the e$ect estimate includes the
possibility of little or no di$erence (HR 1.61, 95% CI 0.95 to 2.74;
low-certainty evidence)
• There may be little or no di$erence in overall survival time
between BEV_CRT and CRT (HR 0.83, 95% CI 0.48 to 1.44; low-
certainty evidence)
• TMZ may be associated with shorter overall survival time
compared with CRT (HR 1.42, 95% CI 1.01 to 1.98; low-certainty
evidence)
• The evidence on e$ects of BEV_RT compared with TMZ was
graded very low-certainty.
Ranking the treatments according to e7ectiveness
Table 9 gives an overview of mean SUCRA ranking of treatments
according to relative e$ects on overall survival. BEV with CRT was
ranked as the best treatment and supportive care only as the
worst treatment. The second best treatment was CRT and the third
best treatment was TMZ. These rankings should be interpreted
with caution as they do not take into account the certainty of the
evidence.
Sensitivity Analysis
Four sensitivity analyses were conducted and ranking of treatments
relative to each other remained consistent with the main network
findings (Table 9).
Overall survival data from included studies not contributing data to
the NMA
There were five trials (GLARIUS 2016, Green 1983, Roa 2015, Weller
2017 and Stupp 2017a) that did not contribute overall survival data
to the NMA. .
For the elderly subgroup of patients aged 65 and over, Green
1983 reported the number of deaths (103/107) and the death rate
(number of deaths per 10 patient months). The death rate in the
elderly subgroup was significantly higher (P < 0.00001) than in other
age groups, however there was no evaluation of how death rates
compared between the treatment groups.
For the Roa 2015 trial, a separate publication reported survival
data per protocol and by intention-to-treat (ITT) for the 61 elderly
patients (65 and over) who participated (Guedes de Castro 2017).
The median overall survival di$erence was not statistically di$erent
in patients receiving 25 Gy in 5 fractions of radiotherapy compared
to those receiving 40 Gy in 15 fractions of radiotherapy (6.8 months;
95% CI, 4.5-9.1 months compared to 6.2 months; 95% CI, 4.7-7.7
months, respectively, P = 0.936, no hazard ratio provided). The
ITT analysis was conducted separately for 'elderly and not frail'
patients and 'elderly and frail' patients and there was no significant
di$erence in overall survival detected between treatment arms for
either comparison.
For the GLARIUS 2016 trial, a separate abstract reported overall
survival data for the modified intention-to-treat (ITT population for
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patients aged 65 and over (n = 34) compared with younger patients.
In the RT + BEV/IRI arm, younger patients survived significantly
longer compared with those aged 65+ (median overall survival
of 17.5 months for patients aged under 65 versus 13.4 months
for patients aged 65+, P < 0.001). For patients treated with CRT,
no significant di$erence was found between age groups (median
overall survival for younger patients was 20.0 months compared to
17.3 months for patients aged 65+, P = 0.567). Whilst the median
overall survival for patients aged 65+ years was reported as 13.4
months and 17.3 months in the BEV/IRI and TMZ arms, respectively,
there was no direct comparison stating the level of significance for
overall survival between treatment arms performed for this age
group.
Weller 2017 reported the number of deaths for patients with
maximally resected disease (MRD) receiving rindopepimut and TMZ
(31/46) versus TMZ only (36/50), with a corresponding HR of 1.21
(95% CI, 0.71 to 2.06, P = 0.48). This was also reported for the group
of patients with significant residual disease (SRD) (HR 0.68, 95% CI,
0.39-1.19, P = 0.18). Thus, there were no clear di$erences in overall
survival between treatment arms for either participant population.
Lastly, in Stupp 2017a, tumour treating fields plus
adjuvant temozolomide (TTF_AC) was compared with adjuvant
temozolomide only among patients receiving CRT. In the subgroup
of patients 65 years and older, the estimated HR was 0.51 (95%
CI, 0.33 to 0.77) in favour of TTF_AC, with 11% of participants in
the TTF_AC (10/89) and 4% (2/45) in the CRT only group alive by
the end of the study. This trial was not incorporated into NMA
because participants were randomised aMer they had received
radiotherapy and concomitant chemotherapy (i.e. participants
received treatment prior to the study interventions), while other
studies in the NMA randomised participants before they had
received radiotherapy or chemotherapy (i.e. were participants were
treatment-naive).
Other Outcomes
Evidence from pairwise comparisons of trial data pertaining to
elderly participants is reported by treatment comparison below.
Radiotherapy versus supportive care
One study (Keime-Guibert 2007) with 81 participants contributed
data to this comparison.
Health-related quality of life (HRQoL)
Evidence related to HRQoL at 30, 60, 90 and 135 day time points
aMer diagnosis. The data suggested slightly better HRQoL scores
among people receiving supportive care at the first three time
points, and slightly better HRQoL scores for the radiotherapy arm
at the 135 day time point (Analysis 1.1). This study also reported
cognition (Analysis 1.2) and fatigue scores (Analysis 1.3) for these
time points. At the furthest time point (135 days), cognition scores
favoured the supportive care arm, whereas there was no clear
di$erence in fatigue scores between the study arms at any time
point. As evidence was derived from a single small study with high,
unequal attrition (low response rate to questionnaires and more
deaths occurring in the supportive care group), we assessed the
HRQoL findings as low-certainty evidence.
Progression-free survival
Evidence suggested that radiotherapy probably improves
progression-free survival compared with supportive care only
(HR 0.28, 95% CI 0.17 to 0.46; moderate-certainty evidence, with
downgrading as evidence was derived from a small single study).
Severe adverse events
Not reported.
Hypofractionated radiotherapy versus standard radiotherapy (60 Gy)
One included study compared 40 Gy/15 fraction schedule with a
60 Gy/30 fraction schedule (Roa 2004) and another compared a 25
Gy/5 fraction schedule with a 40 Gy/15 fraction schedule (Roa 2015),
therefore data were not pooled.
Health-related quality of life (HRQoL)
Data were reported at four weeks and eight weeks aMer treatment
in Roa 2015 and these suggested that there may be little or no
di$erence in HRQoL between 25 Gy/5 fraction and 40 Gy/15 fraction
schedules at either time point aMer the one-week and three-week
treatment schedules, respectively (Analysis 2.1; Analysis 2.2). In
Roa 2004, HRQoL data were measured using the KPS at three and
six weeks aMer treatment as medians with interquartile ranges
(IQRs) and, similarly suggested little or no di$erence in e$ect on
HRQoL. Subsequent follow-up of participants in Roa 2004 also
suggested little di$erence in average HRQoL scores, however,
attrition increased with time. We downgraded the certainty of this
narrative evidence of little or no di$erence in HRQoL to low (sparse
data [-1] and attrition bias [-1]).
Severe adverse events
There were no instances of grade 3 or higher treatment-related
toxicity in Roa 2004 (Analysis 2.3), and this outcome was not
reported in Roa 2015.
Progression-free survival
This was not reported in Roa 2004. Roa 2015 provided a KM
curve but not a hazard ratio for (HR) progression-free survival.
Alongside the KPM curve, it was reported that median progression-
free survival showed no statistically significant di$erence between
arms (4.2 versus 4.2 months in arms 1 and 2, respectively; P = 0.716).
We did not grade this evidence.
Chemotherapy (TMZ) versus radiotherapy
Two studies contributed overall survival data for this comparison
(Malmstrom 2012; Wick 2012) but only one of them (Wick 2012)
reported additional outcomes separately for the elderly population
of interest.
Health-related quality of life
Wick 2012 reported no clinically meaningful or significant
di$erences in overall QoL scores at 3, 6, or 12 month measurements
or other individual QoL items (emotional function, social function,
nausea and vomiting, fatigue, loss of appetite, future uncertainty),
except for discomfort from communication deficits, which were
greatest for patients in the radiotherapy group who died at between
six and 12 months (P = 0.002). They were presented graphically over
time in a supplementary appendix without raw data.
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Progression-free survival
Evidence from Wick 2012 suggested that there may be little or no
di$erence in event-free survival (where events were progression or
death) between TMZ and standard radiotherapy (373 participants;
HR 1.15, 95% CI 0.92 to 1.44; Analysis 3.1; low-certainty evidence,
downgraded for study design limitations and imprecision).
Severe adverse events
Evidence derived from Wick 2012 (373 participants) suggested that,
compared with standard radiotherapy.
• TMZ increases the risk of thromboembolic events (Analysis
3.2) and increases the risk of severe (grade 3+) neutropenia,
lymphopenia, and thrombocytopenia (Analysis 3.3; Analysis 3.4;
Analysis 3.5; moderate-certainty evidence, downgraded -1 for
imprecision); however the confidence intervals are imprecise
and the actual e$ect may di$er from the point estimate in these
analyses.
• There may be little or no di$erence in the risk of
serious infection, fatigue, nausea and vomiting, weight loss,
neurological symptoms, seizures, elevated liver enzymes, and
cutaneous adverse events (Analysis 3.6; Analysis 3.7; Analysis
3.8; Analysis 3.9; Analysis 3.10; Analysis 3.11; Analysis 3.12;
Analysis 3.13; all low-certainty evidence, downgraded -2 for
serious imprecision).
Chemoradiotherapy (TMZ plus radiotherapy) versus radiotherapy
Evidence from one study (Perry 2017) contributed data to
outcomes other than overall survival for an elderly population. The
radiotherapy schedule used in this study was 40 Gy in 15 fractions.
Health-related quality of life
This was briefly reported in Perry 2017 and investigators noted that
attrition impacted the quantity of data. They conducted analyses
using time to deterioration (with deterioration defined as a 10-point
decrease in the score on the function domain or a 10-point increase
in the score on the symptom domain) and plotted QoL scores
over time. They reported that quote: "only nausea and vomiting
and constipation were associated with significant di$erences in
time to deterioration, which was shorter in the CRT group than in
the radiotherapy alone group. They reported that ".There were no
other clinically important di$erences between trial groups, which
supports our observation that quality of life was similar in the two
treatment groups." We did not grade this evidence.
Progression-free survival
The evidence suggested that chemoradiotherapy delays disease
progression compared with radiotherapy only (562 participants; HR
0.50, 95% CI 0.41 to 0.61; Analysis 4.1; high-certainty evidence).
Severe adverse events
Evidence suggested that chemoradiotherapy probably increases
the risk of grade 3+ neutropenia, thrombocytopenia, and
leucopenia, however the confidence intervals are imprecise and the
actual e$ect may di$er from the point estimate in these analyses.
(Analysis 4.2; Analysis 4.3; Analysis 4.4; Analysis 4.5; moderate-
certainty evidence, downgraded for imprecision).
Other evidence suggested that there is probably little or no
di$erence in grade 3+ anaemia (Analysis 4.6) and other grade 3+
treatment-related toxicity (Analysis 4.7) (both moderate-certainty
evidence, downgraded due to imprecision).
Bevacizumab plus CRT (TMZ plus radiotherapy) versus CRT
One study with 73 participants (AVAglio 2014) contributed data to
this pairwise comparison.
Health-related quality of life
This was reported for overall trial but not for elderly subgroup
specifically (for overall findings, see below).
Progression-free survival
Evidence suggested that adding bevacizumab to
chemoradiotherapy may make little or no di$erence to disease
progression (HR 0.78, 95% CI 0.46 to 1.32; low-certainty evidence,
downgraded due to imprecision and study design limitations;
Analysis 5.1).
Severe adverse events
Evidence suggested that adding bevacizumab to
chemoradiotherapy probably increases the risk of grade 3+
thromboembolic events compared with CRT alone (RR 16.63, 95%
CI 1.00 to 275.42; moderate-certainty evidence, downgraded due to
imprecision; Analysis 5.2). No other adverse events were reported
for the elderly only. Serious adverse events reported for the overall
sample including younger participants can be found below.
Bevacizumab plus radiotherapy versus radiotherapy
One study with 75 participants (ARTE 2018) contributed data to this
pairwise comparison.
Health-related quality of life
In the publication, global health was reported in a forest plot
along with individual HRQoL items, such as cognitive functioning,
emotional functioning and pain, measured with EORTC QLQ-
C30/BN20 scales. Investigators reported that quote: "before
progression, no di$erences were detected for individual scales in a
generalized linear mixed model, except for less favourable values in
arm A for global health (P=0.048) and pain (P=0.027)". No other data
were provided or obtained and we did not grade this evidence.
Progression-free survival
Evidence suggested that adding bevacizumab to radiotherapy
probably delays disease progression (HR 0.46, 95% CI 0.27 to 0.78;
moderate-certainty evidence, downgraded due to study design
limitations; Analysis 6.1).
Severe adverse events
Low-certainty evidence suggested that there may be little or
no di$erence in various grade 3+ adverse events reported
in this study, including thromboembolic events (Analysis 6.3);
haematological events (Analysis 6.2); infections (Analysis 6.4);
fatigue (Analysis 6.5); seizures (Analysis 6.6); headache (Analysis
6.7); neuropsychiatric events (Analysis 6.8); neurological events
(Analysis 6.9); hypertension (Analysis 6.10); cutaneous adverse
events (Analysis 6.11); and gastrointestinal events (Analysis 6.12).
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Other comparisons did not report progression-free survival for the
elderly subgroups of participants.
Health-related quality of life (HRQoL) and adverse event data
not specific to elderly patients
Several of the included studies (AVAglio 2014; GLARIUS 2016;
Green 1983; Malmstrom 2012; Roa 2004; Stupp 2017a; Weller
2017) reported HRQoL or adverse event data for the overall trial
population but not separately for the elderly subgroup of patients.
Although they are not specific to the elderly population, these
overall findings may give some indication of the degree of toxicity of
the treatments and any detriment to patients' quality of life for the
elderly subgroup too. We have therefore presented the main results
below with corresponding P values when available. This evidence
is not rated for certainty.
Health-related quality of life (HRQoL)
• Malmstrom 2012 measured HRQoL at baseline, six weeks and
three months using EORTC QLQ-C30 and BN-20 questionnaires.
Patients in the TMZ arm generally reported better quality of life
than in either of the radiotherapy arms (60 Gy and 34 Gy), but
ratings for global health status were similar.
• AVAglio 2014 reported HRQoL outcomes in a separate
publication (Taphoorn 2015). The addition of BEV to CRT delayed
deterioration (reported as deterioration-free survival (DFS))
across five pre-selected HRQoL scale measures (global health,
physical functioning, social functioning, motor dysfunction and
communication deficit). Deterioration was defined as a clinically
significant deterioration in HRQoL (worsening of 10 or more
points on the respective HRQoL scale), progressive disease, or
death. It was suggested that the delayed disease progression
in the BEV_CRT arm (reported in the main publication) may
have influenced the DFS result. When progressive disease
was excluded as an event, participants treated with BEV_CRT
had a statistically significantly delayed deterioration in HRQoL
domains of communication, social functioning and global
health but not for motor dysfunction or physical functioning.
• GLARIUS 2016, which compared treatment with CRT versus
treatment with RT60 in combination with concomitant and
adjuvant bevacizumab and adjuvant irinotecan, reported
HRQoL using QLQ C30 and BN20 questionnaires measured at
baseline and every three months until death or end of study.
There was no significant di$erence between the treatment arms.
• Weller 2017 compared adding rindopepimut or control to
adjuvant TMZ aMer CRT and reported no significant di$erences
between patients in their trial arms in any of the HRQoL
measures.
• Stupp 2017a reported HRQoL in a separate publication
(Taphoorn 2018). There was no significant di$erence in HRQoL
reported between the trial arms, except for itchy skin which was
more prominent in the TTF arm at 3, 6 and 9 months (P = 0.005,
P = 0008, P = 0.04). There was no significant di$erence at 12
months.
Severe adverse events (Common Terminology Criteria for
Adverse Events (CTCAE) grade 3+)
• Green 1983 reported the percentage of patients in each of
the four trial groups that experienced specific toxicities. The
proportion of patients in the procarbazine arm who su$ered a
grade 3+ dermatologic or allergic reaction (25%) and nausea
and/or vomiting (12.5%) were both significantly higher than for
the other three arms of the trial. Infection rates were highest
for the BCNU and methylprednisolone arm (34.3%) and rates
of uncontrolled diabetes and skeletomuscular complications
were highest for the methylprednisolone arm (3.5% and
7.8% ,respectively).
• Malmstrom 2012 reported toxicity using WHO grading for
adverse events, except for nausea and vomiting for which
they used the CTCAE version 2.0. In the overall population,
episodes of grade 3+ haematological toxicities (neutropenia,
pancytopenia and thrombocytopenia) were only seen in the
TMZ arm. The incidence of grade 3+ seizures and fatigue was
more common in the radiotherapy arms compared to the TMZ
arm. Infection rates were similar across all arms. There were two
patients who had fatal infections, one in the TMZ group and one
in the 60 Gy RT group. There was one death in the TMZ group
attributed to bleeding due to grade 2 thrombocytopenia.
• AVAglio 2014 used CTCAE v3.0 to measure severe adverse events.
Grade 3+ cerebral bleeding events (2.0% versus 0.9%) and
wound healing events (3.3% versus 1.6%) were higher in the BEV
plus CRT arm versus CRT alone. There were also higher rates of
G3+ thrombocytopenia (15% versus 9.8%) and infection rates
(12.8% versus 7.8%) in the BEV arm.
• GLARIUS 2016 used CTCAE v3.0 to measure severe adverse
events. Rates of severe adverse events were 72% for the
bevacizumab (BEV)-irinotecan (IRI) plus RT 60 arm, and 84% in
the CRT arm. For the BEV/IRI/RT60 arm, severe vascular events
were most common (11.8%) and two cerebral haemorrhages
occurred (one fatal). For patients in the CRT arm, severe
haematological toxicity was most common (18.2%).
• In Weller 2017, the most common severe adverse events for
the experimental (rindopepimut) versus placebo arm of the trial
were: thrombocytopenia (9% versus 6%), fatigue (2% versus
5%), brain oedema (2% versus 3%), seizure (2% versus 2%) and
headache (2% versus 3%). There was one death, secondary to
pulmonary embolism, that was assessed as potentially related
to the treatment in the experimental arm.
• Stupp 2017a reported that there was no significant increase
in rates of severe adverse events when TTF were added to
adjuvant chemotherapy (48% versus 44%, P = 0.58). There was
a numerically higher incidence of some adverse events in the
TTF group but the authors report that this was a reflection of the
longer duration of TMZ treatment in this group due to delayed
occurrence of progression and that the di$erence disappeared
when adverse event incidence was normalised to duration of
treatment. There was a higher incidence of skin toxicity (grade 3
in 2%) for the TTF arm compared to the control arm.
Economic evidence
The economic evaluation that was identified (Ghosh 2018) was
a cost-e$ectiveness analysis (CEA) and cost-utility analysis (CUA).
The associated study compared the use of a short course of
radiotherapy in elderly patients based on the trial by Roa 2015. The
trial reports clinical outcomes were expressed as overall survival
and progression-free survival for the CEA and as quality adjusted
life years (QALYs) for the CUA (Table 10).
Direct unit medical costs (i.e. costs which result from the utilisation
of the medical intervention) were collected from the associated
trial (Roa 2015). The costs were broken down for each country
participating in the trial. These costs were shown in an additional
table. No indirect costs (i.e. costs associated with losses as a
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consequence of illness, such as production or leisure time lost to
patients and their families) were included. The direct costs included
the costs of the dexamethasone, magnetic resonance imaging (MRI)
scans, computed tomography (CT) scans and radiotherapy (Table
11). The authors presented costs as USD 2015, but did not describe
the methods for converting the costs from the various participating
countries. The mean total cost of the 25 Gy arm was $2,475 and
the mean total cost for the 40 Gy arm was $2,868. The authors
report that confidence intervals were undefined for the di$erence
in cost due to the negative -cost di$erence, although the scientific
rationale for this statement is unclear, as there is no reason why a CI
could not be estimated when the point estimate for the di$erence in
cost between the short course and commonly used RTs is negative.
The results of the cost-e$ectiveness were expressed as Incremental
Cost E$ectiveness Ratios (ICERs). The reported ICERs in USD were -
$3,062 for the restricted mean overall survival per life-year gained
and -$17,693 USD for the restricted mean progression-free survival.
The presentation of negative ICERs is not advised, as negative data
points have no meaningful ordering (O'Brien 2002). For overall
survival, the study reports a net benefit with 25 Gy of -$46,907
at a societal willingness to pay level $50,000, a net benefit of -
$93,438 at the $100,000 threshold, and a net benefit of -$159,970
at the $200,000 threshold. For progression-free survival, net benefit
is reported as -$1,933 at the $50,000 threshold, -$4,241 at the
$100,000, and -$8,680 at the $200,000 threshold. Given the clinical
outcome data presented in the paper, it is unclear how these
numbers are calculated as they do not make intuitive sense.
The utility values for the CUA were derived from three di$erent
mapping algorithms from the EORTC QLQ-C30 questionnaire
(Kontodimopoulos 2009;Kim 2012; McKenzie 2009). Two reviews
have identified limitations in using the EORTC QLQ-C30 mapping
algorithms and the three algorithms used in this study performed
poorly in validation tests, so their outputs should be used
cautiously (Doble 2016; Woodcock 2018). The authors held the
assumption that the participants would survive for four months
with either treatment. The QALY valued for the 40 Gy treatment
was therefore: QALY overall = 0:333 times the utility obtained
at baseline. However, the QALY calculated using the mapping
algorithm was calculated as: QALY = Utility at month 1 times 0:083
+ Utility at month 4 times 0:333. This would result in a 25 Gy-
treated QALY being calculated for five months, whereas the 40 Gy
treated individual was being calculated for four months, which
was against the authors stated assumption. This means that the
gains calculated for the QALY ICERs may be due to this potential
calculation error rather than the e$ect of the intervention itself.
Stochastic sensitivity analysis was carried out in the form of
bootstrapping to assess sampling uncertainty. The authors did
not carry out a deterministic sensitivity analysis, as variation in
cost and survival e$ect size were analysed using the bootstrap
procedure and cost-e$ectiveness acceptability curves. This is not
in line with current UK guidelines (NICE 2012) who recommend
the use of deterministic and probabilistic sensitivity analysis
to assess parameter uncertainty. The International Society of
Pharmacoeconomics and Outcomes Research (ISPOR) guidelines
also recommend the examination of parameter uncertainty
(Husereau 2013).
The authors conclude that since their ICER values are less than the
threshold, they can conclude that the 25 Gy radiotherapy is cost-
e$ective. The review authors cannot replicate the results of this
economic evaluation from the data presented and the study results
should be considered with extreme caution. As this was the only
study identified and has potential quality issues, this demonstrates
a paucity of economic evidence regarding the management of
newly diagnosed glioblastoma in the elderly.
Quality of Economic studies
The quality of the trial on which Ghosh 2018 is based (Roa 2015)
has been discussed in Risk of bias in included studies. The study
was found to have a low risk of bias (with the exception of the
blinding, which was open-label). The CHEERs checklist (Husereau
2013) and the CHEC checklist (Evers 2005) were applied to the study
to assess the quality of economic evaluation as recommended
by the current guidelines (Shemilt 2018). The results from these
can be found in Table 6 and Table 7. The results of the CHEERS
reporting checklist show that there a number of parameters are
not reported (e.g. sources of costs, time horizon, perspective).
The results of the CHEC checklist show that there a number of
issues with the methodological quality of the study, including
inappropriate costing and analysis methods.
D I S C U S S I O N
Summary of main results
The review included 12 studies involving approximately 1818
elderly participants and several di$erent treatment comparisons.
Seven treatment options could be connected in a network meta-
analysis (NMA) for the outcome of overall survival. Other treatments
and outcomes were evaluated in pairwise comparisons where data
were available.
Overall survival
We found high-certainty evidence that chemoradiotherapy results
in a 33% lower risk of death on average over the course of the
disease aMer diagnosis (20% to 44% lower), or about a 50% increase
in survival time compared to treatment with hypofractionated
radiotherapy (RT) (40 Gy) alone. Other evidence was assessed as
moderate to very low certainty, with most evidence graded as low
or very low certainty, meaning that the e$ect estimates may be
substantially di$erent from those estimated in our network meta-
analysis (NMA). However, all treatments evaluated led to a clear
increase in survival time relative to supportive care only, except for
the bevacizumab plus radiotherapy option.
In terms of treatment rankings, bevacizumab (BEV) added to
chemoradiotherapy (CRT) ranked as the best treatment, CRT
ranked second best, temozolomide (TMZ) ranked third best,
hypofractionated radiotherapy fourth, and supportive care only
ranked last. These ranking should be interpreted with caution as
they do not take into account the certainty of the evidence, notably
that there may be little or no di$erence in overall survival when BEV
is added to CRT. Therefore, the higher position of BEV_CRT in the
ranking is not supported by evidence of a clear survival benefit over
CRT. On sensitivity analysis, when CRT40 (with 40 Gy RT) and CRT60
(with 60 Gy RT) interventions were considered separately, CRT (with
RT40 Gy) ranked first in the larger of the two networks thus created.
Summary of findings with illustrative e$ects can be found in
the Summary of findings for the main comparison, Summary
of findings 2 and Summary of findings 3. We were unable
to conduct subgroup analyses by age threshold (65+ or 70+
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year threshold), or methylguanine-DNA-methyltransferase (MGMT)
methylation status; few included studies reported the latter and
where these data were present, they were usually reported for the
sample overall and not for the elderly subgroup.
Quality of life
Moderate-certainty narrative evidence suggests that overall, there
may be little di$erence in quality of life between TMZ and
radiotherapy, except for discomfort from communication deficits,
which were more common with radiotherapy. Data on quality of
life for other treatment comparisons were sparse and negatively
impacted by attrition, with the limited available evidence derived
from elderly participants suggesting little or no di$erence in
quality of life with radiotherapy versus supportive care only,
and short course versus longer/standard radiotherapy courses
(Summary of findings 4). Narrative evidence from a single study
of chemoradiotherapy versus radiotherapy only suggesting little
di$erence in quality of life was not graded.
Progression-free survival
High-certainty evidence shows that chemoradiotherapy delays
disease progression compared with hypofractionated radiotherapy
only. Moderate-certainty evidence suggests that radiotherapy
with 60 Gy probably delays disease progression compared
with supportive care only and that bevacizumab with
radiotherapy probably delays disease progression compared with
hypofractionated radiotherapy alone. Evidence for other treatment
comparisons is of low or very low certainty.
Severe adverse events
Moderate-certainty evidence suggests that severe haematological
toxicities and thromboembolism are more common with TMZ than
with radiotherapy and the risk probably increases with the addition
of BEV to CRT.
Economic evaluations
The review identified a single economic evaluation in the target
population. This study had a number of issues relating to
methodological quality so the results should be interpreted very
cautiously. This demonstrates a current lack of economic evidence
evaluating di$erent strategies of managing of newly diagnosed
glioblastoma in the elderly. Other economic evaluations that were
identified did not consider the over 65's with newly diagnosed
glioblastoma as a relevant population or subgroup.
Overall completeness and applicability of evidence
The only outcome that could be assessed in a network was that of
overall survival. Thus, it is not known how the treatment options
compare with regard to the other important review outcomes,
such as quality of life or severe adverse events. This is a serious
limitation of the evidence gathered in this review as a treatment
ranked as best for overall survival, for example, could be worst
for quality of life. More research on quality of life among patients
receiving treatment for glioblastoma is necessary to elucidate these
other relative e$ects. However, attrition is a notable problem for
investigators gathering these sorts of data.
In general, the review evidence is applicable to elderly patients with
a Karnofsky Performance Score of more than 70 per cent, i.e. those
patients capable of self-care (see Table 3). We found little evidence
to inform guidance on the most appropriate treatments for people
with KPS less than 70 percent. Two studies that evaluated di$erent
hypofractionated radiotherapy regimen included patients at the
frailer end of the spectrum, using a KPS of 50 percent (Roa
2004; Roa 2015). Evidence from Roa 2015 suggested little or no
di$erence in the median survival between a 25 Gy/5 fraction
regimen and the 40Gy/15 fraction regimen among elderly and frail
patients; however, the e$ectiveness of the 25Gy/5 fraction regimen
could not be evaluated against other possible treatment options
in the network due to insu$icient data. Malmstrom 2012 also
permitted entry to their trial of patients (7/291 patients) with a WHO
performance status of 3 if this was specifically due to neurological
status. However, this was a minority of patients and the outcomes
for these patients were not reported separately.
Data were also relatively scarce for certain treatments, particularly
newer treatment options (e.g. those employing bevacizumab)
and some treatment options lacked overall survival data in
a comparable form (e.g. radiotherapy given as 25Gy in five
fractions); therefore, such treatments could not be ranked at all
against other treatments. Crucially, we were unable to compare
chemoradiotherapy utilising 60 Gy in 30 fractions (standard)
with hypofractionated regimens, either directly or indirectly, due
to limitations of the network connections. Therefore, we could
not ascertain a network e$ect estimate for standard versus a
hypofractionated chemoradiotherapy regimen, nor rank these
di$erent regimen.
One study (Roa 2015) compared two hypofractionated
chemoradiotherapy regimen (25 Gy in five fractions versus 40 Gy in
15 fractions). Unfortunately, we were unable to compare and rank
the 25 Gy radiotherapy regimen because the overall survival data
in this study were reported as median survival times with P-values,
rather than as time-to-event data (HRs and 95% CIs). The di$erence
in median survival was not statistically significant (P=0.936). We
rated the resulting evidence as low-certainty. We were unable to
obtain the relevant time-to-event data from the investigators for
this review.
In addition to the limitations of the evidence with respect to
performance status mentioned above, there were very few data on
health-related quality of life (HRQOL) and severe adverse e$ects
reported specifically for elderly patients. In studies where the
elderly were a subgroup of a sample with a broader age range,
these outcomes were frequently reported by investigators for the
overall sample. When we found no specific data on these outcomes
for the elderly, we reported the main findings for the broader age
group at the end of the results section. However the applicability of
these findings to an elderly population is not known and the actual
relative e$ects may be quite di$erent.
Quality of the evidence
The network evidence that was rated as high quality/certainty was:
• chemoradiotherapy increases time to death and delays disease
progression compared with hypofractionated radiotherapy.
Evidence of moderate quality/certainty, meaning that our actual
e$ect may di$er somewhat from our point estimate (or may change
with further research), included the following:
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• chemoradiotherapy increases the risk of grade 3+
neutropenia, thrombocytopenia, and leucopenia compared
with hypofractionated radiotherapy alone;
• bevacizumab plus chemoradiotherapy increases time to death
compared with hypofractionated radiotherapy alone;
• standard radiotherapy increases time to death and delays
disease progression compared with supportive care only;
• bevacizumab plus radiotherapy delays disease progression
compared with hypofractionated radiotherapy alone;
• temozolomide increases the risk of grade 3+ thromboembolic
events, neutropenia, lymphopenia, and thrombocytopenia
compared with standard radiotherapy; and
• bevacizumab plus chemoradiotherapy increases the risk of
thromboembolic events compared with chemoradiotherapy
alone.
Other evidence was low or very low quality/certainty and the e$ect
estimates (if any) are likely to change with further research. Data on
quality of life were sparse and the certainty of the evidence tended
to be of very low quality/certainty or unrateable.
SUCRA sSurface under the cumulative ranking curve) ranking
does not take into account the certainty of the evidence and a
high-ranked treatment may be based on low-certainty evidence
(Mbuagbaw 2017). In our main NMA, the evidence on bevacizumab
added to chemoradiotherapy compared with chemotherapy alone
was less robust than the evidence on chemoradiotherapy alone;
however, it ranked higher than the latter. When compared with
chemoradiotherapy, low-certainty evidence suggested that the
addition of bevacizumab to chemoradiotherapy did not improve
overall survival, highlighting that rankings should be interpreted
with caution and that more research evidence may be needed to
improve the certainty of the rankings.
Potential biases in the review process
There were some important di$erences between trial inclusion
criteria, treatments and outcome reporting that could not be
accounted for in this review process and could have contributed to
potential bias.
Definitions of 'the elderly'
Eight trials defined the elderly subgroup as 65+ years old (ARTE
2018; GLARIUS 2016; Green 1983; Perry 2017; Roa 2015; Stupp
2017a; Weller 2017; Wick 2012), and only three studies contributed
data for the elderly according to the review focus of 70+ years
old (AVAglio 2014; Keime-Guibert 2007; Malmstrom 2012) (Table 2).
People aged between 65 and 70 years were shown to have a longer
median survival compared with those of 70+ years (6 months versus
3.2 months, respectively) in a large UK audit (Brodbelt 2015). Our
decision to pool data for these studies was pragmatic and taken at
the protocol stage, because we knew that data specifically for the
70+ age group would be sparse.
We also included one study (Roa 2004) that defined elderly patients
as aged 60+ years because the review protocol dictated that the
overall results from trials including younger patients could be
included if the proportion of patients in the trial aged over 65 years
exceeded 80%. In Roa 2004, the mean participant age was 72.4
years for patients treated with 60 Gy and 71.0 years for patients
treated with 40 Gy. The standard deviation for these groups was 5.4
and 5.5 years, respectively. Therefore the majority of participants
in this trial were likely to be aged over 65 years; whether the
proportion exceeded 80% as per our inclusion criteria is unclear.
AMer attempting to contact the authors of Roa 2004, with no further
information on the proportion of patients included aged over 65
years obtained, we decided to include this study based on this
rationale. The median survival of 5.1 months in the RT60 arm of
this trial was similar to the median survival reported by Malmstrom
2012 for patients aged 70+ who received 60 Gy (5.2 months), and
less than the median survival reported for patients aged 70+ in
Keime-Guibert 2007 (29.1 weeks), who received 50 Gy, and for
patients aged 65+ in Wick 2012 (9.6 months) who received 60 Gy.
As younger participants survive longer than older participants, the
e$ect of including studies with 65+ year old participants might have
over-estimated the beneficial e$ects of treatments for the 70+ year
old age group.
Radiotherapy treatment
Green 1983 was the oldest study included in the review and was
published 21 years before the next included study (Roa 2004). As
whole brain radiotherapy was used (WBRT) was used in Green
1983, the radiotherapy volume treated was much larger than the
treatment volumes specified for the other trials that included
radiotherapy. The larger treatment volume and likely sub-optimal
planning and treatment delivery techniques would be considered
unacceptable by modern standard and is likely to have a$ected
the tolerability of the treatment and the rate of adverse events,
especially for elderly patients. Whilst we included this trial, it
did not contribute survival data to the NMA or data for pairwise
comparisons of other review outcomes, therefore any potential
bias introduced by including this study would be minimal.
Timing of randomisation
Most trials randomised patients in the period following surgical
resection when they were radiotherapy- and chemotherapy-naive.
Two trials (Stupp 2017a; Weller 2017) performed randomisation
aMer patients had completed concomitant CRT and both specified
that patients must have received at least 90% of the planned
radiotherapy dose (60 Gy). This will have selected for a group of
patients with a better prognosis than those in trials using the earlier
time point of randomisation, by excluding those patients who were
unable to tolerate treatment due to adverse events or who died
or progressed prior to finishing radiotherapy. Whilst Stupp 2017a
reported relevant time-to-event data for the elderly subgroup, we
did not include these data in the NMA due to the risk of intransitivity.
Survival times
Most of the included studies (including Stupp 2017a and Weller
2017, which randomised participants aMer concomitant CRT)
calculated overall survival from the time of randomisation, but for
several studies the starting point for overall survival analysis was
not described (ARTE 2018; AVAglio 2014; GLARIUS 2016) and for one
trial (Wick 2012), overall survival was measured from the date of
surgery.
Tumour response assessment
For those trials that reported a response rate or progression-
free survival, several (ARTE 2018; AVAglio 2014; Keime-Guibert
2007; Perry 2017; Stupp 2017a; Weller 2017; Wick 2012) used
repeated magnetic resonance imaging (MRI) for the basis of
their assessments. Roa 2015 did not specify the modality of
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imaging and in Keime-Guibert 2007, imaging was permitted with
MRI or computed tomography (CT). ARTE 2018 and Weller 2017
used the response assessment in neuro-oncology (RANO) criteria
(Wen 2010), GLARIUS 2016; Stupp 2017a; Wick 2012 specified
the MacDonald criteria (MacDonald 1990), and AVAglio 2014;
Keime-Guibert 2007; Perry 2017 described their response criteria,
which were based on specific MRI appearances and/or steroid
use and symptoms. Roa 2015 did not specify the criteria used.
Although there are similarities between these response criteria, the
di$erences may mean that the response rate or progression-free
survival. results across these trials are not comparable.
Extent of surgical resection
Extent of surgical resection influences prognosis (Pessina 2018).
Most trials permitted inclusion of patients who had undergone
biopsy or partial or complete surgical resection. In the Keime-
Guibert 2007 trial, which was one of the older included studies, at
least half the participants had biopsy only. Including this trial in
the NMA might, therefore, have led to the e$ect on overall survival
estimated for other treatments to be slightly over-estimated.
In the trial by Weller 2017, the primary analysis was conducted on
patients who had maximal surgical resection (MRD) only. Whilst in
the context of NMA, this could have favourably biased the e$ect
of the study intervention, Weller 2017 did not contribute data to
the NMA, therefore did not bias the NMA findings. The extent of
resection was not described in ARTE 2018, and we did not evaluate
the extent of possible bias from including this trial; however, the
direct evidence derived from this trial in the NMA was rated low
certainty.
Molecular subtypes
Two trials included patients with disease of particular molecular
subtypes only, which may not have been comparable with
patients included in other trials. Weller 2017 specified that only
patients with glioblastoma with confirmed epidermal growth factor
receptor (EGFR) vIII expression were eligible for trial inclusion. The
rationale was that rindopepimut was most likely to be active in
disease expressing this mutation. This explains the relatively small
number of patients enrolled (n = 745) compared to the number
assessed for eligibility (n = 4652). In the GLARIUS 2016 trial, only
patients with unmethylated MGMT were eligible for trial inclusion.
As MGMT methylation has a known prognostic e$ect on survival of
patients with glioblastoma , it is important to consider the results
of this trial and how they compare to results from other trials in this
context.
Analysis and grading
For the main NMA for overall survival, comparing all treatments
with supportive care only, we made the following assumptions:
• that it was reasonable to pool data on chemoradiotherapy
(combined TMZ and radiotherapy), irrespective of the
radiotherapy dose schedule used (40 Gy/15 fractions and 60
Gy/30 fractions in Perry 2017 and AVAglio 2014, respectively);
• that data on a 50 Gy/28 fraction radiotherapy schedule from the
one study (Keime-Guibert 2007) employing this unconventional
dose schedule could be pooled with those of 60 Gy/30 fraction.
The rationale for the first assumption was that 'standard'
chemoradiotherapy might include either radiotherapy schedule
combined with TMZ. In addition, pairwise analysis suggested
that there was no clear di$erence in overall survival between
40 Gy/15 and the 60 Gy/30 schedules when employed without
chemotherapy. However, the decision to pool these data was also
influenced by the fact that pooling these data would facilitate
a connected network. To evaluate the extent to which the first
assumption impacted the findings of the review, we conducted a
sensitivity analysis by not pooling these data, which resulted in a
network with a disconnected (separate) comparison (Figure 6C).
Findings of the relative e$ects of the interventions were similar
to the main findings and made no di$erence to the treatment
ranking of chemoradiotherapy. In grading this evidence, we
therefore did not downgrade the evidence on chemoradiotherapy
for intransitivity (di$erences in study characteristics that may
modify treatment e$ect) because intransitivity did not appear to
have a serious impact on the estimates of e$ect.
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Figure 6.   Network diagrams for four sensitivity analyses
 
With respect to the second assumption, we performed a sensitivity
analysis by pooling the Keime-Guibert 2007 data (RT50 Gy) with
the 40 Gy/15 fraction node (Figure 6A) and found that this also
made no di$erence to the treatment rankings. Similarly, we did not
downgrade the evidence for intransitivity.
The only loop in the network was derived from a single study with
three arms (Malmstrom 2012), which led to duplication of data at
the hypofractionated RT node in the main analysis. To evaluate the
impact of this on the findings, we performed a sensitivity analysis
by removing one of the study arms (TMZ versus hypofractionated
RT) (Figure 6B). This made little di$erence to e$ect estimates
and treatment rankings, therefore we did not downgrade for
intransitivity (di$erences in study characteristics that may modify
treatment e$ect).
Where studies evaluated the radiotherapy schedules only (i.e.
without chemotherapy), we did not pool data for 40 Gy/15 and 60
Gy/30 schedules. However, we conducted an exploratory analysis
by collapsing these nodes to evaluate the extent to which so doing
would have impacted on the review findings.
Because most treatments were not part of a loop in the main
network analysis, and the only loop came from a single study
such that the results for the nodes in the loop correlated with one
another, it was not possible to calculate indirect estimates of e$ect.
This meant that we had to adopt a modified grading approach as
it was not possible to assess incoherence (di$erences between the
direct and indirect estimates of e$ect).
Calculation of absolute risk of death
As an assumed baseline risk for supportive care, we used survival
data from Keime-Guibert 2007. Whilst this is an older study and
had a lower proportion of patients having had maximal surgical
resection, it was the only one to evaluate supportive care only.
Noting that in the an epidemiological glioblastoma study (Brodbelt
2015), the death rate for the 70+ age group was approximately
50% at three months from diagnosis (with a median survival of
3.2 months reported), we felt that the Keime-Guibert 2007 data
were a reasonable baseline against which to illustrate the potential
e$ects of the di$erent treatments. Relative to the Keime-Guibert
2007 data, it could be argued then, for the relevant comparisons,
that the estimates of more recent interventions relate to maximal
surgical resection plus the experimental option (e.g. CRT) and not
just the experimental option alone.
Agreements and disagreements with other studies or
reviews
Our review evidence on hypofractionated (40 Gy) versus standard
radiotherapy, suggesting little or no di$erence in overall survival
between these radiotherapy doses, contrasts with evidence from
Bleehen 1991, a trial conducted among mostly younger patients,
which implied that higher radiotherapy doses were more e$ective.
Bleehen 1991 compared postoperative treatment with 60 Gy RT in
30 fractions with 45 Gy RT in 20 fractions for patients with grade
3 or grade 4 glioma aged 18+ years, reporting that the higher
dose significantly improved overall survival in this study. Although
61% (n = 272) of patients in Bleehen 1991 had a diagnosis of
glioblastoma and 32% (n = 140) were aged over 60, no subgroup
analyses for an elderly cohort were reported and therefore it is
impossible to know if the same survival advantage would have been
seen for the group of older (65+) patients in this trial.
Reyes-Botero 2018 was a single-arm, non-randomised phase II trial
(n = 66) which treated patients aged 70+, and with a : Karnofsky
performance score (KPS) of under 70 with TMZ 130-150 mg/m2
per day for five days every four weeks concomitantly with BEV
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10 mg/kg every two weeks. Median overall survival of 23.9 weeks
(95% confidence interval (CI), 19 to 27.6 weeks) was less than
observed for patients of the same age treated with TMZ alone using
the same schedule (9.0 months, 95% CI, 6.2 to 11.8 months) in a
trial included in this NMA (Malmstrom 2012), however the patients
in Malmstrom 2012 had better performance status. The adverse
events which occurred from using TMZ and BEV were reported by
the Reyes-Botero 2018 authors to be tolerable; however, there were
three deaths from pulmonary embolism, intestinal perforation and
cerebral haemorrhage, which were recorded as probably being
attributed to treatment. These are in keeping with the characteristic
adverse events accompanying treatment with BEV described in
trials included in this review (ARTE 2018; AVAglio 2014; GLARIUS
2016).
We know from service audits, surveys and guidelines (Brodbelt
2015; NCCN 2018; NICE 2018; Palmer 2018), that best supportive
care is oMen the most popular treatment option for patients with
poorer performance status. Although most studies in our review
included relatively fit patients (KPS over 60 to 70), two trials (Roa
2004; Roa 2015) included unfit (KPS as low as 50) elderly patients.
Findings from these two trials suggest that less intensive and less
toxic treatment options, such as 40 Gy in 15 fractions or 25 Gy in
five fractions, may be appropriate in selected cases. Interestingly,
the median survival for unfit, elderly patients in Roa 2015 (reported
in Guedes de Castro 2017) was superior in both treatment arms (40
Gy in 15 fractions (6.2 months; 95% CI, 4.7 to 7.7 months), 25 Gy in
five fractions (6.8 months; 95%, 4.5 to 9.1 months)), compared with
survival outcomes previously reported for fitter elderly patients
receiving best supportive care alone (median overall survival 3.9
months, Keime-Guibert 2007).
Gállego 2011 was a single-arm phase II trial of TMZ (150 to
mg/m2/day 200 mg/m2/day for five days every four weeks until
progression) in elderly (age >70 years) and frail (KPS less than
70) patients. Median overall survival was six months and, in the
small subgroup of patients known to have MGMT methylated
disease, median survival was 31 weeks. Overall, quality of life
and cognition improved on treatment and approximately one
third of patients showed an improvement in KPS of at least 10
points. Although not a direct comparison, this survival time is also
longer than reported for fitter elderly patients receiving supportive
care alone (Keime-Guibert 2007). In line with conclusions from
Roa 2004 and Roa 2015, this suggests that active treatment in
carefully selected patients of poorer performance status can be
well-tolerated without significant deterioration in quality of life.
Cost-e$ectiveness evaluations of glioblastoma treatments specific
to elderly populations are needed. A Canadian observational study
that reported a median overall survival of six months among its
elderly glioblastoma cohort, found that at least one in five of
these over 65-year-olds spent more than 20% of their remaining
time as inpatients (Moroney 2017); therefore, understanding the
potential resource implications of this group is important. There are
existing economic evaluation studies in non-elderly populations,
but we are unsure of their quality and applicability. Specifically,
we are uncertain about the applicability of some recent economic
evaluations on BEV and tumour treating fields (TTF) that have
been conducted in non-elderly populations with newly diagnosed
glioblastoma (Bernard Arnoux 2016; Gazauskas 2019; Kovic 2015).
A U T H O R S '   C O N C L U S I O N S
Implications for practice
Evidence from recent service audits and surveys show a wide
variation in treatment practice, with an oMen large proportion
of elderly glioblastoma patients not treated with any active
treatment aMer surgical intervention (Chong 2018; Palmer 2018;
Solth 2018). The evidence in this review may, therefore, be
useful to clinicians and patients considering active treatment by
facilitating discussions around the likely magnitude of benefit from
various active treatment options compared with supportive care
alone. It is important to note that age alone is unlikely to be
the best determinant of optimal treatment of older people with
glioblastoma , which requires an holistic patient-centred approach.
Comparing seven interventions in a network with best supportive
care, mainly among elderly people capable of self-care, the
estimates for the relative e$ects of active treatment suggest a
survival benefit in most scenarios. The exception was the treatment
of bevacizumab (BEV) with radiotherapy, where the 95% confidence
interval (CI) included the possibility of no di$erence. Where
illustrative median survival times were estimated, they suggest that
all may o$er some months of survival benefit (illustrative median
overall survivals of 6.8 to 7.7 months for standard radiotherapy
and chemotherapy options, respectively) compared with best-
supportive care only (median of 3.2 months for the 70+ age group
in Brodbelt 2015).
Chemoradiotherapy (CRT) performs well in this analysis for
elderly patients with good performance status. Although no direct
comparison of CRT with 60 Gy versus 40 Gy was possible, CRT with
40 Gy was more e$ective and ranked higher than : temozolomide
(TMZ) or radiotherapy alone. Also, the available evidence suggests
that hypofractionated (40 Gy) regimen may be as e$ective and well-
tolerated as standard 60 Gy regimen. Even shorter radiotherapy
schedules (25 Gy in five fractions and 34 Gy over two weeks) have
been tested in the elderly, but unfortunately it was not possible to
comment on their e$ectiveness relative to 40 Gy or other treatment
options because the 34 Gy regimen was included in the 40 Gy node
for this network meta-analysis (NMA )and the 25 Gy regimen did
not contribute survival data to the NMA. It is therefore not possible
to deduce if there are any important di$erences between the
hypofractionated regimens, or whether shorter regimens should or
could be used in practice.
We know from previous surveys and guidelines (NCCN 2018; NICE
2018), that best supportive care is oMen the most popular treatment
option for patients with poorer performance status. We found little
evidence to guide clinical practice in this regard, although findings
from individual studies suggest that less intensive and less toxic
treatment options may be appropriate.
BEV has a high-treatment ranking, but it is not clear what added
benefit, if any, is derived from the addition of BEV to CRT or
radiotherapy alone. BEV_CRT improves survival compared with
radiotherapy alone with moderate certainty; however, CRT alone is
also superior to radiotherapy alone. When BEV_RT was compared
with radiotherapy alone, the evidence was more uncertain. In light
of the evidence found, there is currently no justification for adding
BEV to radiotherapy or CRT, outside of a clinical trial setting.
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Implications for research
Hypofractionated radiotherapy
An important gap in knowledge highlighted by this review is the
relative e$ectiveness and tolerability of CRT with hypofractionated
regimen (40 Gy or other regimen) compared with standard CRT
for elderly patients. In terms of giving short-course radiotherapy
alone, the most commonly used regimen tested being 40 Gy in
15 fractions. Alternative regimens such as 25 Gy in five fractions
used in patients with poor performance status (Roa 2015) and 34
Gy in 3.4 Gy fractions over two weeks in fit patients (Malmstrom
2012) have shown encouraging outcomes for elderly patients
when compared to 40 Gy in 15 fractions (Roa 2015) or 60 Gy in
30 fractions (Malmstrom 2012), respectively. Future research to
compare shorter regimens, such as 25 Gy in five fractions, against
40 Gy in 15 fractions in fitter patients would be useful. Shorter, but
equally e$ective treatments save days on treatment for patients
and could potentially be a more e$icient use of resources. It would
be important to measure toxicity in fitter patients receiving higher
radiotherapy doses per fraction, as adverse side e$ects not seen in
frailer patients may emerge in fitter patients if they live for longer.
Studies which assess the cost-e$ectiveness of both the provision of
the radiotherapy and the resulting complications could potentially
inform future decision making about the most e$icient strategy
radiotherapy for elderly patients.
Bevacizumab (BEV)
The limitations of the evidence for using BEV to treat elderly
patients with glioblastoma have been outlined. More certain
evidence of beneficial e$ects and cost-e$ectiveness of BEV use
would be needed before using it in this population outside of
clinical trials.
Other systemic anti-cancer treatment (SACT)
Apart from TMZ, no systemic anti-cancer agents have made
an important contribution to improving survival for elderly
patients with glioblastoma . We await the results of a trial
using hydroxychloroquine (NCT01602588) and a trial using a type
of immunotherapy, which has o$ered such impressive benefits
in other malignancies (NUTMEG 2018), although has yet to
show promise for patients with glioblastoma .It would also be
informative to assess the cost-e$ectiveness of these drugs in elderly
populations.
Tumour treating fields (TTF)
The trial of TTF combined with adjuvant chemotherapy reported
the longest overall survival compared with the other interventions
(Table 5), however, participants comprised a selected group
with a more favourable prognosis. More research is required to
understand if the survival benefit reported in this trial would still
be demonstrated if elderly patients had been randomised prior
to CRT. Also, health-related quality of life (HRQoL) and adverse
events were only reported for the overall trial cohort. Any impact
on HRQoL and tolerability of wearing a portable device for at least
18 hours per day and managing technical issues relating to the
device may di$er for elderly patients compared to those in younger
categories and it would be important to report these outcomes
for elderly patients separately. Cost-e$ectiveness studies should be
conducted alongside these trials.
Definition of elderly and reporting of HRQoL for elderly patients
Any future trials for elderly patients with glioblastoma would
benefit from using a clear definition of the elderly. We have chosen
aged 70+ for our definition and trials including younger patients
oMen use 70 as an age cut-o$ (e.g. Bleehen 1991; Stupp 2017a).
Despite the importance of understanding toxicity and tolerability
of treatments for older patients, HRQoL and adverse event data
for elderly patients with glioblastoma are sparse and any future
research which clearly articulates these outcomes for elderly
patients would be welcomed.
Prediction of patients most likely to benefit from treatment
Two of the trials included in this analysis used molecular subtyping
to choose the patients to include in their studies (GLARIUS 2016;
Weller 2017). Future research that allows tailoring of treatments,
with improved therapeutic index, based on molecular subtyping
(Pinzi 2017) and other predictive biomarkers may mean that more
specific, less toxic treatments could be o$ered to patients. This
would be particularly useful for older patients who are less likely to
tolerate combined, intensive treatment regimens.
Additional approaches to guide treatment decisions that require
further investigation to guide treatment decisions for elderly
patients with glioblastoma include the use of novel imaging
techniques (Pinzi 2017) and geriatric and frailty assessment
prior to treatment. It has been shown that specific cognitive
and frailty evaluation is seldom performed prior to treatment
but, when used, has been reported to alter treatment decisions
by neuro-oncologists in up to 50% of cases. (Lorimer 2016).
Further investigation into which assessments are both useful and
pragmatic to perform in the clinic will help clinicians make better
informed treatment decisions for their patients.
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Accrual dates: March 2013 to August 2015
Trial reg: NCT01443676
Funding: Roche Pharma (Basel, Switzerland)
Participants No. enrolled: 75
No. analysed: 75
Inclusion criteria: age 65 years or older, newly diagnosed supratentorial glioblastoma, eligible for first
infusion of bevacizumab between 28 and 49 days after surgery for glioblastoma, Karnofsky perfor-
mance score (KPS) of 60 or more, stable or decreasing corticosteroid dose within 5 days before enrol-
ment, availability of paraffin-embedded tissue for central pathology review and determination of O6-
methylguanine DNA methyltransferase (MGMT) promoter methylation status, and adequate haema-
tological, renal and liver function. An amendment (November 2013) requested the absence of MGMT
promoter methylation when it became clear that MGMT promoter methylation predicted larger benefit
from TMZ alone than from RT alone in patients with GBM aged 65+.
Age: approx. median 70 years (range 65 - 79, 65 - 87 arm A and arm B)
Gender: 36% female, 64% male
Used diagnostic criteria: WHO classification (2007)
Molecular type of GBM: MGMT methylated 21%, MGMT unmethylated 73%, missing (5%) (data for all
participants). Note the amendment to alter inclusion criteria based on MGMT promoter methylation
status in the first year of trial recruitment.
Performance status: KPS of 60 or more.
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Interventions Arm A: RT was administered to the gross tumour volume plus a 2 cm margin over 3 weeks, in 15 frac-
tions of 2.66 Gy, to a total 40.0 Gy. Bevacizumab was administered intravenously at 10 mg/kg body-
weight every 2 weeks.
Arm B: RT was administered to the gross tumour volume plus a 2 cm margin over 3 weeks, in 15 frac-
tions of 2.66 Gy, to a total 40.0 Gy.
Outcomes Primary endpoint: OS (ITT population)
Secondary endpoints
Survival rate at 12 months
Adverse events
Median PFS
PFS rate at 6 months
Median deterioration-free survival (DFS) from baseline
Cognitive functioning (serial MMSE measurements)
Median time on steroids from study entry.
Exploratory endpoints:subgroup analysis for PFS and OS by cognitive function (MMSE), KPS, disease
methylation characteristics.
Notes The authors concluded that the ARTE trial did not confirm the hypothesis that the combination of be-
vacizumab with hypofractionated RT prolongs OS in elderly glioblastoma patients.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Patients were allocated to treatment arms using a web-based randomisation
system without stratification in a 2 : 1 distribution
Allocation concealment
(selection bias)






Blinding of outcome as-
sessment (detection bias) 
All outcomes




Low risk No patient was lost to follow-up for OS
Selective reporting (re-
porting bias)
Low risk All predefined outcomes were reported.
Other bias Low risk None noted
ARTE 2018  (Continued)
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Methods Design: phase III RCT
Country: multi-country
Accrual dates: June 2009 through March 29, 2011
Trail reg: NCT00943826
Funding: F. Hoffmann–La Roche
Participants No. enrolled: 921 (70+, N= 73)
No. analysed: 921 (70+, N= 73)
Inclusion/exclusion criteria: 18 years of age or older with newly diagnosed, histologically confirmed,
supratentorial glioblastoma.
Addiional Inclusion criteria: WHO performance status of 2 or lower; the use of stable or decreasing
glucocorticoid doses within the 5 days before randomisation; adequate healing of craniotomy or cra-
nial-biopsy site; adequate hematological, hepatic, and renal function; and acceptable blood coagula-
tion levels.
Investigators submitted available tumour tissue blocks for pathological central review and analysis of
status with respect to O-6-methylguanine–DNA MGMT.
Treatment had to be initiated between 29 and 48 days after the most recent surgery.
Exclusion criteria: evidence of recent symptomatic intracranial haemorrhage on MRI, prior chemother-
apy or immunotherapy for glioblastoma or low-grade astrocytoma, prior radiotherapy (RT) to the brain,
a history of intracranial abscess within 6 months before randomisation, or a serious nonhealing wound.
Age: approx. 57 years (all participants, in subgroup not given)
Gender: 37% female 63% male
Molecular type of GBM: MGMT methylated 26%, MGMT unmethylated 50%, missing (24%) (all partici-
pants)
Performance status: WHO performance status of 2 or less 0 (50%), 1 or 2 (50%)
Interventions Arm 1: patients received concomitant RT (60 Gy as 2-Gy fractions 5 days/week) + oral temozolomide (75
mg per m2 of body-surface area per day for max. 49 days), in combination with intravenous bevacizum-
ab (10 mg per kg of body weight) every 2 weeks. The last concomitant doses of TMZ and bevacizumab
were administered on the day of the last dose of RT.
Arm 2: patients received concomitant RT (60 Gy as 2-Gy fractions 5 days/week) + oral temozolomide
(75 mg per m2 of body-surface area per day for max. 49 days), in combination with intravenous place-
bo every 2 weeks. The last concomitant doses of TMZ and placebo were administered on the day of the
last dose of RT.
The concomitant-therapy phase in both arms was followed by a 28-day treatment break. In the main-
tenance phase, patients received TMZ (150 mg per m2 per day on days 1 to 5 during the first cycle and
200 mg per m2 per day during subsequent cycles if unacceptable toxic effects did not develop) + IV be-
vacizumab (10 mg per kg) or placebo every 2 weeks, for six 4-week cycles. In the monotherapy phase,
IV bevacizumab (15 mg per kilogram) or placebo was continued every 3 weeks until the disease pro-
gressed or unacceptable toxic effects developed.
Outcomes Co-primary endpoint: investigator assessed PFS and OS at 1 and 2 years from date of randomisation.
Survival estimates determined using Kaplan-Meier methods.
Secondary endpoints: PFS assessed by independent review
Safety
HRQoL (QLQ-C30 and BN20)
AVAglio 2014 
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Notes All the data were collected by the sponsor and were analysed by an author employed by the sponsor,
who vouched for the accuracy of the data. They summarised that their interpretation of the results is
that this trial showed that the combination of bevacizumab with standard RT plus TMZ for the treat-
ment of newly diagnosed glioblastoma did not improve OS but resulted in a 4.4-month improvement
in median PFS, with quality of life and functional status maintained; however, there was an increase in
adverse events associated with bevacizumab therapy. The authors did not comment on the applicabili-
ty of the evidence to elderly patients specifically.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Performed centrally with the use of an interactive voice-response system, with









Low risk The study sponsor, study investigators, and patients were unaware of the
study-group assignments.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk In addition to investigator-assessed progression, radiologists at an indepen-
dent review facility analysed all MRI scans. The independent reviewers were
unaware of the study-group assignments, with read-only access to previous re-
views until the final imaging data set was reviewed; at completion of the study,
a review of the entire scan series verified the time of progression on MRI. In a
final independent review, the determination of progression was calculated
with the use of a prespecified algorithm that combined the assessment of the
scans by the independent reviewer with the investigator’s neurologic evalua-




Low risk ITT analysis
Selective reporting (re-
porting bias)
Low risk Pre-specified outcomes are reported




Methods Design: phase II RCT Randomisation 2:1
Country: Germany
Accrual dates: 2009 to 2011
Trial reg: NCT00967331
Funding: Roche
Participants No enrolled: 566
GLARIUS 2016 
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No analysed: 182
Inclusion criteria: chemotherapy- and radiotherapy-naive with newly diagnosed GBM; age older than
18 years, unmethylated MGMT (ratio < 0.6)12; adequate healing of craniotomy; KPS of 70% or greater;
stable or decreasing corticosteroids within 5 days before random assignment; and adequate hemato-
logical, hepatic, renal, and coagulation function.
Exclusion: stereotactic biopsy only; overt recent haemorrhage on brain magnetic resonance imaging
(MRI); significant vascular disease; history of recurrent thromboembolism; evidence of bleeding diathe-
sis or coagulopathy; gastrointestinal fistula or perforation; history of intra-abdominal or intracranial
abscess within 6 months; serious non-healing wound, ulcer, or bone fracture; and Gilbert-Meulen-
grachts disease.
Age: included patients aged over 18 years. Median age was 56 years; 34 were aged 65+.
Gender: 114 (67.1%) male. 56 (32.9%) female.
Molecular type of GBM:unmethylated MGMT GBM only. Patients were classified as nmMGMT if the ratio
of MGMT to the b-actin reference gene (ACTB) was less than 0.6.
Performance status: KPS of 70% or greater. KPS 90-100 (134 (78.8%)), KPS 70-80 (34 (20%)), NR (2
(1.2%))
Interventions Arm 1: 60 Gy RT + TMZ concomitant and adjuvant. Daily TMZ (75 mg/m2) during RT followed by six
courses of TMZ. This arm included an optional predefined cross-over at recurrence: patients could re-
ceive second-line BEV+IRI provided by the sponsor.
Arm 2: 60 Gy RT + BEV + IRI. BEV (bevacizumab) (10 mg/kg every 2 weeks) during RT followed by mainte-
nance BEV (10 mg/kg every 2 weeks) plus IRI (irinotecan) (125 mg/m2 every 2 weeks).
Outcomes Primary endpoint: PFS at 6 months (modified ITT population). Estimated using binary proportions, a
contingency table and Fisher's exact test for significance.
Secondary endpoints:PFS in months (with HR), 1 year PFS rate, Median OS (with HR) calculated with
a proportional Cox regression model 1 and 2 year OS rates, Change in HRQoL parameters over time,
Change in KPS over time, change in MMSE over time, safety.
Notes Thirty-four patients were 65+ years old and these findings were reported in a related conference ab-
stract (Kebir 2016).
The authors concluded quote: "BEV/IRI resulted in a superior PFS-6 rate and median PFS compared
with TMZ. However, BEV+IRI did not improve OS, potentially because of the high crossover rate. BEV
+IRI did not alter QOL compared with TMZ. BEV/IRI prolonged progression-free survival but OS was
similar in both treatment arms. In the Cox model, age emerged as an independent prognostic factor in
BEV/IRI treated patients only (Hazard Ratio, 2.72, p<0.001)."
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Patients were allocated to treatment arms using a web-based randomisation
system without stratification in a 2 : 1 distribution
Allocation concealment
(selection bias)
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Blinding of outcome as-
sessment (detection bias) 
All outcomes




Low risk No patient was lost to follow-up for OS
Selective reporting (re-
porting bias)
Low risk All predefined outcomes are reported
Other bias High risk All patients in this study had MGMT unmethylated GBM, which is associated
with shorter survival time that MGMT-methylated tumours. Therefore, this may




Methods Design: 4-arm RCT
Country: USA
Accrual dates: January 1976 to April 1978
Trial reg: not given
Funding: National Cancer Institute, National Institute for Health, Department of Health and Human Ser-
vices
Participants No. randomised: 609 (overall) (65+, N = not specified)
No. analysed: 527 (overall) (65+, N = 107)
Inclusion criteria: histologically-demonstrated supratentorial malignant glioma, patient age > =15
years, and absence of major medical illness which could preclude treatment on any arm.
Exclusion criteria: any antineoplastic therapy prior randomisation, other than surgery (and convention-
al doses of corticosteroids within certain prescribed limits).
Age: approx. 56 years overall
Gender: 35% female, 65% male
Molecular type of GBM: not reported (older study)
Performance status: median Karnofsky performance status at baseline 70
Interventions Arm 1: carmustine administered IV at a dose of 80 mg/m2/day on 3 successive days every 8 weeks.
Dosage was decreased to 60 mg/m2/day for the same indications of toxicity used for BCNU
Arm 2: high dose (400 mg/m2/day) oral methyl-prednisolone in three divided doses for 7 consecutive
days without taper. After a 3-week interval, the treatment was repeated and continued in this 1 week
on and 3 weeks o$ cycle.
Arm 3: procarbazine given orally at a total dose of 150 mg/m2/day in three or four divided doses for 28
consecutive days every 8 weeks
Arm 4: BCNU plus high-dose methyl-prednisolone (as in mono arms)
All participants received a total dose pf 6000 rads in 30-35 fractions of 172-200 rads, 5 days/week over 6
to 7 weeks, delivered to the whole brain by parallel opposed ports with megavoltage equipment.
Green 1983 
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Outcomes Survival
Reported using theMantel-Haenszel model for comparison of survivals; no HRs)
Death rates
Adverse events
Notes The authors concluded quote: "This study indicates that BCNU and procarbazine are moderately use-
ful agents in conjunction with RT for patients with malignant glioma. Both procarbazine and BCNU pro-
vide a significantly increased survival for patients with malignant glioma compared with methylpred-
nisolone, even though the latter had been given in high doses to enhance possible oncoloytic effect.
However, there was not a significant difference in survival between the groups of patients receiving ei-
ther procarbazine or BCNU alone.".
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "Patients were randomised to one of the four treatment groups by
means of a telephone call to the BTSG Operations Office."
Allocation concealment
(selection bias)
Low risk Quote:"Patients were randomised to one of the four treatment groups by





High risk No specific details given in the primary journal publication but likely to be un-
blinded as some treatments IV and some oral treatments.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
High risk Primary endpoint based on survival so that will have a low risk of bias but it




Low risk Primary outcomes as specified in the methods were reported for the total ran-
domised population (Other analysis done on the "valid study group" which ex-
cluded 82 patients would be high risk).
Selective reporting (re-
porting bias)
Low risk All predefined outcomes reported
Other bias Unclear risk Taken from the text in the paper: "The data in table 2 suggest heterogeneity
with respect to dose of RT received. However, this could be produced by varia-
tions in the number of patients surviving long enough to receive a full course,
and in fact, the heterogeneity in mean RT dose disappears if calculations are
limited to those patients surviving over 2 months. The group randomised to
procarbazine received fewer course of chemotherapy than the other groups,
but the heterogeneity (in mean number of courses) among the four treatment




Methods Design: phase III RCT (a triangular sequential design for two-sided alternatives)
Country: France
Accrual dates: Feb 2001 to Jan 2005
Keime-Guibert 2007 
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Trial reg: NCT00430911
Funding: Research grant Programme Hospitalier de Recherche Clinique.
Participants No. enrolled: 85
No. analysed: 85
Inclusion criteria: patients 70 years of age or older; if they had histologically-proven, newly diagnosed
glioblastoma multiforme or anaplastic astrocytoma on the basis of the WHO classification and a KPS of
70 or more.
Exclusion criteria: not reported.
Age: approx. 74 years
Gender: 37% female, 63% male
Type of surgical procedure: biopsy (n = 44; 52%), partial resection (n = 14; 16.5%) or complete resection
(n = 25; 29%).
Used diagnostic criteria: WHO classification
Molecular type of GBM: not reported
Performance status: KPS of 70 or more.
Interventions Arm 1: supportive care plus RT (delivered by means of linear accelerators with a nominal energy of 6
mV or more, consisted of fractionated focal irradiation, at a dose of 1.8 Gy per fraction, given once daily
5 days per week, for a total dose of 50 Gy. The dose was defined according to the guidelines of the Inter-
national Commission on Radiation Units and Measurements.
Arm 2: supportive care only; supportive care consisted of treatment with corticosteroids and anticon-
vulsant agents, physical and psychological support, and management by a palliative care team.
Outcomes Primary endpoint: survival as per ITT population. Median survival for both arms reported with a HR for
death using a log-rank test.
Secondary endpoints: PFS; change in performance status (KPS) over time; safety and tolerance of treat-
ment but not clear which tool used to grade toxicity; HRQoL reported using EORTC QLQ-C30 and BN20.
Few patients were alive after the first four follow-up intervals (day 135) therefore HRQoL evaluated at
days 1,30,60, 90 and 135 only. HRQoL reported as the change in mean HRQoL scores over time. Global
assessment of deterioration over time also reported; cognitive functioning change over time reported
using MMSE, Neuro-psychiatric Inventory (NPI) and the Mattis Dementia Rating Scale (MDRS).
Notes Authors concluded that quote: "RT increases the median survival of elderly patients with glioblastoma
who have a good performance status at the start of treatment. As compared with supportive care, RT in
such patients does not cause further deterioration in the Karnofsky performance status, health-related
quality of life, or cognitive functions, but the survival benefit is modest." The trial was discontinued at
the first interim analysis, which showed that with a preset boundary of efficacy, RT and supportive care
were superior to supportive care alone.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Randomisation was performed at the data centre of the Delegation for Clini-
cal Research of the Assistance Publique – Hôpitaux de Paris, and patients were
stratified according to the treatment centre
Keime-Guibert 2007  (Continued)
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Allocation concealment
(selection bias)
Low risk Randomisation was performed at the data centre of the Delegation for Clini-
cal Research of the Assistance Publique – Hôpitaux de Paris, and patients were





High risk None (open-label)
Blinding of outcome as-
sessment (detection bias) 
All outcomes




Low risk Comparisons between the two groups were made on an ITT basis; but low re-




Low risk All relevant outcomes were reported
Other bias Unclear risk Six patients received 90% or less of the planned radiation dose because of tu-
mour progression (in five patients) and sudden death related to a pulmonary
embolus (in one patient).
One patient who was assigned to the RT group did not receive radiation be-
cause another tumour (duodenal cancer) developed before the start of RT; this




Methods Design: phase III RCT
Country: multi-country
Accrual dates: 2 February 2000, and 18 June 2009
Trial reg: NCBTSG (the Nordic)
Funding: Lion’s Cancer Research Foundation, University of Umeå (Sweden); Cancer Fonden Sweden,
and an unrestricted grant from Merck. Schering-Plough provided financial support for the study-group
meetings. MDxHealth did the MGMT promoter methylation testing free of charge. In France, Merck pro-
vided temozolomide free of charge.
Participants No. enrolled: 342, 291 randomised
No. analysed: 291 altogether (123 in 70+ subgroup)
Inclusion criteria: patients with newly diagnosed, histologically confirmed glioblastoma (WHO grade IV
astrocytoma) and aged 60 years or older were eligible. To resemble the characteristics of patients seen
in clinics, patients with WHO performance scores 0–2 (even if neurological deficits gave them a perfor-
mance score of 3) could be included. Patients were required to have adequate haematological levels
(neutrophil count 1·5×109/L or higher, platelets 100×109/L or higher, and haemoglobin 100 g/L or high-
er), renal (creatinine concentrations in serum less than 1·5 times the upper limit of normal), and liver
(bilirubin concentrations in serum less than 1·5 times the upper limit of normal and aspartate amino
transferase and alanine aminotransferase no more than three times the upper limit of normal) func-
tions, and were expected by the doctor to tolerate all treatment options.
Exclusion criteria: other primary cancers, except radically-treated squamous-cell or basal cell carcino-
ma of the skin or other curatively treated malignancy without relapse at least 2 years after diagnosis,
Malmstrom 2012 
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WHO performance score 3 to 4 (except a score of 3 owing to neurological deficits), any disorder that
was likely to interfere with the study treatment, previous therapy for any brain tumour, except surgery
or medical treatment within 3 years for other malignant diseases, and previous RT to the head that
would prevent further irradiation.
Age: approx. median age for patients in three treatment groups was 70 years (70 years (range 60 to 88)
in the TMZ, 70 years (60 to 83) in the hypofractionated RT, and 70 years (60 to 80) in the standard RT
group); the median age for the additional 51 patients randomised only to two treatment groups was 3
years older (73 years, range 60 to 83).
Gender: 40.7% female, 59.3% male
Type of surgical procedure: biopsy 26.7%, resection (partial or complete) 73.3%
Used diagnostic criteria: WHO 2007 criteria
Molecular type of GBM: MGMT methylated 45%, MGMT unmethylated 55%, (data for 203 participants)
Performance status (PS): WHO 0-2. (NB. In the results section, there were patients with WHO PS 3 in-
cluded. The inclusion criteria allowed inclusion of patients with WHO PS 3 if their neurological status
specifically gave them a PS of 3).
Interventions Arm 1: temozolomide (200 mg/m2 on days 1–5 of every 28 days for up to six cycles),
Arm 2: hypofractionated RT (34 Gy administered in 3.4 Gy fractions over 2 weeks)
Arm 3: standard RT (60 Gy administered in 2 Gy fractions over 6 weeks)
Outcomes Primary endpoint: OS from date of randomisation estimated by the Kaplan-Meier method.
Secondary endpoints: HRQoL (change in mean scores from baseline values for each treatment group at
6 weeks and 3 months); safety
Notes After 15 October 2004, patients younger than 65 years who were deemed fit to receive combined treat-
ment were excluded, owing to positive results of the European Organisation for Research and Treat-
ment of Cancer (EORTC) trial on concomitant and adjuvant temozolomide and RT for glioblastoma. The
age cut-o$ of 65 years was based on subgroup analyses in that trial, which showed an increase in me-
dian survival for patients younger than 65 years who received combined treatment, whereas no such
benefit was seen for older patients.
The authors of this trial concluded that quote: "Our findings suggest that temozolomide chemothera-
py or hypofractionated RT over 2 weeks might be valid alternative strategies, and that MGMT promoter
methylation status might be a useful biomarker to help make treatment decisions."
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Computer-generated randomisation schedule
Allocation concealment
(selection bias)
Unclear risk The randomisation lists were generated by computer and were only available
to the Oncology Centre sta$. Each time a new patient was to be randomised,
the participating institution sent a randomisation form to the Oncology Centre






High risk Patients and study sta$ were aware of treatment assignment.
Malmstrom 2012  (Continued)
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Blinding of outcome as-
sessment (detection bias) 
All outcomes




Unclear risk Randomised 342, analysed 291 (85%); dropouts were balanced between TMZ
and hypofractionated RT; no dropouts in standard RT arm
Selective reporting (re-
porting bias)
Low risk All predefined clinical outcomes are reported
Other bias Unclear risk Quote: "At the time the study started, common practice included refraining
from standard RT and offering a hypofractionated short course of RT or with-
holding antitumour therapy for patients older than 60 years who had a poor
outlook. For these reasons, some centres were permitted to randomise pa-
tients to only two of the treatment groups (TMZ or hypofractionated RT) if this




Methods Design: phase III RCT
Country: multi-country
Accrual dates: November 2007 to September 2013
Trial reg: NCT00482677
Funding: supported by grants (015469 and 021039) from the Canadian Cancer Society Research Insti-
tute, by an unrestricted grant from Schering-Plough (now Merck), and by the EORTC Cancer Research
Fund from Belgium.
Participants No. enrolled: 562
No. analysed: 562
Inclusion criteria: 65 years of age or older who had newly diagnosed glioblastoma (WHO grade IV astro-
cytoma), which was histologically confirmed after surgery or biopsy performed less than 28 days before
randomisation. Patients were deemed by their physicians not to be suitable to receive conventional RT
(60 Gy in 30 fractions over a period of 6 weeks) in combination with TMZ. Eligible patients had an East-
ern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2
Age: approx. median age was 73 years (range, 65 to 90), with 29.5% of the patients older than 75 years
of age
Gender: 39% female, 61% male
Type of surgical procedure: 68.3% of the participants underwent partial or complete surgical resection
Used diagnostic criteria: WHO classification
Molecular type of GBM: MGMT methylated 46.6%, MGMT unmethylated 53.4% (data for 354 partici-
pants)
Performance status: ECOG 0-2
Interventions Arm 1: radiation was planned with the use of three-dimensional planning systems for a total dose of
40.05 Gy, administered in 15 daily fractions over a period of 3 weeks
Perry 2017 
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Arm 2: concomitant temozolomide was administered with RT at a dose of 75 mg per m2 of body-sur-
face area per day for 21 consecutive days from day 1 until the final day of RT. Adjuvant temozolomide
was administered at a dose of 150 to 200 mg perm2 per day for 5 consecutive days of a 28-day cycle for
up to 12 cycles or until disease progression.
Use of antiemetic and infection prophylaxis was at the discretion of the investigator.
Outcomes Primary endpoint: OS from date of randomisation
Secondary endpoints: OS rate at 12, 18 and 24 months according to treatment group and MGMT status;
PFS; safety
HRQoL(using QLQ-C30 and QLQ-B20) reported as time to deterioration
Notes Authors concluded that quote; "In elderly patients with glioblastoma, the addition of temozolomide to
short-course radiotherapy resulted in longer survival than short-course radiotherapy alone."
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Treatment assignment was performed centrally with the randomisation al-









High risk None (open-label)
Blinding of outcome as-
sessment (detection bias) 
All outcomes




Low risk Low risk overall because final analysis populations included the ITT popula-
tion (all randomly assigned patients) for all efficacy end points and the as-
treated population (all patients who received at least one dose of trial treat-
ment) for safety and drug-exposure analyses. However, attrition was a major
problem for quality of life data that impacted the quality of these findings.
Selective reporting (re-
porting bias)
Low risk All predefined outcomes are reported




Methods Design: phase III RCT
Country: Canada
Accrual dates: between 1996 and 2001
Trial reg: N/A
Roa 2004 
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Funding: Alberta Cancer
Participants No. randomised: 100
No. analysed: 95
Inclusion criteria: age >= 60 years, histologically confirmed GBM, and KPS >= 50
Exclusion criteria: previous cranial RT, concomitant or prior invasive cancer (except non melanomatous
skin cancer and carcinoma-in-situ), failure to commence RT for GBM within 6 weeks of surgical diagno-
sis, and inability to comply with follow-up requirements. Patients were also ineligible if pre- and post-
operative imaging studies were unavailable for review
Mean age: (SD). 72.4 years (5.4) in the 6-week arm and 71.0 years (5.5)
Gender: 42% female, 58% male
Type of surgical procedure: biopsy 39% (37/95); subtotal resection 52% (49/95); total resection 9%
(9/95)
Used diagnostic criteria: unclear (the diagnosis of GBM was confirmed centrally on all cases)
Molecular type of GBM: NR
Performance status: KPS of 50 or more
Interventions Arm 1: short-course RT (40 Gy in 15 daily fractions over 3 weeks)
Arm 2: 60Gy in 30 fractions over 6 weeks; patients receiving standard RT were treated in two phases.
RT started within 6 weeks of surgery; the absorbed dose was to be within 10% of the prescribed dose.
Chemotherapy was not prescribed before or during RT but could be given at the time of disease recur-
rence
Outcomes Primary endpoint: OS from date of randomisation. Survival curves generated using Kaplan-Meier
method and relative risk calculated using a proportional hazards model.
Secondary endpoints: OS from date of diagnosis; proportion of patients alive at 6 months; HRQoL (KPS
and FACT-Br v3); corticosteroid requirement
Notes Authors also evaluated post-treatment corticosteroid requirements and found that fewer patients in
the short-course arm required an increase in their post-treatment daily dose of corticosteroids (23%
versus 49%).
Authors concluded that quote; "There is no difference in survival between patients receiving standard
RT or short-course RT. In view of the similar KPS scores, decreased increment in corticosteroid require-
ment, and reduced treatment time, the abbreviated course of RT seems to be a reasonable treatment
option for older patients with GBM."
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk An independent statistician at the coordinating centre (Cross Cancer Institute)
produced computer-generated randomisation lists; Patients were stratified by
extent of resection (biopsy versus any degree of resection, as defined by the
operative report) and KPS (<70 v >=70).
Allocation concealment
(selection bias)
Low risk An independent statistician at the co-ordinating centre (Cross Cancer Insti-
tute) produced computer-generated randomisation lists; Strata-specific, se-
quentially-numbered, sealed opaque envelopes containing the treatment as-
signment were supplied by the statistician to the research nurse at the coordi-
Roa 2004  (Continued)
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nating centre; once patient eligibility had been determined and consent was
obtained, participating centres contacted the co-ordinating nurse by fax to re-
quest randomisation. The next envelope in the appropriate strata was opened





Unclear risk No details given
Blinding of outcome as-
sessment (detection bias) 
All outcomes




Low risk Out of 100 randomised (51 standard RTand 49 shorter course RT) - overall
dropout 5% (2 withdrawals and 2 deaths standard RT versus 1 withdrawal in
short RT); 12 versus 5 participants did not complete the treatment
Selective reporting (re-
porting bias)
Low risk All predefined outcomes are reported




Methods Design: phase III RCT non-inferiority
Country: multi-country
Accrual dates: 2010 and 2013 (from Kepka 2014)
Trial reg: NCT01450449
Funding: supported by the International Atomic Energy Agency (IAEA) under the IAEA Coordinated Re-
search Activities.
Participants No. enrolled: 98 (65+, N = 61)
No. analysed: 96 (65+, N = 59)
Inclusion criteria: frail patients were defined as 50 years old with a KPS of 50% to 70%; elderly and frail
patients were defined as 65 years old with a KPS of 50% to 70%; and elderly patients were defined as 65
years old with a KPS of 80% to 100%.
Inclusion criteria: histopathologically-confirmed newly diagnosed GBM (WHO grade 4); initial surgery/
biopsy at diagnosis performed 6 weeks before random assignment; age 50 years at time of entry; KPS
50%; no previous chemotherapy or RT exposure
Exclusion criteria: patients fulfilling either of the following criteria were not eligible for the study: histo-
ry of other malignancy or history of a serious infection or underlying medical condition
Age: approx. No average; 50 to 65 years 37 (37.8%), > 65 61 (62.2%)
Gender: 53% female, 47% male
Type of surgical procedure: stereotactic biopsy (13.3%), partial resection (65.3%), total macroscopic re-
section (21.4%)
Used diagnostic criteria: WHO classification
Molecular type of GBM: NR
Roa 2015 
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Performance status: KPS of 50% or more
Interventions Arm 1: short-course RT (25 Gy in five fractions delivered in 1 week)
Arm 2: standard RT (40 Gy in 15 fractions delivered in 3 weeks)
Outcomes OS from date of randomisation calculated using Kaplan-Meier estimates to obtain median survival time
Secondary outcomes: PFS; HRQoL (assessed using QLQ-C30 and QLQ-BN20); Adverse events
Notes We extracted data on the elderly subgroup from the substudy reported by Guedes de Castro 2017. Au-
thors concluded that quote: "short-course RT regimen of 25 Gy in 5 fractions is an acceptable treatment
option for patients aged 65 years, mainly those with a poor performance status or contraindication to
chemotherapy". Authors planned to report detailed HRQOL data in a separate paper.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Random assignment was performed using Excel with the RAND option func-
tion (Microsoft, Redmond, WA).
Allocation concealment
(selection bias)





High risk None (open-label)
Blinding of outcome as-
sessment (detection bias) 
All outcomes




Low risk Randomised 98 elderly and/or frail, analysed 96
Selective reporting (re-
porting bias)
Low risk All predefined outcomes were reported (HRs were calculated from Kaplan
Meier plots)




Methods Design: phase III RCT
Country: multi-country
Accrual dates: July 2009 and December 2014
Trial reg: NCT00916409
Funding: Novocure Ltd.
Participants No. enrolled: 695 (65+, N = 134)
Stupp 2017a 
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No. analysed: 695 (65+, N = 134) maintenance temozolomide alone (150 to 200 mg/m2/day for 5 days
every 28 days for 6 cycles)
Inclusion criteria: aged 18 years or older, had a KPS of 70 or higher (a score of ≥70 ensures indepen-
dence in activities of daily living), and had newly diagnosed and histologically confirmed supratentorial
glioblastoma (WHO grade IV astrocytoma).
Exclusion criteria:pPatients with evidence of progressive disease following radiochemotherapy, in-
fratentorial tumour location, and severe co-morbidities were excluded
Mean age not given for over 65+, only for the group as a whole (median 56 years, range 19 to 83 in arm 1
and median 57 years, range 19 to 80 in arm 2)
Gender: for the total sample was 68% male and 32% female
Used diagnostic criteria: WHO classification
Molecular type of GBM: MGMT methylated 37%, MGMT unmethylated 53%, invalid sample (9%) (data
for 571 participants)
Performance status: KPS of 70 or higher
Interventions Arm 1: tumour treating fields therapy plus maintenance temozolomide after standard chemoradio-
therapy (up to 60Gy); delivered through 4 transducer arrays with 9 insulated electrodes each placed on
the shaved scalp and connected to a portable device set to generate 200-kHz electric fields within the
brain; All treatment was delivered on an outpatient basis and at home.
Arm 2: maintenance temozolomide alone (150 to 200mg/m2/day for 5 days every 28 days for 6 cycles).
If tumour progression occurred, second-line therapy was offered per local practice.
Outcomes Primary endpoint: PFS in ITT population
Secondary endpoint: OS
Exploratory endpoints:
Percentage of patients alive and progression-free at 6 months
Annualised survival rates
HRQoL (QLQ-30 and QLQ-BN20) reported in a separate article (Taphoorn 2018). Mean change in HRQoL
from baseline, deterioration free survival (DFS) and time to deterioration (TTD).
MMSE
KPS
Adverse events and tolerability
Notes Prior use of implanted carmustine wafers was allowed and randomisation was after patients had
completed chemoradiation. Authors concluded for entire population that quote: "In the final analy-
sis of this randomised clinical trial of patients with glioblastoma who had received standard ra-
diochemotherapy, the addition of tumour treating fields to maintenance TMZ chemotherapy versus
maintenance temozolomide alone, resulted in statistically significant improvement in progression-free
survival and overall survival."
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Patients were randomised at a ratio of 2:1; performed using a central web-
based randomisation system and was stratified by extent of resection (biop-
sy, partial resection, gross total resection) and by the methylation status of the
Stupp 2017a  (Continued)
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Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk All MRIs were reviewed by 2 blinded central independent radiologists (BioClin-
ica Inc) and were evaluated for tumour response and progression (Macdon-
ald criteria); For cases in which the 2 reviewers were not in agreement, a third




Low risk For the main population: ITT for primary outcome, PP for secondary (OS);
Overall 53 lost to follow-up (7.6%); 39/466 versus 14/229 (8.4% versus 6.1%) - 9
versus 1 disease progression
Selective reporting (re-
porting bias)
Low risk All pre-specified outcomes are reported
Other bias High risk In the context of the review, this trial may represent a high risk of bias due to
the timing of randomisation, because patients that die during CRT or have se-
vere early toxicities would have dropped out by the time of randomisation.
Novocure Ltd had a role in the design and conduct of the study, collection,
management, and analysis of the data. After the release of the interim results,
26 patients in the TMZ only arm with favourable prognostic factors and who
had received more cycles of maintenance TMZ crossed over to receive TTF.
These patients were analysed in the group to which they had been randomised
(ITT analysis). The effect of this might have led to an underestimation the im-




Methods Design: Phase III RCT
Country: multi-country
Accrual dates:12 April 2012, and 15 December 2014
Trial Reg: NCT01480479
Funding: Celldex Therapeutics, Inc
Participants Inclusion criteria: 18 years or older with confirmed GBM histology and EGFRvIII expression analysis
by real time (RT) PCR. Patients must have undergone maximal surgical resection and have completed
standard RT (up to 60 Gy) with concomitant TMZ (75 mg/m2 per day). To be eligible, at least 90% of the
planned RT dose had to be delivered. Patients had to have tumour tissue specimens (paraffin-embed-
ded) from surgical resection available for central pathology review, MGMT status determination, and
analysis of ECFRvIII status.
Exclusion criteria: disease progression during chemoradiation, any additional tumour-specific treat-
ment for GBM, inability to taper corticosteroids to 2 mg of dexamethasone or lower (or equivalent) per
day for at least 3 days before randomisation, ECOG PS of 3 or higher in the week before randomisation,
diffuse leptomeningeal disease, gliomatosis cerebri, infratentorial disease, active infection, metastatic
disease, and immunosuppressive disease.
Weller 2017 
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No. enrolled: 745 (65+, N = 174)
No. analysed: 745 (65+, N = 174)
Molecular type of GBM: MGMT methylated 34%, MGMT unmethylated 59%, missing (7%) (data for all
participants)
Interventions Arm 1: rindopepimut plus maintenance TMZ
Arm 2: control plus maintenance TMZ only
All participants received standard chemoradiotherapy before randomisation and had to have received
at least 90% of the planned RT dose to be eligible for trial inclusion.
Outcomes Primary endpoint: OS from date of randomisation in patients with newly diagnosed, EGFRvIII positive
GBM and minimal residual disease (MRD) (modified ITTanalysis). OS analysis included HR and sum-
marised using the Kaplan-Meier method.
Secondary endpoints: OS in all patients (ITT), OS in patients with significant residual disease (SRD),
PFS, proportion of patients achieving an objective tumour response (using RANO criteria). Included re-
quirement for corticosteroids.
HRQoL (MDASI-BT, QLQ-C30 and QLQ-BN20), Humoral responses to EGFR vIII, Post-treatment EGFRvIII
expression status. Survival rates at 1,2 and 3 years. Adverse events
Notes Standard RT dose was stated as "up to 60Gy" and standard TMZ dose was 75mg/m2 per day
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Patients quote: "were randomly assigned (1:1) to the treatment groups with a
prespecified randomisations sequence with a block size of four."
Allocation concealment
(selection bias)






Low risk Study treatments were prepared in the pharmacy and given to study sta$ in
blinded pre-loaded syringes.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Quote:"The retrospective imaging review committee assessment, masked to
treatment assignment and investigator assessments, was used for the primary




Low risk Low attrition for primary outcome
Selective reporting (re-
porting bias)
Unclear risk HRQoL not yet reported. Will possibly come with a future publication.




Methods Design: phase III RCT | non-inferiority trial with a 25% margin
Wick 2012 
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Country: Germany
Accrual dates: 15 May 2005 to 2 November 2010 (last randomisation on 2 Nov 2009)
Trial reg: NCT01502241
Funding: Merck, Sharp & Dohme
Participants No. enrolled: 412
No. analysed: 373
Inclusion criteria: de novo histologically confirmed AA or GB and > 65 years of age, KPS score > 60, no
prior systemic chemotherapy or RT to the brain, and adequate bone marrow reserve, liver, and renal
function.
Exclusion criteria: failure to confirm AA or GB would have resulted in exclusion from the ITT population.
Age: approx. 71.5 years
Gender: 53% female, 47% male
Type of surgical procedure: resection: complete 28% partial 30% biopsy 39%
Used diagnostic criteria: inclusion into the trial was based on local diagnosis. Histological diagnoses
were confirmed centrally according to the WHO classifications 2000 and 2007; there was no change in
the diagnostic criteria for AA or GB between the two versions of the WHO classification
Molecular type of GBM: MGMT methylated 20%, MGMT unmethylated 36%, inconclusive/missing (44%)
(data for all analysed participants)
Performance status: unclear
Interventions Arm 1: standard RT (60 Gy in 30 x 2 Gy fractions)
Arm 2: temozolomide (TMZ)a one week on/one week o$ schedule
Outcomes The primary endpoint was OS, measured in days from surgery to death. Secondary efficacy end points
included event-free survival (EFS), best response, HRQOL (QLQ-C30 and QLQ-BN20 and safety.
Notes Author conclusions: NOA-08 broadens the spectrum of primary treatment of elderly patients with ma-
lignant gliomas by demonstrating the non-inferiority of primary treatment of elderly patients with ma-
lignant gliomas with TMZ alone. It implements MGMT promoter methylation as a relevant biomarker to
decide, when patients may be under-treated with primary RT alone.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Participant allocation was done according to an electronically-generated
randomisation list in blocks of variable length without stratification. The se-
quence was generated prior to study start at the independent Contract Re-
search Organization (CRO), Alcedis (Gießen, Germany).
Allocation concealment
(selection bias)
Low risk Enrolment was done at the study site by an investigator. Assignment was ini-
tiated by FAX transmission from the study site to the CRO for single patients
fulfilling the eligibility criteria. A responsible project manager at the CRO per-
formed the randomisation process and reported the assignment to the trial
group via FAX transmission to the study site.
Wick 2012  (Continued)
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High risk Blinding of investigators or participants was impossible.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
High risk Similarly the data had to be analysed with knowledge of the group assign-




High risk Overall dropout rate less than 20% with moderate imbalance between TMZ
and RT with higher dropout in the RT group (5% versus 14%)
Selective reporting (re-
porting bias)
Low risk Pre-specified outcomes were reported.
Other bias Unclear risk None noted.
Wick 2012  (Continued)
BCNU: carmustine; BEV: bevacizumab; DFS: deterioration-free survival; GBM: glioblastoma; HR: hazard ratio; HRQoL: health-related
quality of life; IRI: irinotecan; nITT: intention-to-treat; IV: intravenous; kg: kilogram; KPS: Karnofsky performance score; MGMT:
methylguanine-DNA-methyltransferase; MMSE: Mini Mental State Exam; MRI: magnetic resonance imaging; OS: overall survival; PFS:
progression-free survival; RCT: randomised controlled trial; RT: radiotherapy; SD: standard deviation; TMZ: temozolomide; TTF: tumour
treating fields; WHO: World Health Organization.
 
Characteristics of excluded studies [ordered by study ID]
 
Study Reason for exclusion
Ali 2018 Ineligible population - no data for the elderly subgroup. This is a recent report of an older trial
(RTOG 9006) with negative findings, for which recruitment occurred from 1990 to 1994. Hyperfrac-
tionated RT (72 Gy in 60 twice-daily fractions) was compared with standard RT (60 Gy in 30 daily
fractions) for GBM treatment and the authors reported that there was no indication of, or trend to-
wards, benefit with hyperfractionated RT for GBM. Although the study included 235/694 people 60
years of age and older, findings for the older subgroup were not reported separately.
Armstrong 2013 Ineligible population - no data for the elderly subgroup. This is a report of a secondary analysis of
RTOG 0525 trial (NCT00304031) comparing conventional adjuvant temozolomide (TMZ) with dose-
intensive TMZ in patients with newly diagnosed glioblastoma on quality of life outcomes. The tri-
al recruited patients age 21 to 84 years. The proportion of patients age 65 or more is unknown and
analysis was stratified only by age threshold of 50 years.
Athanassiou 2005 Ineligible population - no data for the elderly subgroup. This is a report of a phase 2 trial of TMZ
and radiotherapy in comparison to radiotherapy alone in patients with newly diagnosed glioblas-
toma multiforme. The trial recruited patients age 18 and more with unknown proportion of elderly
patients (65 years or more). The age (> 50 years) is evaluated as a predictor for time to progression
and overall survival - HR 1.75 (P value 0.067) and 1.86 (P value 0.058), respectively.
Balana 2016 Ineligible population - no data for the elderly subgroup. This is a report of a phase 2 GENOM 009
trial of bevacizumab (BEV) and TMZ in comparison to TMZ alone as neoadjuvant treatment in pa-
tients with unresected glioblastoma. The trial recruited patients age 18 to maximum 75 years. The
number of participants available for analysis for progression-free survival, overall survival and toxi-
city was 93 (45 TMZ and 48 TMZ + BEV) with unknown proportion of participants age over 65 or 70.
Bampoe 2000 Ineligible population - no data for the elderly subgroup. This is a report of a trial of brachythera-
py as a boost treatment (plus radiotherapy versus radiotherapy alone) on quality of life in patients
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with glioblastoma multiforme. The recruitment occurred between 1986 and 1996. The inclusion
age was 18 to maximum of 70 years, thus there was no relevant subgroup of patients in this trial.
Batchelor 2013 Ineligible population - recurrent glioblastoma. This is a report of a phase 3, placebo-controlled, RE-
GAL trial (NCT00777153) in patients with recurrent glioblastoma.
Beije 2015 Ineligible population - recurrent glioblastoma. This is a report of a side study of BELOB trial
(NTR1929) in patients with recurrent glioblastoma.
The side study assessed the kinetics of the circulating endothelial calls and their prognostic value.
Bent 2009 Ineligible study design. This is a report of a side study of EORTC Brain Tumor Group Study 26951
in participants with anaplastic oligodendroglial tumours or anaplastic oligoastrocytoma. The side
study assessed the correlation between MGMT methylation status and outcome and therapy given
in EORTC cohort.
Bhandari 2013 Ineligible study population. This is a conference abstract of a study which full text was published in
2017 (Bhandari 2017). The study did not include an elderly subgroup.
Bhandari 2017 Ineligible study population - no data for the elderly subgroup. This is a report of a comparative
study of adjuvant TMZ six cycles versus extended 12 cycles in newly diagnosed glioblastoma multi-
forme. The study recruited 40 postoperative participants between 2012 and 2013 (age range 18 to
65 years). The report does not present any relevant age-related data analysis.
Bleehen 1981 Ineligible study population - no data for the elderly subgroup. This is a report of a randomised tri-
al of misonidazole and radiotherapy (4 weeks with 43.52 GY and 56.56 over 5.5 weeks) for grades 3
and 4 cerebral astrocytoma. The accrual stopped at the end of 1978, and a total of 55 participants
age 18 to 75 years was recruited across three arms. The proportion of those age 65 (or 70) or over is
unclear. The report does not present any relevant age-related data analysis.
Bleehen 1991 Ineligible study population - no data for the elderly subgroup. This is a report of a randomised trial
of two radiotherapy doses in the treatment of grades 3 and 4 astrocytoma. The study randomised
474 patients between 1983 and 1988 (age range 18 -73 years). There were a total of 140 participants
age 60-73. The proportion of participants age 65 (or 70) or over is unknown. The report does not
present any relevant age-related data analysis.
Blumenthal 2015 Ineligible study population - no data for the elderly subgroup. This is a report of a phase 3 ran-
domised trial of radiation therapy (RT) and O6-benzylguanine + BCNU compared with RT and BCNU
alone in newly diagnosed glioblastoma and gliosarcoma (SWOG S0001). The study was terminated
in 2015, at the time of the interim analysis, per recommendation of the Data and Safety Monitoring
Committee. Up to that point, 183 participants were registered. The proportion of participants age
65 or over is unknown (stratification only by below/above 50 years). The report does not present
any relevant age-related data analysis.
Blumenthal 2018 Not a suitable study design. Not a RCT, an exploratory analysis of RTOG 0525 and RTOG 0825 data.
Bogdahn 2011 Wrong population - recurrent glioblastoma. This is a report of a phase 2 randomised trial of target-
ed therapy for high-grade (recurrent /refractory) glioblastoma multiforme or anaplasticastrocy-
toma with TGF-beta2 inhibitor trabedersen.
Boiardi 1992 Wrong population - recurrent glioblastoma. This is a report of a randomised trial of '8-drugs-in-
one-day' combination in treatment of recurrent glioblastoma multiforme.
Boisen 2018 Not a suitable study design. This is a report with a secondary analysis of plasma YKL-40 as a bio-
marker for BEV efficacy using data from AVAglio trial (Chinot et al. 2014)
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Bower 1997 Wrong population - recurrent glioblastoma. This is a report of a phase 2 randomised trial of TMZ in
recurrent or progressive for high-grade glioblastoma multiforme.
Boxerman 2013 Not a suitable study design. This is a report of a secondary analysis using RTOG 0625 and ACRIN
6677 studies to investigate whether early post-treatment progression on FLAIR or post-contrast MRI
predict overall survival.
Brandes 2016 Wrong population - recurrent glioblastoma. This is a report of a phase 2 randomised, non-compar-
ative study of fotemustine or BEV for patients with recurrent glioblastoma (AVAREG).
Brisman 1976 Wrong population - no data for the elderly subgroup. This is a report of a study evaluating adjuvant
nitrosourea chemotherapy with carmustine (BCNU), lomustine (CCNU), or semustine (methyl CC-
NU) in addition to surgery and radiotherapy.The study included 62 participants between 1970 and
1972. Overall, there were less than 20 participants age 65 years or more (18 patients).
Brown 2016 Wrong population - recurrent glioblastoma. This is a report of a phase 2 randomised trial com-
paring cediranib plus gefitinib with cediranib plus placebo in subjects with recurrent/progressive
glioblastoma.
Buckner 2001 Wrong population - no data for the elderly subgroup. This is a report of a phase 3 study of RT plus
carmustine with or without recombinant interferon-alpha in the treatment of patients with newly
diagnosed high-grade glioblastoma. The study enrolled 383 participants between 1990 and 1994 of
which 41% (146) are over 60 years of age. The report does not present any relevant age-related da-
ta analysis.
Buckner 2006 Wrong population - no data for the elderly subgroup. This is a report of a phase 3 trial of carmus-
tine and cisplatin compared with carmustine alone and standard RT or accelerated RT in patients
with glioblastoma multiforme (NCCT 93-72-52 and SWOG 9503). The study included 451 partic-
ipants between 1994 and 1999 of which 34% (137) are over 60 years of age. The report does not
present any relevant age-related data analysis.
Carpentier 2017 Wrong population no data for the elderly subgroup. This is a report of a phase 2 randomised trial
of an intracerebral injection of CpG oligonucleotide for newly diagnosed glioblastoma. The study
recruited 81 participants. The median age is around 60 years (range 42-78), and the proportion of
those age 65 (or 70) or over is unknown. The report does not present any relevant age-related data
analysis.
Castro 1997 Wrong population - insufficient details regarding population's age. This is a report of randomised
study of two doses of neon ion irradiation therapy for glioblastoma. The study recruited 15 partici-
pants of unknown age.
Catterall 1980 Not a suitable study design. This is a report of a controlled, non-randomised, pilot study comparing
fast neutrons with megavoltage X-rays in the treatment of glioblastoma.
Chamberlain 2005 Not a suitable study design. This is a correspondence to the editor of a journal regarding quote:
"Abbreviated course of radiation therapy in older patients with glioblastoma multiforme" (Roa
2004).
Chang 1983 Wrong population - no data for the elderly subgroup. This is a report of a randomised trial of post-
operative RT and combined postoperative RT with chemotherapy in the management of malignant
gliomas. The study enrolled 626 participants between 1974 and 1976. The proportion of trial partic-
ipants age 65 (or 70) or over is unknown (27% were 60 years or over). The report does not present
any relevant age-related data analysis.
Chauffer 2014 Wrong population - no data for the elderly subgroup. This is a report of a phase 2 randomised
trial of irinotecan and BEV as neo-adjuvant to TMZ-based chemoradiation compared with TMZ-
chemoradiation for unresectable glioblastoma (TEMAVIR trial, ANOCEF group). The study included
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120 participants (age 18-70) between 2009 and 2011. The proportion of those age 65 (or 70) or over
is unknown. The report does not present any relevant age-related data analysis.
Chinnaiyan 2018 Wrong population - no data for the elderly subgroup. This is a report of a phase 2 randomised study
of everolimus in combination with chemoradiation (EVE+RT+TMZ) in newly diagnosed glioblas-
toma (NRG Oncology RTOG 0913). The study randomised 171 participants (age 18 or over) between
2012 and 2013. The proportion of those age 70 or over is around 16% (28/171). In the study, the EVE
+RT+TMZ combination was significantly more toxic than RT+TMZ on its own with no results report-
ed for the elderly subgroup.
Chong 2018 Wrong study design - an audit of treatments for the elderly with glioblastoma in a clinical setting in
the UK.
Cianfriglia 1980 Wrong population - no data for the elderly subgroup. This is a report of randomised trial of CC-
NU-chemotherapy in hemispheric supratentorial glioblastoma. The study recruited 103 partici-
pants (age 12 to 80) of which 24 were 60-69 years old and three 70-79 years old.
Clarke 2009 Wrong population - no data for the elderly subgroup. This is a report of a phase 2 randomised trial
comparing chemotherapy followed by either dose-dense or metronomic TMZ in patients with new-
ly diagnosed glioblastoma. The study involved 85 participants (age 18-70) between 2005 and 2007.
The median age in the trial is 56.3 years (range 21-71), and the proportion of those age 65 (or 70) or
over is unknown.
Cohen 2005 Not a suitable study design. This is a approval summary from the Food and Drug Administration or-
ganisation in the US for TMZ combined with RT for the treatment of newly diagnosed glioblastoma
multiforme. The report summarises the findings of Stupp et al. trial (N Engl J Med 2005; 352:987-96)
where the age cap was at 70 years, and the analysis was stratified by < 50 or >= 50.
Combs 2008 Wrong population - no data for the elderly subgroup. This is a report of a randomised trial evalu-
ating toxicity and outcomes in patients with primary glioblastoma treated with postoperative ra-
diochemotherapy comparing two TMZ regimens. The study involved 160 participants between
1999 and 2007. The median age in the study is 60 years and the proportion of those age 65 (or 70) or
over is unknown. The report does not contain any relevant age-related data analysis.
Corn 1994 Not a suitable study design. This is a report of an exploratory analysis of white matter changes in
participants of a trial living more than 18 months. The trial is a phase 1/2 dose-seeking study that
evaluated twice-daily RT for supratentorial high grade malignant gliomas.
Curran 1992 Wrong population - no data for the elderly subgroup. This is a report of a randomised trial com-
paring an accelerated hyperfractionated RT (1.6 Gy twice daily fractions) and bis-chlorethyl ni-
trosourea for malignant glioma. The trial recruited 304 participants (age 18-70) between 1987 and
1989. The proportion of participants age 65 (or 70) or over is unknown. The report does not contain
any relevant age-related data analysis.
Das 2017 Not a suitable study design. This is an opinion piece summarising the available evidence on the
management of glioblastoma in the elderly patients.
Deutsch 1989 Wrong population - no data for the elderly subgroup. This is a report of a randomised trial compar-
ing BCNU with RT, streptozotocin with RT, BCNU with hyperfractionated RT, and BCNU following
misonidazole with RT in the postoperative treatment of malignant glioma (BTCG study 77-02). The
trial recruited 557 participants (age 15 or over) between 1978 and 1980. The median age in the trial
was 58 years (range 15 to 82 years), and the proportion of those age 65 or over is 24.4%. The trial re-
port presents the overall survival data by age for all trial participants without accounting for treat-
ment allocation.
Dherijha 2018 Not a suitable study design. Not a RCT, a retrospective study of survival in elderly patients in two UK
hospitals.
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Dinapoli 1993 Wrong population - no data for the elderly subgroup. This is a report of a phase 3 randomised trial
comparing PCNU and carmustine combined with RT in high-grade glioma. The trial recruited 346
participants (age 18 or over) between 1985 and 1989. The median age in the trial was 59 (age range
21 to 84 years), and the proportion of those age 65 (or 70) or over is unknown. The trial reports the
overall survival by age group for all trial participants without accounting for treatment allocation.
Du 2018 Wrong population - no data for the elderly subgroup. This is a report of a randomised trial of tim-
orazolamide combined with three-dimensional conformal RT on residual disease after surgery of
glioblastoma. The trial recruited 58 participants between 2013 and 2015. The average age in the
study was around 45 years (age range 28-78), and the proportion of those 65 (or 70) or over is un-
known. The report does not contain any relevant age-related data analysis.
Duncan 1986 Wrong population - no data for the elderly subgroup. This is a report of a randomised trial of mixed-
schedule (neutron/photon) irradiation in the treatment of supratentorial astrocytoma (grade 3 &
4). The study involved 61 participants between 1979 and 1982. The study population was stratified
by age group "16-39", "40-59", and "60 and over" with 25 participants in the final group. The report
does not contain any relevant age-related data analysis.
Elinzano 2018 Wrong population - no data for the elderly subgroup. This is a report of a randomised phase 2 trial
comparing poliglumex and RT with combined TMZ and RT for glioblastoma without MGMT methy-
lation. The study randomised 63 participants between 2011 and 2014. Participants' age ranged
from 21 to 82 years and the proportion of those age 65 (or 70) or over is unknown. The report does
not contain any relevant age-related data analysis.
Eljamel 2008 Wrong population - no data for the elderly subgroup. This is a report of a randomised phase 3 trial
comparing ALA and Photofrin® fluorescence-guided resection with repetitive photo-dynamic thera-
py in patients with glioblastoma. The study recruited 27 participants (dates not given) whose mean
age was 59.8 years; the proportion of those age 65 (or 70) or over is unknown. The report does not
contain any relevant age-related data analysis.
Elliott 1997 Wrong population - no data for the elderly subgroup. This is a report of a randomised trail compar-
ing RT combined with dibromodulcitol with RT and BCNU in high grade (3 and 4) astrocytoma. The
study included 238 participants between 1980 and 1985 with 52% (118/229) being 60 years of age
or more. No relevant age-related subgroup analysis - one of stratification factors is age < 55 or >=
55 years.
Espana 1978 Not a suitable study design. This is a report of a one-arm phase 2 trial evaluating dianhydrogalacti-
ol in malignant glioma.
Eyre 1983 Wrong population - no data for the elderly subgroup. This is a report of a randomised trial compar-
ing RT and CCNU with RT, CCNU and procarbazine in patients with glioblastoma following surgery.
The study recruited 117 participants between 1974 and 1975. The median age is around 50 years of
age, and the proportion of those age 65 (or 70) or over is unknown. The report does not contain any
relevant age-related data analysis.
Farkkila 1994 Wrong population - no data for the elderly subgroup. This is a report of a randomised trial compar-
ing intratumoral recombinant gamma-interferon as adjuvant to open cytoreduction and external
irradiation of 60 Gy in adults with high-grade cerebral glioma. The study recruited 32 participants
(years unknown). The age ranged from 18 to 71 years, and the proportion of those age 65 (or 70) or
over is unknown. The report does not contain any relevant age-related data analysis.
Felzmann 2013 Abstract associated with the poster Felzmann 2014.
Felzmann 2014 Conference poster with limited information. This is a conference poster of a randomised trial evalu-
ating safety and efficacy of individualised dendritic cell-based cancer immune therapy for glioblas-
toma. The study recruited 105 participants (years unknown). The age ranged from 18 to 70 years,
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and the proportion of those age 65 and over is unknown. The report does not contain any relevant
age-related data analysis.
Field 2015 Wrong population - recurrent glioblastoma. This is a report of a randomised phase 2 trial of carbo-
platin and bevacizumabin recurrent glioblastoma.
Field 2017 Wrong population - recurrent glioblastoma. This is a secondary analysis of health-related quali-
ty of life outcomes from a randomised phase 2 trial of carboplatin and bevacizumabin recurrent
glioblastoma (Field 2015).
Fischer 1985 Wrong population - no data for the elderly subgroup. This is a report of a randomised trial of RT
with or without Levamisole in glioblastoma. The study randomised 25 participants (years un-
known) of which only 10 were over 65 years of age.
Fulton 1984 Wrong population - no data for the elderly subgroup. This is a report of a randomised trial compar-
ing misonidazole combined with hyperfractionation in malignant glioma. The randomisation to
three arms (RT, fractionated RT and fractionated RT with misonidazole) took place between 1981
and 1982. Subsequently RT arm was dropped and a high dose fractionated RT added. Overall, 128
people with glioblastoma were evaluated (age range 18 to 70) of which 47 were over 60 years of
age. The report does not contain any relevant age-related data analysis.
Gaber 2013 Wrong population - no data for the elderly subgroup. This is a report of a randomised trial compar-
ing toxicity and efficacy of continuous daily radiosensitiser doses of TMZ concomitant with RT in
glioblastoma. The study recruited 60 participants between 2009 and 2012. The mean age is around
48 years, and the proportion of those age 65 (or 70) or over is unknown (> 50 years 26 participants).
The report does not contain any relevant age-related data analysis.
Gilbert 2013 Wrong population - no data for the elderly subgroup. This is a report of a randomised phase 3 trial
of dose dense TMZ for newly diagnosed glioblastoma. The study randomised 833 participants be-
tween 2006 and 2008. The inclusion age is between 18 and 70 years (no mean or median given), and
the proportion of those age 65 (or 70) or over is unknown (>= 50 years 610 participants). The report
does not contain any relevant age-related data analysis.
Glinski 1993 Wrong population - no data for the elderly subgroup. This is a preliminary report of a randomised
trial of a postoperative hypofractionated RT compared with conventionally fractionated RT in ma-
lignant gliomas. The study recruited 108 participants (44 with histologically-proven glioblastoma
and 64 with anaplastic astrocytoma) between 1984 and 1989. The median age is around 45 years,
and the proportion of those age 65 (or 70) or over is unknown. The report does not contain any rel-
evant age-related data analysis.
Grossman 2003 Wrong population - no data for the elderly subgroup. This is a report of a randomised phase 3 trial
comparing three cycles of infusional carmustine and cisplatin followed by RT with RT and concur-
rent carmustine in newly diagnosed supratentorial glioblastoma (ECOG trial 2394). The study ran-
domised 219 participants between 1996 and 1999. The median age is 55 years, and the proportion
of those age 65 (or 70) or over is unknown. The report does not contain any relevant age-related
data analysis.
Halperin 1993 Not a suitable study design. This is a report with the findings of an analysis of RT data from the CNS
Cancer Consortium's randomised trial (AZQ versus BCNU) in primary malignant brain tumours. The
aim of this analysis was to evaluate the influence of boost field size.
Halperin 1996 Wrong population - no data for the elderly subgroup. This is a report of a randomised phase 3 trial
(two-stage randomisation) of external beam RT, mitomycin C, carmustine, and 6-mercaptopurine
for anaplastic glioma of the brain. During the first randomisation, 327 participants were allocated
to respective treatments and 164 at the second one (years not given). The mean age of participants
at the time of first randomisation is 53 years, and the proportion of those age 65 (or 70) or over is
unknown. The report does not contain any relevant age-related data analysis (stratification < 45
years versus >= 45 years).
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Harada 1996 Wrong population - insufficient details regarding population's age. This is a conference abstract of
a randomised trial of two therapies (RT and MCNU and RT with MCNU with Interferon-beta) for a
malignant glioma. The study recruited unspecified number of participants of unknown age.
Hatlevoll 1985 Wrong population - no data for the elderly subgroup. This is a report of a randomised trial of com-
bined modality treatment of high grade (3 and 4) in operated astrocytoma. The study recruited 280
participants (years unknown) age between 20 and 69 years, thus there is no relevant subgroup of
patients in this trial.
Henriksson 2006 Wrong population - no data for the elderly subgroup. This is a report of a randomised phase 3 trial
comparing three cycles of infusional carmustine and cisplatin followed by RT with RT and concur-
rent carmustine in newly diagnosed supratentorial glioblastoma (ECOG trial 2394). The study ran-
domised 219 participants between 1996 and 1999. The median age is 55 years, and the proportion
of those age 65 (or 70) or over is unknown. The report does not contain any relevant age-related
data analysis.
Hiesiger 1995 Wrong population - no data for the elderly subgroup. This is a report of a randomised trial of in-
tra-arterial cisplatin compared with intravenous PCNU for primary brain tumours (Brain Tumor Co-
operative Group trial 8420A).The study randomised 311 participants of a median age 45. The the
proportion of those age 65 (or 70) or over is unknown. The report does not contain any relevant
age-related data analysis.
Hildebrand 1994 Wrong population - no data for the elderly subgroup. This is a report of a randomised trial of adju-
vant chemotherapy (dibromodulcitol and BCNU) given postoperatively in patients with newly di-
agnosed malignant gliomas.The study run between 1989 and 1991, and 269 participants were ran-
domised to RT or RT with chemotherapy. The median age in the study is 54 years with range be-
tween 19 and 79. The proportion of those age 65 (or 70) or over is unknown. The report does not
contain any relevant age-related data analysis.
Hitchon 1999 Wrong population - no data for the elderly subgroup. This is a report of a long-term follow-up of
patients randomised trial to treatment with and without brachytherapy.The study randomised 26
participants 15 years of age or older (mean age around 56 years). The proportion of those age 65 (or
70) or over is unknown. The report does not contain any relevant age-related data analysis.
Hofland 2014 Wrong population - no data for the elderly subgroup. This is a report of a randomised phase 2 tri-
al of a neoadjuvant BEV and irinotecan compared with BEV and TMZ followed by concomitant
chemoradiotherapy in patients with newly diagnosed glioblastoma. Overall, 65 participants were
randomised between 2008 and 2010. The median age is around 60 years (age range 30-77 years)
with unknown proportion of participants age 65 (or 70) or over. The report does not contain any
relevant age-related data analysis.
Imbesi 2006 Wrong population - no data for the elderly subgroup. This is a report of a randomised phase 3 tri-
al comparing intravenous and intraarterial ACNU in patients with a newly diagnosed glioblastom-
a.Overall, 43 participants were included in the study. The mean age is around 56 years (age range
32 - 69 years) and there was no relevant subgroup of patients in this trial.
Iwadate 1993 Wrong population - no data for the elderly subgroup. This is a report of a randomised trial of in-
tra-arterial mannitol infusion prior to ACNU and cisplatin for malignant brain tumours. The study
randomised 98 participants (years unknown) age between 6 and 69 years, thus there was no rele-
vant subgroup of patients in this trial.
Jeremic 1999 Wrong study design. This is a report of a phase 2 trial (single arm) of short course RT in elderly and
frail patients with glioblastoma. The study involved 47 elderly and frail participants between 1987
and 1993. The age range of included participants was 60 to 76 with a median of 69 years.
Karacetin 2011 Wrong population - no data for the elderly subgroup. This is a report of a randomised trial com-
paring concomitant TMZ and RT with RT alone in newly diagnosed glioblastoma. The study includ-
ed 40 participants between 2004 and 2006. The median age is 51 years (age range 19-73) with un-
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known proportion of participants age 65 (or 70) or over. The report does not contain any relevant
age-related data analysis.
Kim 2011 Wrong population - no data for the elderly subgroup. This is a report of phase 3 randomised trial of
RT followed by adjuvant TMZ with or without neoadjuvant ACNU-CDDP chemotherapy in newly di-
agnosed glioblastoma. The study included 82 participants (48.8% of the target sample) between
2005 and 2007; six participants were subsequently excluded due to ineligibility leaving data from
76 participants available for the analysis. The mean age is around 51 years in both arms with an un-
known proportion of participants age 65 years (or 70) or over. The trial was prematurely terminated
due to unacceptable toxicity.
Knerich 1990 Wrong population - no data for the elderly subgroup. This is a report of a randomised trial compar-
ing single versus multiple drug therapy in the combined treatment of malignant gliomas. The study
included 173 participants between 1983 and 1989. The age of majority of the participants is be-
tween 51 and 77 years, and the proportion of participants age 65 years (or 70) or over is unknown.
The report does not contain any relevant age-related data analysis.
Koc 2008 Wrong study design. This is a report of a prospective evaluation of fluorescein sodium-guided
surgery in glioblastoma.
Kocher 2008 Wrong population - no data for the elderly subgroup. This is a report of a randomised trial of post-
operative radiotherapy and simultaneous TMZ without adjuvant chemotherapy for glioblastoma.
The study included 65 participants between 2002 and 2004. The median age is 58 and 59 years in
RT and RT+TMZ arms, respectively with range 34 and 69 years; there is no relevant subgroup of pa-
tients in this trial.
Kochii 2000 Wrong population - no data for the elderly subgroup. This is a report of a randomised trial of in-
tra-arterial versus intravenous infusion of ACNU in newly diagnosed glioblastoma.
The study included 84 participants between 1987 and 1995. The mean age is 54 and 59 years in in-
tra-arterial and intravenous arms, respectively with range from 16 to 78 years. The proportion of
participants age 65 years (or 70) or over in unknown. The report does not contain any relevant age-
related data analysis.
Kong 2017 Wrong population - no data for the elderly subgroup. This is a report of phase 3 randomised trial of
autologous cytokine-induced killer cell immunotherapy in newly diagnosed glioblastoma.
The study included 180 participants between 2008 and 2012. The mean age is 55 and 54 years in CIK
immunotherapy and control arms, respectively with range from 19 to 68 years. The proportion of
participants age 65 years (or 70) or over in unknown. The report does not contain any relevant age-
related data analysis.
Lamers 2008 Ineligible population and design - no data for the elderly subgroup. This is a report of cost-effec-
tiveness of concomitant and adjuvant TMZ for newly diagnosed glioblastoma in comparison to ra-
diotherapy. The report does not contain any relevant age-related data.
Lanzetta 2003 Ineligible population - no data for the elderly subgroup. This is a report of phase 2 randomised trial
of TMZ with radiochemotherapy for newly diagnosed glioblastoma. The study included 21 partici-
pants between 1999 and 2001. The median age of participants is 44 years with an unknown propor-
tion of participants age 65 years (or 70) or over.The report does not contain any relevant age-relat-
ed data.
Lee 2015 Ineligible population - no data for the elderly subgroup. This is a report of a multi-centre, phase
2, randomised trial of radiotherapy( RT) and TMZ for newly diagnosed glioblastoma. The study in-
cluded 106 participants; the median age of participants is 55 years in RT and 59 years in TMZ arm.
The proportion of participants age 65 yeas (or 70) or over in unknown and the report does not con-
tain any relevant age-related data.
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Lenartz 2000 Ineligible population - no data for the elderly subgroup. This is a report of a randomised trial to
evaluate the effect of adjuvant treatment of glioma with ML-1 standardised mistletoe extract. The
study included 38 participants between 1994 and 1995. The mean age of participants is 57 years
with an unknown proportion of participants age 65 years (or 70) or over. The report does not con-
tain any relevant age-related data.
Levin 1979 Ineligible population - no data for the elderly subgroup. This is a report of phase 3 randomised tri-
al of BCNU, hydroxyurea, and(RT versus BCNU combined with RT for primary malignant gliomas.
The study included 99 participants of unspecified age, and the report does not contain any relevant
age-related data.
Levin 2000 Ineligible population - no data for the elderly subgroup. This is a report of phase 3 randomised tri-
al of chemotherapy (post radiotherapy) an Alpha-Difluoromethylornithine-Procarbazine, N-(2-
Chloroethyl)-N'-cyclohexyl-N-nitrosurea, Vincristine (DFMO-PCV) in comparison to PCV for glioblas-
toma. The study included 272 participants between 1998 and 1999. The median age of participants
is 53 years in DEMO-PCV and 50 years in PCV arm with an unknown proportion of participants age
65 (or 70) or over. The report does not contain any relevant age-related data.
Levin 2006 Ineligible population - no data for the elderly subgroup. This is a report of a randomised, dou-
ble-blind, placebo-controlled trial of marismastat after surgery and radiotherapy for glioblastoma.
The study included 162 participants between 1996 and 19999. The median age of participants is
around 57 years with an unknown proportion of participants age 65 years (or 70) or over. The report
does not contain any relevant age-related data.
Lissoni 1993 Ineligible population - no data for the elderly subgroup. This is a report of a randomised trial of ra-
diotherapy (RT) compared to RT with the long-acting opioid antagonist naltrexone (NTX) for malig-
nant glioma. The study included 21 participants between 1990 and 1992. The median age of partic-
ipants is 52 years in RT and 49 years in RT+NTX arm; the proportion of participants age 65 (or 70) or
over is less than 20.
Lorimer 2016 Not an RCT, a study examining prognostic factors.
Ludgate 1988 Ineligible population - no data for the elderly subgroup. This is a report of a randomised trial of su-
perf ractionated radiotherapy (RT) for malignant gliomas. The study included 76 participants of un-
specified age between 1981 and 1983. The proportion of participants age 65 years (or 70) or over in
unknown. The report does not contain any relevant age-related data.
Mallick 2018 Wrong population - a small study with no elderly subgroup.
Mao 2015 Ineligible population - no data for the elderly subgroup. This is a report of phase 2 randomised,
open-label, trial of early postsurgical TMZ with concomitant RT for newly diagnosed glioblastoma.
The study included 99 participants between 2008 and 2012. The mean age of all participants is 50.2
(SD 11.8) years. The proportion of participants age 65 (or 70) or over is unknown, and the report
does not contain any relevant age-related data.
Marshall 2006 Ineligible population - no data for the elderly subgroup. This is a secondary analysis of a ran-
domised trial of cisplatin with concurrent radiotherapy in glioblastoma on hearing loss. The study
included 451 participants, of which 230 randomised to arms C (standard RT with carmustine and
cisplatin), and D (accelerated RT with carmustine and cisplatin). The mean age of participants at
baseline is 55.8 years, and the proportion of participants age 65 (or 70) or over is unknown. The re-
port does not contain any relevant age-related data.
McCarthy 2017 This is a commentary on the results of the Stupp 2005 trial.
Montemor 2008 Ineligible population - no data for the elderly subgroup. This is a report of a randomised trial of
chemoradiotherapy with weekly paclitaxel (GR1) in comparison to RT alone (GR2) for anaplastic as-
trocytoma (AA) and glioblastoma (GB). The study included 61 participants between 1998 and 2002.
The median age of participants range from 35.29 years in GR1/AA group to 54.33 years in GR2/GB;
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the proportion of participants age 65 (or 70) or over is unknown. The report does not contain any
relevant age-related data.
MRC 1983 Ineligible population - no elderly patients. An RCT of radiotherapy (45 Gy in 20 fractions)plus mis-
onidazole versus radiotherapy with placebo. No therapeutic benefit was reported with misonida-
zole.
Muragaki 2017 Insufficient information - this is a conference abstract of a randomised trial of autologous forma-
lin-fixed tumour vaccine in newly diagnosed glioblastoma.
Nabors 2015 Ineligible population - no data for the elderly subgroup. This is a report of phase 2, open-label ran-
domised trial (CORE study) of two cilengitide regimens in combination with standard care in new-
ly diagnosed glioblastoma and unmethylated MGMT. The study included 265 participants between
2009 and 2013. The median age of participants in the arms range from 55.6 years (standard cilengi-
tide) to 57.7 years (control) years; the proportion of participants age 65 (or 70) or over is unknown.
The report does not contain any relevant age-related data.
Napolitano 1999 Not a suitable study design. This is a report of phase 2 clinical, sequential, study of radiotherapy
and a combination of BCNU and tamoxifen.
Nelson 1988 Ineligible population - no data for the elderly subgroup. This trial with four treatment arms (60 Gy
to the whole brain; 60 Gy plus 10-Gy boost; 60 Gy plus carmustine (BCNU); and 60 Gy plus semus-
tine plus dacarbazine) included Grade 3 and 4 gliomas and stratified findings by under or over 50
years. Eight patients were over 70 years.
Payne 1982 Ineligible population - no data for the elderly subgroup. This is a report of a randomised trial of
chemotherapy with hypofractionated or standard radiotherapy for malignant astrocytoma. The
study included 157 participants between 1977 and 1980. The median age of participants at base-
line is 56 years, and the proportion of participants age 70 and over less than 20 participants (n =
13).
Peszynski 1988 Ineligible population - no data for the elderly subgroup. This is a report of a randomised trial of ra-
diotherapy alone in comparison to radiotherapy with CCNU. The study included 139 participants,
of which none was over 65 years of age.
Phillips 2003 Ineligible population - no data for the elderly subgroup. This is a report of a randomised trial of two
options of radiotherapy (35 Gy in 10 fractions vs 60 Gy in 30 fractions) for glioblastoma in elderly.
The study included 69 participants between 1990 and 1996. The median age of participants is 58
and 59 years in 60 Gy and 35 Gy arms, respectively. The proportion of participants age 65 (or 70) or
over is unknown. The report does not contain any relevant age-related data.
Pinzi 2017 This is an editorial on postoperative chemoradiotherapy in elderly patients with glioblastoma.
Prados 2001 Ineligible population - no data for the elderly subgroup. This is a report of phase 3 randomised tri-
al of accelerated hypofractionation with or without difluromethylornithine (DFMO) in comparison
with standard radiotherapy with or without DFMO in newly diagnosed glioblastoma. The study in-
cluded 231 participants, and their median age is 57 years. The proportion of participants age 65 (or
70) or over in unknown. The report does not contain any relevant age-related data.
Reagan 1976 Ineligible population - no data for the elderly subgroup. This is a report of a randomised trial of
three treatment schedules: radiotherapy (RT) alone, CCNU, and combination of both. The study
included 63 participants between 1970 and 1972. The mean age of participants is 52.3, 53 and 58
years in RT, CCNU and the combined arms, respectively. The proportion of participants age 65 (or
70) or over is unknown. The report does not contain any relevant age-related data.
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Reyes-Botero 2018 Ineligible study design - a non-randomised phase II trial (n = 66) that treated patients aged 70+, and
with a KPS of under 70 with TMZ 130-150 mg/m2 per day for 5 days every 4 weeks concomitantly
with bevacizumab 10 mg/kg every two weeks.
Shapiro 1976 Ineligible population - no data for the elderly subgroup. This is a report of a randomised trial of car-
mustine (group A) and vincristine (group B). The study included 33 participants; the median age of
participants is 60 years in group A and 58 in group B. The proportion of participants age 65 (or 70)
or over is unknown. The report does not contain any relevant age-related data.
Shapiro 1989 Ineligible population - no data for the elderly subgroup. This is a report of a randomised trial of
three chemotherapy (BCNU alone, alternating course BCNU and procarbazine and BCNU with hy-
droxyurea alternating procarbazine and VM-26) and two radiotherapy regimens for malignant
glioma. The study included 571 participants between 1980 and 1981. The median age of partici-
pants is 56 years (range 15 - 84), and the proportion of participants age 65 and or over is 21%, but
the report does not contain any relevant age-related data.
Shapiro 1992 Ineligible population - no data for the elderly subgroup. This is a report of a randomised trial of in-
tra-arterial versus intravenous BCNU, with or without 5-fluorouracil (intravenous) for newly diag-
nosed glioma. The study included 505 participants, and the median age is 56 years. The proportion
of participants age 65 (or 70) or over is 21.4%, but the report does not contain any relevant age-re-
lated data.
Sharma 2003 Ineligible population - no data for the elderly subgroup. This is a report of a randomised trial of two
different radiotherapy regimens. The study included 50 participants age less than 60 years of age
between 1996 and 1998.
Simpson 1976 Ineligible population - no data for the elderly subgroup. This is a report of a randomised trial of two
different radiotherapy regiments. The study included 134 participants of unspecified age between
1965 and 1968. The report does not contain any relevant age-related data.
Sneed 1998 Ineligible population - no data for the elderly subgroup. This is a report of phase 2/3 randomised
trial of brachytherapy boost with or without hyperthermia for glioblastoma. The study included
112 participants between 1990 and 1995. The median age of participants is 54 years (range 21-78).
The proportion of participants age 65 (or 70) or over is unknown, and the report does not contain
any relevant age-related data.
Socha 2016 Ineligible population - recurrent glioblastoma.
Soffietti 2017 Not an RCT, a single-arm study.
Solero 1979 Ineligible population - no data for the elderly subgroup. This is a report of a randomised trial of ra-
diotherapy alone, in combination with BCNU or CCNU. The study included 105 participants of un-
specified age between 1972 and 1976.
Solomon 2013 Ineligible population - no data for the elderly subgroup. This is a report of a randomised trial of ra-
diotherapy (RT) with nimotuzumab or placebo for high-grade glioma (anaplastic astrocytoma and
glioblastoma). The study included 70 participants between 2005 and 2010. The mean age of partici-
pants is 45.5 and 47.2 years in arm without and with nimotuzumab, respectively. The proportion of
participants age 65 (or 70) or over in unknown and the report does not contain any relevant age-re-
lated data.
Solth 2018 Ineligible study design - a clinical audit of treatment of GBM in the elderly in a UK setting.
Souhami 2004 Ineligible population - no data for the elderly subgroup. This is a report of a randomised trial of
stereotactic radiosurgery (SRS) with standard radiotherapy (RT) and carmustine versus RT with car-
mustine for glioblastoma (report of RTOG 93-05 protocol). The study included 203 participants be-
tween 1994 and 2000. The mean age of participants is 55.5 and 56.4 years in RT alone and RT+SRS,
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respectively. The proportion of participants age 65 (or 70) or over in 26.5%, but the report does not
contain any relevant age-related data.
Stadler 1984 Ineligible population - no data for the elderly subgroup. This is a report of 6-month follow-up data
from a randomised trial of misonidazole and radiotherapy for high-grade astrocytoma (The Vienna
study). There were 45 participants available for the analysis by 1983 (study start in 1977). The mean
age of participants is 52 years in misonidazole with RT arm and 56 years in arm with RT alone. The
proportion of participants age 65 (or 70) or over and the report does not contain any relevant age-
related data.
Stragliotto 2013 Not relevant study objective. This is a report of a randomised trial of add-on therapy of valganci-
clovir in cytomegalovirus-positive glioblastoma.
Stummer 2006 Not relevant study objective. This is a report of a randomised trial of fluorescence-guided surgery
with 5-aminolevulinic acid for resection of malignant glioma.
Stummer 2011 This is a secondary report from the randomised 5-aminolevulinic acid study (Stummer 2006).
Stummer 2017 Not relevant study objective. This is a report of a randomised trial comparing three different doses
of 5-aminolevulinic acid for resection of malignant glioma.
Stupp 2002 Not a suitable study design. This is a report of a study investigating the safety, tolerability, and sur-
vival of radiotherapy with temozolomide (TMZ) followed by adjuvant TMZ for newly diagnosed
glioblastoma.
Stupp 2005 Ineligible population - no data for the elderly subgroup. This is a report of a randomised trial of ra-
diotherapy (RT) alone vs RT with temozolomide (TMZ) both followed by adjuvant TMZ. The study
included 573 participants between 2000 and 2002. The median age of the participants is 56 years,
and the proportion of participants age 65 (or 70) or over in unknown.
Stupp 2009 Ineligible population. This is a report with a five-year follow-up data of the Stupp 2005 trial.
Stupp 2014 Ineligible population - no data for the elderly subgroup. This is a report of phase 3 randomised tri-
al of cilengitide with the standard of care for newly diagnosed glioblastoma with methylated MGMT
(CENTRIC EORTC 26071-22072). The study included 545 participants between 2008 and 2011.The
median age of the participants is 58 years in both arms with an unknown proportion of participants
age 65 (or 70) or over. The report does not contain any relevant age-related data.
Stupp 2015 Ineligible population - no data for the elderly subgroup. This is a report of an interim analysis of the
randomised trial of Tumor-Treating Fields with temozolomide (TMZ) in comparison to TMZ alone
for glioblastoma. The study included 315 participants between 2009 and 2014. The mean age of the
participants in the sample is 55.8 years (median 57) in both arms with an unknown proportion of
participants age 65 (or 70) or over. The report does not contain any relevant age-related data.
Szczepanek 2013 Ineligible population - no data for the elderly subgroup. This is a report of a randomised trial of ra-
diotherapy (RT) alone in comparison to RT with temozolomide (TMZ) both followed by adjuvant
TMZ. The study included 58 participants between 2003 and 2005. The mean age of the participants
is 55 years, and the proportion of participants age 65 (or 70) or over is unknown.
Takakura 1986 Ineligible population - no data for the elderly subgroup. This is a report of a randomised trial of ra-
diotherapy (RT) alone in comparison to RT with ACNU for malignant gliomas. The study included
105 participants between 1980 and 1981. Neither the median age of the participants nor the pro-
portion of participants age 65 (or 70) or over is given.
Taphoorn 2005 Ineligible population. This is a secondary analysis of Stupp 2005 trial focusing on the quality of life
data.
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Urtasun 1982 Ineligible population - no data for the elderly subgroup. This is a report of a randomised trial of ra-
diotherapy and misonidazole for high-grade glioma. The study included 59 participants. The mean
age of participants was 55, 56 and 59 years in RT alone, RT with metronidazole and RT with mis-
onidazole respectively. The proportion of participants age 65 (or 70) or over is unknown, and the
report does not contain any relevant age-related data.
Ushio 1985 Ineligible population - no data for an elderly subgroup. 13/105 patients were over 60 in this Japan-
ese trial.
Vellayappan 2017 This is an editorial on combined-modality hypofractionated radiotherapy for elderly with glioblas-
toma.
Wakabayashi 2018 Inelgible population - no elderly subgroup.
Wang 2008 No PDF available.
Weller 2003 Ineligible population - no data for the elderly subgroup. This is a report of a randomised trial of ra-
diotherapy with ACNU and VM26 in comparison to RT with ACNU and Ara-C for glioma (glioblas-
toma or anaplastic gliomas). The study included 375 participants between 1994 and 2000. The me-
dian age of the participants is 50 and 51 years in ACNU + VM26 and ACNU+Ara-C arm. The propor-
tion of participants age 65 (or 70) or over is unknown, and the report does not contain any relevant
age-related data.
Werner-Wasik 1996 Ineligible population - no data for the elderly subgroup. This is a report of phase 1/2 randomised
trial of two regimens of radiotherapy (hypofractionated versus accelerated hypofractionated), both
with carmustine for malignant gliomas. The study included 747 participants between 1983 and
1989. The mean age of the participants is 52.3 years in the study, and the proportion of participants
age 65 (or 70) or over is unknown. The report does not contain any relevant age-related data.
Westphal 2003 Ineligible population - no data for the elderly subgroup. This is a report of phase 3 randomised tri-
al of chemotherapy with BCNU wafer for primary malignant glioma. The study included 240 partic-
ipants between 1997 and 1999. The mean age of the participants is 52.6 in the wafer arm and 53.6
years in the placebo arm. The proportion of participants age 65 (or 70) or over is unknown, and the
report does not contain any relevant age-related data.
Westphal 2006 Ineligible population. This is a secondary analysis of long-term follow-up data of a Westphal 2003
trial.
Westphal 2013 Not relevant study objective. This is a report of phase 3 randomised trial of locally applied aden-
ovirus-mediated gene therapy with a prodrug converting enzyme (herpes-simplex-virus thymidine
kinase; sitimagene ceradenovec) followed by intravenous ganciclovir in patients with newly diag-
nosed resectable glioblastoma (ASPECT).
Westphal 2015 Ineligible population - no data for the elderly subgroup. This is a report of phase 3, open-label ran-
domised trial of nimotuzumab for newly diagnosed glioblastoma. The study included 149 partic-
ipants between 2007 and 2010. The mean age of participants in the experimental arm is 52.9 and
55.9 years in the control arm. The proportion of participants age 65 (or 70) or over in unknown. The
report does not contain any relevant age-related data.
Wick 2009 Ineligible population - no data for the elderly subgroup. This is a report of phase 3 randomised trial
of sequential radiochemotherapy with procarbazine, lomustine, and vincristine or temozolomide
for anaplastic glioma. The study included 318 (analysed data from 274) participants between 1999
and 2005. The median age of the participants is 44 in RT arm and 42 years in PCV or TMZ arm. The
proportion of participants age 65 (or 70) or over is unknown, and the report does not contain any
relevant age-related data.
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Wick 2016 Ineligible population - no data for the elderly subgroup. This is a report of phase 2 randomised tri-
al of radiotherapy (RT) and temsirolimus (TEM) in comparison to radiochemotherapy with temo-
zolomide for newly diagnosed glioblastoma without MGMT (EORTC 26082). The study included 257
participants between 2009 and 2012. The median age of the participants is 55 and 58 years in TEM
and standard of care arm, respectively. The proportion of participants age 65 (or 70) or over is un-
known, and the report does not contain any relevant age-related data.
Yang 2018 Ineligible population - no data for the elderly subgroup. This is a report of a randomised trial of ra-
diotherapy (RT) with concomitant and adjuvant temozolomide (TMZ) versus RT with concomitant
and adjuvant local delivery of ACNU rendezvousing with oral TMZ. The study included only partici-
pants age 18 to 65 years.
Zhu 2017 Ineligible population. This is a secondary analysis of Stupp 2015 trial focusing on the quality of life
data.
ACNU: nimustine; BCNU: carmustine; BEV: bevacizumab; CCNU: lomustine; CDDP: cisplatin; CIK: cytokine-induced killer cells;GBM:
glioblastoma; HR: hazard ratio; KPS: Karnofsky performance score; MGMT: methylguanine-DNA-methyltransferase; MRI: magnetic
resonance imaging; PCV: procarbazine and vincristine; RT: radiotherapy; SRD: stereotactic radiosurgery; TEM: temsirolimusTMZ:
temozolomide; RTOG:Radiation Therapy Oncology Group.
 
Characteristics of ongoing studies [ordered by study ID]
 
Trial name or title A randomised trial investigating the additional benefit of Hydroxychloroquine (HCQ) to short
course radiotherapy (SCRT) in patients aged 70 years and older with high grade gliomas (HGG) Clin-
icalTrials.gov Identifier: NCT01602588
Methods Phase II, parallel two-arm, open-label RCT with randomisation in 1:2 ratio
Participants Target sample: 57
Actual enrolment: 54
Inclusion: aged 70+. ECOG PS 0 or 1.
Interventions Reference arm: short course RT alone. Dose is 30 Gy in 6 fractions given on alternate days over 2
weeks.
Experimental arm: short course RT plus hydroxychloroquine 200 mg orally twice daily from 14 days
after surgery until progression.
Outcomes Analysis will be by ITT, whereby patients will be examined according to the assigned treatment.
Primary outcome: survival time at 1 year.
Secondary outcomes
Toxicity/adverse events during and up to 30 days after treatment.
One-year cause-specific survival and 6-month progression-free survival.
HRQoL – difference between HRQoL at 8 weeks post treatment compared to baseline will be as-
sessed. HRQoL questionnaires used are QLQ-C30 and BN20.
Corticosteroid dependence.
Starting date Opened to recruitment on 21st May 2012.
NCT01602588 
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Study completion date: November 2017.
Contact information Professor Susan Short, St James’s University Hospital, Leeds
UCL (sponsor)
CRUK (funder)
Notes Authors were contacted on 16/03/2020 and we were informed that publication of the full paper was




Trial name or title A randomised phase II study of NivolUmab and TeMozolomide versus temozolomide alone in newly
diagnosed Elderly patients with Glioblastoma (NUTMEG) to analyse overall survival.
Study registration ID: ACTRN12617000267358
Methods Phase II parallel two-arm, multi-centre, open-label RCT with randomisation in 2:1 ratio
Participants Target sample size: 102
Adults 65 years or above, with newly diagnosed histologically confirmed GBM (WHO grade IV
glioma including gliosarcoma) following surgery.
Interventions Intervention
Patients will receive radiotherapy (40 Gy/15 fractions, weekdays over 21 days) concomitantly with
temozolomide (TMZ) tablets 75 mg/m2 daily for 21 days.
After a 4-week break the experimental group will receive nivolumab intravenous infusions (240 mg
days 1 and 15 every 28 days for cycles 1-4; then 480 mg day 1 every 28 days for cycles 5-6) with con-
comitant adjuvant TMZ tablets days 1-5, every 28 days) for 6 cycles. TMZ will be dosed at 150 mg/
m2 for the first cycle. If well tolerated TMZ is then given at 200 mg/m2 for cycles 2 - 6.
Comparator
Patients will receive RT (40 Gy/15 fractions) concomitantly with temozolomide (TMZ) 75 mg/m2.
Patients assigned to the control group will receive the standard treatment of adjuvant TMZ (150
mg/m2 to 200 mg/m2 days 1-5 every 28 days) for 6 cycles.
Outcomes Overall survival, progression-free survival, adverse events, QoL, neurological functioning
Patients are assessed at baseline then every 8 weeks until study treatment finishes/disease pro-
gression.
Starting date 02/03/2018
Contact information NUTMEG Trial Co-ordinator
nutmeg@ctc.usyd.edu.au
Notes The study aims to evaluate whether the combination of adjuvant nivolumab with TMZ improves
overall survival outcomes for this patient population.
NUTMEG 2018 
GBM: glioblastoma; MGMT: methylguanine-DNA-methyltransferase; HRQoL: health-related quality of life; RCT: randomised controlled
trial; RT: radiotherapy; TMZ: temozolomide;WHO: World Health Organization
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Statistical method Effect size
1 HRQOL 1   Mean Difference (IV, Random, 95% CI) Subtotals only
1.1 At 30 days 1 59 Mean Difference (IV, Random, 95% CI) -4.20 [-6.33, -2.07]
1.2 At 60 days 1 45 Mean Difference (IV, Random, 95% CI) -4.70 [-7.33, -2.07]
1.3 At 90 days 1 39 Mean Difference (IV, Random, 95% CI) -7.60 [-11.03, -4.17]
1.4 At 135 days 1 26 Mean Difference (IV, Random, 95% CI) 10.70 [6.01, 15.39]
2 Cognition 1   Mean Difference (IV, Random, 95% CI) Subtotals only
2.1 At 30 days 1 59 Mean Difference (IV, Random, 95% CI) -0.40 [-3.24, 2.44]
2.2 At 60 days 1 45 Mean Difference (IV, Random, 95% CI) -5.60 [-9.20, 0.00]
2.3 at 90 days 1 39 Mean Difference (IV, Random, 95% CI) -21.0 [-25.18, -16.82]
2.4 at 135 days 1 26 Mean Difference (IV, Random, 95% CI) -13.0 [-18.84, -7.16]
3 Fatigue 1   Mean Difference (IV, Random, 95% CI) Subtotals only
3.1 At 30 days 1 59 Mean Difference (IV, Random, 95% CI) 2.10 [-0.49, 4.69]
3.2 At 60 days 1 45 Mean Difference (IV, Random, 95% CI) 8.60 [4.77, 12.43]
3.3 At 90 days 1 39 Mean Difference (IV, Random, 95% CI) 11.70 [8.24, 15.16]
3.4 At 135 days 1 26 Mean Difference (IV, Random, 95% CI) 0.5 [-6.68, 7.68]
4 Progression-free sur-
vival
1 81 Hazard Ratio (Random, 95% CI) 0.28 [0.17, 0.46]
 
 
Analysis 1.1.   Comparison 1 Radiotherapy (50 Gy) versus supportive care, Outcome 1 HRQOL.
Study or subgroup RT Supportive care Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
1.1.1 At 30 days  
Keime-Guibert 2007 31 57.6 (3.5) 28 61.8 (4.7) 100% -4.2[-6.33,-2.07]
Subtotal *** 31   28   100% -4.2[-6.33,-2.07]
Heterogeneity: Not applicable  
Test for overall effect: Z=3.86(P=0)  
Favours supportive care 10050-100 -50 0 Favours RT
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Study or subgroup RT Supportive care Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
   
1.1.2 At 60 days  
Keime-Guibert 2007 23 55.6 (3.9) 22 60.3 (5) 100% -4.7[-7.33,-2.07]
Subtotal *** 23   22   100% -4.7[-7.33,-2.07]
Heterogeneity: Not applicable  
Test for overall effect: Z=3.51(P=0)  
   
1.1.3 At 90 days  
Keime-Guibert 2007 22 49.1 (4) 17 56.7 (6.3) 100% -7.6[-11.03,-4.17]
Subtotal *** 22   17   100% -7.6[-11.03,-4.17]
Heterogeneity: Not applicable  
Test for overall effect: Z=4.34(P<0.0001)  
   
1.1.4 At 135 days  
Keime-Guibert 2007 16 58.8 (4.5) 10 48.1 (6.7) 100% 10.7[6.01,15.39]
Subtotal *** 16   10   100% 10.7[6.01,15.39]
Heterogeneity: Not applicable  
Test for overall effect: Z=4.47(P<0.0001)  
Favours supportive care 10050-100 -50 0 Favours RT
 
 
Analysis 1.2.   Comparison 1 Radiotherapy (50 Gy) versus supportive care, Outcome 2 Cognition.
Study or subgroup RT Supportive care Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
1.2.1 At 30 days  
Keime-Guibert 2007 31 59.6 (4.9) 28 60 (6.1) 100% -0.4[-3.24,2.44]
Subtotal *** 31   28   100% -0.4[-3.24,2.44]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.28(P=0.78)  
   
1.2.2 At 60 days  
Keime-Guibert 2007 23 57.4 (6.7) 22 63 (5.6) 100% -5.6[-9.2,-2]
Subtotal *** 23   22   100% -5.6[-9.2,-2]
Heterogeneity: Not applicable  
Test for overall effect: Z=3.05(P=0)  
   
1.2.3 at 90 days  
Keime-Guibert 2007 22 42.8 (7.1) 17 63.8 (6.2) 100% -21[-25.18,-16.82]
Subtotal *** 22   17   100% -21[-25.18,-16.82]
Heterogeneity: Not applicable  
Test for overall effect: Z=9.84(P<0.0001)  
   
1.2.4 at 135 days  
Keime-Guibert 2007 16 43.8 (6.7) 10 56.8 (7.8) 100% -13[-18.84,-7.16]
Subtotal *** 16   10   100% -13[-18.84,-7.16]
Heterogeneity: Not applicable  
Test for overall effect: Z=4.36(P<0.0001)  
Favours supp care 10050-100 -50 0 Favours RT
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Analysis 1.3.   Comparison 1 Radiotherapy (50 Gy) versus supportive care, Outcome 3 Fatigue.
Study or subgroup RT Supportive care Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
1.3.1 At 30 days  
Keime-Guibert 2007 31 39.5 (4.9) 28 37.4 (5.2) 100% 2.1[-0.49,4.69]
Subtotal *** 31   28   100% 2.1[-0.49,4.69]
Heterogeneity: Not applicable  
Test for overall effect: Z=1.59(P=0.11)  
   
1.3.2 At 60 days  
Keime-Guibert 2007 23 48.9 (6.3) 22 40.3 (6.8) 100% 8.6[4.77,12.43]
Subtotal *** 23   22   100% 8.6[4.77,12.43]
Heterogeneity: Not applicable  
Test for overall effect: Z=4.4(P<0.0001)  
   
1.3.3 At 90 days  
Keime-Guibert 2007 22 52.8 (5) 17 41.1 (5.8) 100% 11.7[8.24,15.16]
Subtotal *** 22   17   100% 11.7[8.24,15.16]
Heterogeneity: Not applicable  
Test for overall effect: Z=6.63(P<0.0001)  
   
1.3.4 At 135 days  
Keime-Guibert 2007 16 57.9 (5.3) 10 57.4 (10.8) 100% 0.5[-6.68,7.68]
Subtotal *** 16   10   100% 0.5[-6.68,7.68]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.14(P=0.89)  
Favours supportive care 10050-100 -50 0 Favours RT
 
 
Analysis 1.4.   Comparison 1 Radiotherapy (50 Gy) versus supportive care, Outcome 4 Progression-free survival.




Hazard Ratio Weight Hazard Ratio
  N N (SE) IV, Random, 95% CI   IV, Random, 95% CI
Keime-Guibert 2007 39 42 -1.3 (0.255) 100% 0.28[0.17,0.46]
   
Total (95% CI)       100% 0.28[0.17,0.46]
Heterogeneity: Not applicable  
Test for overall effect: Z=5(P<0.0001)  
Favours RT 1000.01 100.1 1 Favours supportive care
 
 
Comparison 2.   Short-course radiotherapy versus standard radiotherapy





Statistical method Effect size
1 HRQOL at 4 weeks 2   Mean Difference (IV, Random, 95%
CI)
Subtotals only
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Statistical method Effect size
1.1 RT (40 Gy) vs RT (60 Gy) 1 85 Mean Difference (IV, Random, 95%
CI)
0.0 [0.0, 0.0]
1.2 RT (25 Gy) vs RT (40 Gy) 1 40 Mean Difference (IV, Random, 95%
CI)
3.40 [-8.33, 15.13]
2 HRQOL at 8 weeks 2   Mean Difference (IV, Random, 95%
CI)
Subtotals only
2.1 RT (40 Gy) vs RT (60 Gy) 1 72 Mean Difference (IV, Random, 95%
CI)
0.0 [0.0, 0.0]
2.2 RT (25 Gy) vs RT (40 Gy) 1 24 Mean Difference (IV, Random, 95%
CI)
0.0 [-13.58, 13.58]
3 Treatment toxicity G3+ 1   Risk Ratio (M-H, Random, 95% CI) Subtotals only
3.1 RT (40 Gy) vs RT (60 Gy) 1 61 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
 
 
Analysis 2.1.   Comparison 2 Short-course radiotherapy versus standard radiotherapy, Outcome 1 HRQOL at 4 weeks.
Study or subgroup Short course Standard Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
2.1.1 RT (40 Gy) vs RT (60 Gy)  
Roa 2004 43 0 (0) 42 0 (0)   Not estimable
Subtotal *** 43   42   Not estimable
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
2.1.2 RT (25 Gy) vs RT (40 Gy)  
Roa 2015 20 51.7 (18) 20 48.3 (19.8) 100% 3.4[-8.33,15.13]
Subtotal *** 20   20   100% 3.4[-8.33,15.13]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.57(P=0.57)  
Favours standard 10050-100 -50 0 Favours short course
 
 
Analysis 2.2.   Comparison 2 Short-course radiotherapy versus standard radiotherapy, Outcome 2 HRQOL at 8 weeks.
Study or subgroup Short course RT Standard RT Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
2.2.1 RT (40 Gy) vs RT (60 Gy)  
Roa 2004 38 0 (0) 34 0 (0)   Not estimable
Subtotal *** 38   34   Not estimable
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
Favours standard 10050-100 -50 0 Favours short course
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Study or subgroup Short course RT Standard RT Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
2.2.2 RT (25 Gy) vs RT (40 Gy)  
Roa 2015 12 48.6 (18.4) 12 48.6 (15.4) 100% 0[-13.58,13.58]
Subtotal *** 12   12   100% 0[-13.58,13.58]
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
Favours standard 10050-100 -50 0 Favours short course
 
 
Analysis 2.3.   Comparison 2 Short-course radiotherapy versus
standard radiotherapy, Outcome 3 Treatment toxicity G3+.
Study or subgroup Short course RT Standard RT Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
2.3.1 RT (40 Gy) vs RT (60 Gy)  
Roa 2015 0/35 0/26   Not estimable
Subtotal (95% CI) 35 26 Not estimable
Total events: 0 (Short course RT), 0 (Standard RT)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
Favours short course 1000.01 100.1 1 Favours standard
 
 
Comparison 3.   Chemotherapy versus radiotherapy





Statistical method Effect size
1 Progression-free survival 1   Hazard Ratio (Random, 95% CI) Subtotals only
1.1 TMZ vs RT (60 Gy) 1 373 Hazard Ratio (Random, 95% CI) 1.15 [0.92, 1.44]
2 Thromboembolic event G3+ 1   Risk Ratio (M-H, Random, 95% CI) Subtotals only
2.1 TMZ vs RT (60 Gy) 1 373 Risk Ratio (M-H, Random, 95% CI) 2.74 [1.26, 5.94]
3 Neutropenia G3+ 1   Risk Ratio (M-H, Random, 95% CI) Subtotals only
3.1 TMZ vs RT (60 Gy) 1 373 Risk Ratio (M-H, Random, 95% CI) 7.30 [1.70, 31.31]
4 Lymphopenia G3+ 1   Risk Ratio (M-H, Random, 95% CI) Subtotals only
4.1 TMZ vs RT (60 Gy) 1 373 Risk Ratio (M-H, Random, 95% CI) 41.99 [5.85, 301.31]
5 Thrombocytopenia G3+ 1   Risk Ratio (M-H, Random, 95% CI) Subtotals only
5.1 TMZ vs RT (60 Gy) 1 373 Risk Ratio (M-H, Random, 95% CI) 3.19 [1.07, 9.53]
6 Infection G3+ 1   Risk Ratio (M-H, Random, 95% CI) Subtotals only
6.1 TMZ vs RT (60 Gy) 1 373 Risk Ratio (M-H, Random, 95% CI) 1.39 [0.86, 2.26]
Treatment of newly diagnosed glioblastoma in the elderly: a network meta-analysis (Review)









Cochrane Database of Systematic Reviews





Statistical method Effect size
7 Fatigue/asthenia G3+ 1   Risk Ratio (M-H, Random, 95% CI) Subtotals only
7.1 TMZ vs RT (60 Gy) 1 373 Risk Ratio (M-H, Random, 95% CI) 1.10 [0.63, 1.91]
8 Nausea/vomiting G3+ 1   Risk Ratio (M-H, Random, 95% CI) Subtotals only
8.1 TMZ vs RT (60 Gy) 1 373 Risk Ratio (M-H, Random, 95% CI) 5.48 [0.67, 45.05]
9 Weight loss G3+ 1   Risk Ratio (M-H, Random, 95% CI) Subtotals only
9.1 TMZ vs RT (60 Gy) 1 373 Risk Ratio (M-H, Random, 95% CI) 4.57 [0.22, 94.47]
10 Neurological symptoms G3+ 1   Risk Ratio (M-H, Random, 95% CI) Subtotals only
10.1 TMZ vs RT (60 Gy) 1 373 Risk Ratio (M-H, Random, 95% CI) 1.31 [0.82, 2.10]
11 Seizures G3+ 1   Risk Ratio (M-H, Random, 95% CI) Subtotals only
11.1 TMZ vs RT (60 Gy) 1 373 Risk Ratio (M-H, Random, 95% CI) 1.19 [0.60, 2.39]
12 Elevated liver enzymes G3+ 1   Risk Ratio (M-H, Random, 95% CI) Subtotals only
12.1 TMZ vs RT (60 Gy) 1 373 Risk Ratio (M-H, Random, 95% CI) 1.71 [0.97, 3.03]
13 Cutaneous adverse event G3+ 1   Risk Ratio (M-H, Random, 95% CI) Subtotals only
13.1 TMZ vs RT (60 Gy) 1 373 Risk Ratio (M-H, Random, 95% CI) 0.91 [0.06, 14.49]
 
 
Analysis 3.1.   Comparison 3 Chemotherapy versus radiotherapy, Outcome 1 Progression-free survival.
Study or subgroup CT RT log[Hazard
Ratio]
Hazard Ratio Weight Hazard Ratio
  N N (SE) IV, Random, 95% CI   IV, Random, 95% CI
3.1.1 TMZ vs RT (60 Gy)  
Wick 2012 195 178 0.1 (0.114) 100% 1.15[0.92,1.44]
Subtotal (95% CI)       100% 1.15[0.92,1.44]
Heterogeneity: Not applicable  
Test for overall effect: Z=1.23(P=0.22)  
Favours CT 1000.01 100.1 1 Favours RT
 
 
Analysis 3.2.   Comparison 3 Chemotherapy versus radiotherapy, Outcome 2 Thromboembolic event G3+.
Study or subgroup CT RT Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
3.2.1 TMZ vs RT (60 Gy)  
Wick 2012 24/195 8/178 100% 2.74[1.26,5.94]
Favours CT 1000.01 100.1 1 Favours RT
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Study or subgroup CT RT Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Subtotal (95% CI) 195 178 100% 2.74[1.26,5.94]
Total events: 24 (CT), 8 (RT)  
Heterogeneity: Not applicable  
Test for overall effect: Z=2.55(P=0.01)  
Favours CT 1000.01 100.1 1 Favours RT
 
 
Analysis 3.3.   Comparison 3 Chemotherapy versus radiotherapy, Outcome 3 Neutropenia G3+.
Study or subgroup CT RT Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
3.3.1 TMZ vs RT (60 Gy)  
Wick 2012 16/195 2/178 100% 7.3[1.7,31.31]
Subtotal (95% CI) 195 178 100% 7.3[1.7,31.31]
Total events: 16 (CT), 2 (RT)  
Heterogeneity: Not applicable  
Test for overall effect: Z=2.68(P=0.01)  
Favours CT 1000.01 100.1 1 Favours RT
 
 
Analysis 3.4.   Comparison 3 Chemotherapy versus radiotherapy, Outcome 4 Lymphopenia G3+.
Study or subgroup CT RT Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
3.4.1 TMZ vs RT (60 Gy)  
Wick 2012 46/195 1/178 100% 41.99[5.85,301.31]
Subtotal (95% CI) 195 178 100% 41.99[5.85,301.31]
Total events: 46 (CT), 1 (RT)  
Heterogeneity: Not applicable  
Test for overall effect: Z=3.72(P=0)  
Favours CT 1000.01 100.1 1 Favours RT
 
 
Analysis 3.5.   Comparison 3 Chemotherapy versus radiotherapy, Outcome 5 Thrombocytopenia G3+.
Study or subgroup CT RT Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
3.5.1 TMZ vs RT (60 Gy)  
Wick 2012 14/195 4/178 100% 3.19[1.07,9.53]
Subtotal (95% CI) 195 178 100% 3.19[1.07,9.53]
Total events: 14 (CT), 4 (RT)  
Heterogeneity: Not applicable  
Test for overall effect: Z=2.08(P=0.04)  
Favours CT 1000.01 100.1 1 Favours RT
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Analysis 3.6.   Comparison 3 Chemotherapy versus radiotherapy, Outcome 6 Infection G3+.
Study or subgroup CT RT Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
3.6.1 TMZ vs RT (60 Gy)  
Wick 2012 35/195 23/178 100% 1.39[0.86,2.26]
Subtotal (95% CI) 195 178 100% 1.39[0.86,2.26]
Total events: 35 (CT), 23 (RT)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.33(P=0.18)  
Favours CT 1000.01 100.1 1 Favours RT
 
 
Analysis 3.7.   Comparison 3 Chemotherapy versus radiotherapy, Outcome 7 Fatigue/asthenia G3+.
Study or subgroup CT RT Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
3.7.1 TMZ vs RT (60 Gy)  
Wick 2012 24/195 20/178 100% 1.1[0.63,1.91]
Subtotal (95% CI) 195 178 100% 1.1[0.63,1.91]
Total events: 24 (CT), 20 (RT)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.32(P=0.75)  
Favours CT 1000.01 100.1 1 Favours RT
 
 
Analysis 3.8.   Comparison 3 Chemotherapy versus radiotherapy, Outcome 8 Nausea/vomiting G3+.
Study or subgroup CT RT Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
3.8.1 TMZ vs RT (60 Gy)  
Wick 2012 6/195 1/178 100% 5.48[0.67,45.05]
Subtotal (95% CI) 195 178 100% 5.48[0.67,45.05]
Total events: 6 (CT), 1 (RT)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.58(P=0.11)  
Favours CT 1000.01 100.1 1 Favours RT
 
 
Analysis 3.9.   Comparison 3 Chemotherapy versus radiotherapy, Outcome 9 Weight loss G3+.
Study or subgroup CT RT Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
3.9.1 TMZ vs RT (60 Gy)  
Wick 2012 2/195 0/178 100% 4.57[0.22,94.47]
Subtotal (95% CI) 195 178 100% 4.57[0.22,94.47]
Total events: 2 (CT), 0 (RT)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.98(P=0.33)  
Favours CT 1000.01 100.1 1 Favours RT
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Analysis 3.10.   Comparison 3 Chemotherapy versus radiotherapy, Outcome 10 Neurological symptoms G3+.
Study or subgroup CT RT Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
3.10.1 TMZ vs RT (60 Gy)  
Wick 2012 36/195 25/178 100% 1.31[0.82,2.1]
Subtotal (95% CI) 195 178 100% 1.31[0.82,2.1]
Total events: 36 (CT), 25 (RT)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.14(P=0.25)  
Favours CT 1000.01 100.1 1 Favours RT
 
 
Analysis 3.11.   Comparison 3 Chemotherapy versus radiotherapy, Outcome 11 Seizures G3+.
Study or subgroup CT RT Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
3.11.1 TMZ vs RT (60 Gy)  
Wick 2012 17/195 13/178 100% 1.19[0.6,2.39]
Subtotal (95% CI) 195 178 100% 1.19[0.6,2.39]
Total events: 17 (CT), 13 (RT)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.5(P=0.62)  
Favours CT 1000.01 100.1 1 Favours RT
 
 
Analysis 3.12.   Comparison 3 Chemotherapy versus radiotherapy, Outcome 12 Elevated liver enzymes G3+.
Study or subgroup CT RT Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
3.12.1 TMZ vs RT (60 Gy)  
Wick 2012 30/195 16/178 100% 1.71[0.97,3.03]
Subtotal (95% CI) 195 178 100% 1.71[0.97,3.03]
Total events: 30 (CT), 16 (RT)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.84(P=0.07)  
Favours CT 1000.01 100.1 1 Favours RT
 
 
Analysis 3.13.   Comparison 3 Chemotherapy versus radiotherapy, Outcome 13 Cutaneous adverse event G3+.
Study or subgroup CT RT Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
3.13.1 TMZ vs RT (60 Gy)  
Wick 2012 1/195 1/178 100% 0.91[0.06,14.49]
Subtotal (95% CI) 195 178 100% 0.91[0.06,14.49]
Total events: 1 (CT), 1 (RT)  
Heterogeneity: Not applicable  
Favours CT 1000.01 100.1 1 Favours RT
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Study or subgroup CT RT Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Test for overall effect: Z=0.06(P=0.95)  
Favours CT 1000.01 100.1 1 Favours RT
 
 
Comparison 4.   Chemoradiotherapy versus radiotherapy





Statistical method Effect size
1 Progression-free survival 1   Hazard Ratio (Random, 95%
CI)
Subtotals only
1.1 TMZ+RT (40 Gy) vs RT (40 Gy) 1 562 Hazard Ratio (Random, 95%
CI)
0.50 [0.41, 0.61]
2 Neutropenia G3+ 1   Risk Ratio (M-H, Random, 95%
CI)
Subtotals only
2.1 TMZ + RT (40 Gy) vs RT (40 Gy) 1 515 Risk Ratio (M-H, Random, 95%
CI)
10.30 [2.45, 43.34]
3 Thrombocytopenia G3+ 1   Risk Ratio (M-H, Random, 95%
CI)
Subtotals only
3.1 TMZ + RT (40 Gy) vs RT (40 Gy) 1 527 Risk Ratio (M-H, Random, 95%
CI)
28.56 [3.92, 207.86]
4 Lymphopenia G3+ 1   Risk Ratio (M-H, Random, 95%
CI)
Subtotals only
4.1 TMZ + RT (40 Gy) vs RT (40 Gy) 1 521 Risk Ratio (M-H, Random, 95%
CI)
2.65 [1.75, 4.01]
5 Leucopenia G3+ 1   Risk Ratio (M-H, Random, 95%
CI)
Subtotals only
5.1 TMZ + RT (40 Gy) vs RT (40 Gy) 1 528 Risk Ratio (M-H, Random, 95%
CI)
18.16 [2.45, 134.64]
6 Anaemia G3+ 1   Risk Ratio (M-H, Random, 95%
CI)
Subtotals only
6.1 TMZ + RT (40 Gy) vs RT (40 Gy) 1 528 Risk Ratio (M-H, Random, 95%
CI)
6.69 [0.35, 128.88]
7 Treatment toxicity G3+ 1   Risk Ratio (M-H, Random, 95%
CI)
Subtotals only
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Analysis 4.1.   Comparison 4 Chemoradiotherapy versus radiotherapy, Outcome 1 Progression-free survival.
Study or subgroup ChemoRT RT log[Hazard
Ratio]
Hazard Ratio Weight Hazard Ratio
  N N (SE) IV, Random, 95% CI   IV, Random, 95% CI
4.1.1 TMZ+RT (40 Gy) vs RT (40 Gy)  
Perry 2017 281 281 -0.7 (0.101) 100% 0.5[0.41,0.61]
Subtotal (95% CI)       100% 0.5[0.41,0.61]
Heterogeneity: Not applicable  
Test for overall effect: Z=6.84(P<0.0001)  
Favours CRT 1000.01 100.1 1 Favours RT
 
 
Analysis 4.2.   Comparison 4 Chemoradiotherapy versus radiotherapy, Outcome 2 Neutropenia G3+.
Study or subgroup ChemoRT RT Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
4.2.1 TMZ + RT (40 Gy) vs RT (40 Gy)  
Perry 2017 22/266 2/249 100% 10.3[2.45,43.34]
Subtotal (95% CI) 266 249 100% 10.3[2.45,43.34]
Total events: 22 (ChemoRT), 2 (RT)  
Heterogeneity: Not applicable  
Test for overall effect: Z=3.18(P=0)  
Favours CRT 1000.01 100.1 1 Favours RT
 
 
Analysis 4.3.   Comparison 4 Chemoradiotherapy versus radiotherapy, Outcome 3 Thrombocytopenia G3+.
Study or subgroup ChemoRT RT Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
4.3.1 TMZ + RT (40 Gy) vs RT (40 Gy)  
Perry 2017 30/270 1/257 100% 28.56[3.92,207.86]
Subtotal (95% CI) 270 257 100% 28.56[3.92,207.86]
Total events: 30 (ChemoRT), 1 (RT)  
Heterogeneity: Not applicable  
Test for overall effect: Z=3.31(P=0)  
Favours CRT 1000.01 100.1 1 Favours RT
 
 
Analysis 4.4.   Comparison 4 Chemoradiotherapy versus radiotherapy, Outcome 4 Lymphopenia G3+.
Study or subgroup ChemoRT RT Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
4.4.1 TMZ + RT (40 Gy) vs RT (40 Gy)  
Perry 2017 73/268 26/253 100% 2.65[1.75,4.01]
Subtotal (95% CI) 268 253 100% 2.65[1.75,4.01]
Total events: 73 (ChemoRT), 26 (RT)  
Heterogeneity: Not applicable  
Test for overall effect: Z=4.62(P<0.0001)  
Favours CRT 1000.01 100.1 1 Favours RT
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Analysis 4.5.   Comparison 4 Chemoradiotherapy versus radiotherapy, Outcome 5 Leucopenia G3+.
Study or subgroup ChemoRT RT Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
4.5.1 TMZ + RT (40 Gy) vs RT (40 Gy)  
Perry 2017 19/270 1/258 100% 18.16[2.45,134.64]
Subtotal (95% CI) 270 258 100% 18.16[2.45,134.64]
Total events: 19 (ChemoRT), 1 (RT)  
Heterogeneity: Not applicable  
Test for overall effect: Z=2.84(P=0)  
Favours CRT 1000.01 100.1 1 Favours RT
 
 
Analysis 4.6.   Comparison 4 Chemoradiotherapy versus radiotherapy, Outcome 6 Anaemia G3+.
Study or subgroup ChemoRT RT Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
4.6.1 TMZ + RT (40 Gy) vs RT (40 Gy)  
Perry 2017 3/270 0/258 100% 6.69[0.35,128.88]
Subtotal (95% CI) 270 258 100% 6.69[0.35,128.88]
Total events: 3 (ChemoRT), 0 (RT)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.26(P=0.21)  
Favours CRT 1000.01 100.1 1 Favours RT
 
 
Analysis 4.7.   Comparison 4 Chemoradiotherapy versus radiotherapy, Outcome 7 Treatment toxicity G3+.
Study or subgroup ChemoRT RT Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
4.7.1 TMZ + RT (40 Gy) vs RT (40 Gy)  
Perry 2017 38/270 35/258 100% 1.04[0.68,1.59]
Subtotal (95% CI) 270 258 100% 1.04[0.68,1.59]
Total events: 38 (ChemoRT), 35 (RT)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.17(P=0.87)  
Favours CRT 1000.01 100.1 1 Favours RT
 
 
Comparison 5.   Other + chemoradiotherapy versus chemoradiotherapy





Statistical method Effect size
1 Progression-free survival 1   Hazard Ratio (Random, 95% CI) Subtotals only
1.1 BEV+chemoRT (60 Gy) vs
chemoRT
1 73 Hazard Ratio (Random, 95% CI) 0.78 [0.46, 1.32]
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Statistical method Effect size
2 Thromboembolic events G3+ 1   Risk Ratio (M-H, Random, 95% CI) Subtotals only
2.1 BEV+chemoRT (60 Gy) vs
chemoRT
1 73 Risk Ratio (M-H, Random, 95% CI) 16.63 [1.00, 275.42]
 
 
Analysis 5.1.   Comparison 5 Other + chemoradiotherapy versus
chemoradiotherapy, Outcome 1 Progression-free survival.




Hazard Ratio Weight Hazard Ratio
  N N (SE) IV, Random, 95% CI   IV, Random, 95% CI
5.1.1 BEV+chemoRT (60 Gy) vs chemoRT  
AVAglio 2014 39 34 -0.2 (0.269) 100% 0.78[0.46,1.32]
Subtotal (95% CI)       100% 0.78[0.46,1.32]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.92(P=0.36)  
BEV_CRT 1000.01 100.1 1 CRT
 
 
Analysis 5.2.   Comparison 5 Other + chemoradiotherapy versus
chemoradiotherapy, Outcome 2 Thromboembolic events G3+.
Study or subgroup Oth-
er+chemoRT
ChemoRt Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
5.2.1 BEV+chemoRT (60 Gy) vs chemoRT  
AVAglio 2014 9/39 0/34 100% 16.63[1,275.42]
Subtotal (95% CI) 39 34 100% 16.63[1,275.42]
Total events: 9 (Other+chemoRT), 0 (ChemoRt)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.96(P=0.05)  
BEV_CRT 1000.01 100.1 1 CRT
 
 
Comparison 6.   Other + radiotherapy (40 Gy) versus radiotherapy (40 Gy)





Statistical method Effect size
1 Progression-free survival 1   Hazard Ratio (Random, 95% CI) Subtotals only
1.1 BEV+RT vs RT 1 75 Hazard Ratio (Random, 95% CI) 0.46 [0.27, 0.78]
2 Thromboembolic events G3+ 1 75 Risk Ratio (M-H, Random, 95% CI) 2.0 [0.46, 8.73]
3 Haematological events G3+ 1 75 Risk Ratio (M-H, Random, 95% CI) 2.55 [0.13, 51.17]
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Statistical method Effect size
4 Infections G3+ 1 75 Risk Ratio (M-H, Random, 95% CI) 1.17 [0.33, 4.13]
5 Fatigue G3+ 1 75 Risk Ratio (M-H, Random, 95% CI) 0.75 [0.13, 4.20]
6 Seizures G3+ 1 75 Risk Ratio (M-H, Random, 95% CI) 4.59 [0.26, 82.01]
7 Headaches G3+ 1 75 Risk Ratio (M-H, Random, 95% CI) 0.17 [0.01, 4.03]
8 Neuropsychiatric events G3+ 1 75 Risk Ratio (M-H, Random, 95% CI) 2.0 [0.24, 16.97]
9 Neurological events G3+ 1 75 Risk Ratio (M-H, Random, 95% CI) 0.9 [0.34, 2.40]
10 Hypertension G3+ 1 75 Risk Ratio (M-H, Random, 95% CI) 1.0 [0.20, 5.09]
11 Cutaneous adverse events G3+ 1 75 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
12 Gastrointestinal events G3+ 1 75 Risk Ratio (M-H, Random, 95% CI) 0.75 [0.13, 4.20]
 
 
Analysis 6.1.   Comparison 6 Other + radiotherapy (40 Gy) versus
radiotherapy (40 Gy), Outcome 1 Progression-free survival.
Study or subgroup Other+RT RT log[Hazard
Ratio]
Hazard Ratio Weight Hazard Ratio
  N N (SE) IV, Random, 95% CI   IV, Random, 95% CI
6.1.1 BEV+RT vs RT  
ARTE 2018 50 25 -0.8 (0.272) 100% 0.46[0.27,0.78]
Subtotal (95% CI)       100% 0.46[0.27,0.78]
Heterogeneity: Not applicable  
Test for overall effect: Z=2.86(P=0)  
Favours other + RT 1000.01 100.1 1 Favours RT
 
 
Analysis 6.2.   Comparison 6 Other + radiotherapy (40 Gy) versus
radiotherapy (40 Gy), Outcome 2 Thromboembolic events G3+.
Study or subgroup Other+RT RT Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
ARTE 2018 8/50 2/25 100% 2[0.46,8.73]
   
Total (95% CI) 50 25 100% 2[0.46,8.73]
Total events: 8 (Other+RT), 2 (RT)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.92(P=0.36)  
Favours other + RT 1000.01 100.1 1 Favours RT
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Analysis 6.3.   Comparison 6 Other + radiotherapy (40 Gy) versus
radiotherapy (40 Gy), Outcome 3 Haematological events G3+.
Study or subgroup Other+RT RT Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
ARTE 2018 2/50 0/25 100% 2.55[0.13,51.17]
   
Total (95% CI) 50 25 100% 2.55[0.13,51.17]
Total events: 2 (Other+RT), 0 (RT)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.61(P=0.54)  
Favours other + RT 1000.01 100.1 1 Favours RT
 
 
Analysis 6.4.   Comparison 6 Other + radiotherapy (40 Gy) versus radiotherapy (40 Gy), Outcome 4 Infections G3+.
Study or subgroup Other+RT RT Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
ARTE 2018 7/50 3/25 100% 1.17[0.33,4.13]
   
Total (95% CI) 50 25 100% 1.17[0.33,4.13]
Total events: 7 (Other+RT), 3 (RT)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.24(P=0.81)  
Favours other + RT 1000.01 100.1 1 Favours RT
 
 
Analysis 6.5.   Comparison 6 Other + radiotherapy (40 Gy) versus radiotherapy (40 Gy), Outcome 5 Fatigue G3+.
Study or subgroup Other+RT RT Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
ARTE 2018 3/50 2/25 100% 0.75[0.13,4.2]
   
Total (95% CI) 50 25 100% 0.75[0.13,4.2]
Total events: 3 (Other+RT), 2 (RT)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.33(P=0.74)  
Favours other + RT 1000.01 100.1 1 Favours RT
 
 
Analysis 6.6.   Comparison 6 Other + radiotherapy (40 Gy) versus radiotherapy (40 Gy), Outcome 6 Seizures G3+.
Study or subgroup Other+RT RT Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
ARTE 2018 4/50 0/25 100% 4.59[0.26,82.01]
   
Total (95% CI) 50 25 100% 4.59[0.26,82.01]
Total events: 4 (Other+RT), 0 (RT)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.04(P=0.3)  
Favours other + RT 1000.01 100.1 1 Favours RT
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Analysis 6.7.   Comparison 6 Other + radiotherapy (40 Gy) versus radiotherapy (40 Gy), Outcome 7 Headaches G3+.
Study or subgroup Other+RT RT Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
ARTE 2018 0/50 1/25 100% 0.17[0.01,4.03]
   
Total (95% CI) 50 25 100% 0.17[0.01,4.03]
Total events: 0 (Other+RT), 1 (RT)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.1(P=0.27)  
Favours other + RT 1000.01 100.1 1 Favours RT
 
 
Analysis 6.8.   Comparison 6 Other + radiotherapy (40 Gy) versus
radiotherapy (40 Gy), Outcome 8 Neuropsychiatric events G3+.
Study or subgroup Other+RT RT Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
ARTE 2018 4/50 1/25 100% 2[0.24,16.97]
   
Total (95% CI) 50 25 100% 2[0.24,16.97]
Total events: 4 (Other+RT), 1 (RT)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.64(P=0.53)  
Favours other + RT 1000.01 100.1 1 Favours RT
 
 
Analysis 6.9.   Comparison 6 Other + radiotherapy (40 Gy) versus
radiotherapy (40 Gy), Outcome 9 Neurological events G3+.
Study or subgroup Other+RT RT Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
ARTE 2018 9/50 5/25 100% 0.9[0.34,2.4]
   
Total (95% CI) 50 25 100% 0.9[0.34,2.4]
Total events: 9 (Other+RT), 5 (RT)  
Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%  
Test for overall effect: Z=0.21(P=0.83)  
Favours other + RT 1000.01 100.1 1 Favours RT
 
 
Analysis 6.10.   Comparison 6 Other + radiotherapy (40 Gy)
versus radiotherapy (40 Gy), Outcome 10 Hypertension G3+.
Study or subgroup Other+RT RT Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
ARTE 2018 4/50 2/25 100% 1[0.2,5.09]
   
Favours other + RT 1000.01 100.1 1 Favours RT
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Study or subgroup Other+RT RT Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Total (95% CI) 50 25 100% 1[0.2,5.09]
Total events: 4 (Other+RT), 2 (RT)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
Favours other + RT 1000.01 100.1 1 Favours RT
 
 
Analysis 6.11.   Comparison 6 Other + radiotherapy (40 Gy) versus
radiotherapy (40 Gy), Outcome 11 Cutaneous adverse events G3+.
Study or subgroup Other+RT RT Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
ARTE 2018 0/50 0/25   Not estimable
   
Total (95% CI) 50 25 Not estimable
Total events: 0 (Other+RT), 0 (RT)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
Favours other + RT 1000.01 100.1 1 Favours RT
 
 
Analysis 6.12.   Comparison 6 Other + radiotherapy (40 Gy) versus
radiotherapy (40 Gy), Outcome 12 Gastrointestinal events G3+.
Study or subgroup Other+RT RT Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
ARTE 2018 3/50 2/25 100% 0.75[0.13,4.2]
   
Total (95% CI) 50 25 100% 0.75[0.13,4.2]
Total events: 3 (Other+RT), 2 (RT)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.33(P=0.74)  
Favours other + RT 1000.01 100.1 1 Favours RT
 
 
A D D I T I O N A L   T A B L E S
 
Dose fractionation EQD2 (Gy) BED (Gy)
60 Gy/30 fractions 60 75
50 Gy/28 fractions 49 61
40 Gy/15 fractions 42 53
34 Gy/10 fractions 39 48
Table 1.   Table of radiotherapy regimens used in included studies and biologically e7ective doses 
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25 Gy/5 fractions 33 41
Table 1.   Table of radiotherapy regimens used in included studies and biologically e7ective doses  (Continued)
EQD2 and BED calculated for an alpha/beta of 8
EQD2 = equivalent dose; BED = biologically e$ective dose
Gy = Gray
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1 2 3 4
ARTE 2018 ≥ 65 75 64 KPS ≥ 60 21%/73%/5%* RT40 RT40+ BEV - -






GLARIUS 2016 ≥ 65 34 67c KPS ≥ 70 100% unmethylated RT60+TMZ RT60+BEV+IRI - -





Keime-Guibert 2007 ≥ 70 85 63 KPS ≥ 70 - RT50 Supportive
care
- -
Malmstrom 2012 ≥ 70a 123 59 WHO 0-2 45%/55%/NRe RT60 RT30-34 TMZ -




Roa 2004 ≥ 60b 95 47 KPS ≥ 50 - RT60 RT40    
Roa 2015 ≥ 65c 61 58 KPS ≥ 50 - RT40 RT25 - -











Wick 2012 ≥ 65 373 47 KPS ≥ 60 20%/36%/44% RT60 TMZ - -
























































































































































BEV: bevacizumab; ECOG: Eastern Cooperative Oncology Group; Gy: Grays; IRI: irinotecan; KPS: Karnofsky performance score; RIN: rindopepimut; RT: radiotherapy; TTF: tumour
treating fields; TMZ: temozolomide; WHO: World Health Organization
a The whole sample (n = 291) comprised participants ≥ 60 years. The median age was 70 years for all study groups, ranging between 60 and 88 years.
bMedian age was approximately 72 with a standard deviation of 5 years
c Data for the ≥ 65 year age group were reported in the Guedes de Castro 2017 substudy report.
d Gender data specific to the elderly subgroup were not reported separately
e For approximately 70% of participants with MGMT data available








































































ECOG Grade ECOG Status
Normal, no complaints 100 0 Fully active, able to carry on all pre-disease performance
without restriction
Able to carry on normal activities. Minor
signs or symptoms of disease
90 1 Restricted in physically strenuous activity but ambulato-
ry and able to carry out work of a light or sedentary na-
ture, e.g. light house work, office work
Normal activity with effort 80 1 Restricted in physically strenuous activity but ambulato-
ry and able to carry out work of a light or sedentary na-
ture, e.g. light house work, office work
Care for self. Unable to carry on normal
activity or to do active work
70 2 Ambulatory and capable of all self-care but unable to
carry out any work activities. Up and about more than
50% of waking hours
Requires occasional assistance, but able
to care for most of his needs
60 2 Ambulatory and capable of all self-care but unable to
carry out any work activities. Up and about more than
50% of waking hours
Requires considerable assistance and
frequent medical care
50 3 Capable of only limited self-care, confined to bed or
chair more than 50% of waking hours
Disabled. Requires special care and as-
sistance
40 3 Capable of only limited self-care, confined to bed or
chair more than 50% of waking hours
Severly disabled. Hospitalisation indi-
cated though death non imminent
30 4 Completely disabled. Cannot carry on any self-care. To-
tally confined to bed or chair
Very sick. Hospitalisation necessary. Ac-
tive supportive treatment necessary
20 4 Completely disabled. Cannot carry on any self-care. To-
tally confined to bed or chair
Moribund 10 4 Completely disabled. Cannot carry on any self-care. To-
tally confined to bed or chair
Dead 0 5 Dead
Table 3.   Performance scores 
As published in Am J Clin. Oncol: Oken 1982
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1 Green 1983 For 65+ age subgroup,
number of deaths
(overall, no time point
specified) and death
rate (number of deaths
per 10 patient-months)
reported.














2 Roa 2004 (Elderly pa-
tients only in this trial,
defined as age 60 years
or over; mean age was
72 years with SD 5 years)
Median OS reported
(ITT analysis), includ-
ing HR and a KM curve.
Percentage of patients
alive at 6 months also
reported (Table 1 and
Figure 1 of main manu-
script).
Low rates of FACT-Br version
3 completion (45% overall)
by patients precluded mean-
ingful analysis. Protocol spec-
ified FACT-Br completion at
baseline, 3 weeks after start-
ing RT, at the end of RT, and at
3-month intervals thereafter.
Table 2 of main manuscript.
































(Elderly patients only -
aged 70 years or over).
Median OS reported
(ITT analysis), includ-
ing HR and KM curve.
QLQ-C30 and QLQ-BN20 and
completion rate. Changes in
mean score at baseline, day






















































































































































































4 Malmstrom 2012 (Pa-
tients in this trial all
aged over 60 years old
but reported data for
70+ years subgroup)
Median OS and 1 year
survival percentage.
As this study had three
arms, survival analyses
were done using three
pairwise comparisons.
A KM curve was pre-
sented for the over-
all patient population
and a subgroup of pa-
tients aged 60-70 years
and aged over 70. HR
reported for this out-
come (Table 2).




arms combined for this
analysis.
In the supplementary
appendix, OS and KM
reported comparing
the TMZ arm and the
hypofractionated RT
arm. These outcomes
were reported for pa-
tients overall, a sub-
group of patients aged
60-70 and a subgroup
of patients aged over
70. HR reported for
these outcomes.
EORTC QLQ-30v3 and QLQ-
BN20 at baseline, 6 weeks, 3
months and 6 months. Mean
change of score from base-
line reported for each domain
(Figure 4). No data reported






























































































































































































1 year OS probabilities
also reported.
5 Wick 2012 (All elderly
patients – aged over 65
years)
Median OS reported
(ITT analysis) with HR
and KM curve. OS dif-
ferences between pa-
tients with mMGMT
and uMGMT disease al-
so reported (with HR
and KM curve). OS sur-
vival (PP analysis) also
reported but no HR or
KM curve for these out-
comes. Survival % at 6
months and 1 year. Al-
so report proportions
for death, or disease
progression or death
for each arm.
EORTC QLQ-30 and BN20
used for HRQoL assessment.
Results available for 82% of













































6 AVAglio 2014 (comprises
several reports)
Chinot 2014 main re-
port presents findings
for whole sample, elder-
ly subgroup reported in
supplementary appen-
dix. Saran 2016 provides
information on safety
outcomes. Taphoorn
2015 reported HR QoL
outcomes for sample as
a whole.
OS for 60-69 and 70+
subgroups (found in
supplementary appen-
dix 2). No KM curves
for these subgroups.
Taphoorn 2015 reports the re-
sults for QLQ-C30 and QLQ-
BN20 for the whole sample



























7 Roa 2015 (comprises
several reports)
(Guedes de Castro 2017
reports on outcomes
only for those patients




comes for elderly and
frail, and elderly and
not frail subgroups.
No HR reported for OS
outcomes. KM curves
The mean scores from a com-
bination of EORTC QLQC30
and QLQ-BN20 reported
at baseline, 4 weeks and 8
weeks. Categorical scales
were transformed to linear

















































































































































































quality of life results as a
conference abstract).
included in Guedes de
Castro 2017 Figures
1-4.
ence between mean scores
between treatment groups re-
















8 GLARIUS 2016 (compris-
es several reports)
Herrlinger 2016 reports
the main findings for
the whole sample, aged
from 18+ years. Ke-
bir 2016 is an abstract
which reports specifi-
cally on the differences
in OS between younger
and older patients in the
trial.
Median OS for 65+ sub-
group in both arms re-
ported (modified ITT
analysis). No HR or KM
curve available for the
elderly cohort. yes


























9 Perry 2017 (All elderly
patients – aged 65 years
old or over).
Median OS reported
(ITT). KM curve and HR
reported for this out-
come. Median OS al-
so reported for sub-
groups of patients
aged 65-70 years old,
71-75 and 76+. Also re-
ported OS rate at 12,
18 and 24 months for




Up to 18 months post treat-
ment. Baseline/1 week/3
week reported. Time to dete-














10 Weller 2017 (Trial not
restricted to elderly pa-
tients only. Includes pa-
tients aged 18 years +).
Report OS (events per
patient) for patients
aged 65+ subgroup.
The subgroup if further
divided into those who
have minimal residual






































































































































































disease (MRD) and sig-
nificant residual dis-
ease (SRD). There is a
HR given for patients
aged 65+ in the MRD
subgroup and in the
SRD subgroup sepa-
rately. There is no HR
reported for the 65+
group overall. No KM
curves for the elderly
subgroup.
11 Stupp 2017a
(Trial not restricted to el-
derly patients only. In-
cludes patients aged 18
years +). Taphoorn 2018
is separate publication
which reports on HRQoL
outcomes.
Median OS for 65+
subgroup. HR and KM
curve reported for this
outcome in the 65+
subgroup. The propor-
tion of patients in each
arm of the trial who
were alive at the end
of the study also re-
ported.
HR QoL was measured using
EORTC QLQ-C30 and BN20
questionnaires at baseline
and every 3 months for up to
12 months. Mean QoL scores
and mean change from base-
line reported. Outcomes not


























12 ARTE 2018 (All elderly
patients in the trial –
aged 65 years or over)
Median OS (ITT and
PP) and 1 year survival
rate. Also reported OS
depending on molecu-
lar panel subtype. No
HR reported for medi-
an OS differences. KM
curves are shown.
Reported median deteriora-
tion free survival from base-
line. Individual functional and
symptom scores from EORTC
QLQ-C30/BN20 before tumour
progression analysed in a
generalised linear model that













































































































































































































CTCAE: Common Terminology Criteria for Adverse Events; EORTC: European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 or QLQ-BN20 (specific for brain
cancer); FACT-Br: Functional Assessment of Cancer Therapy scale [specific for brain cancer]); HR: hazard ratio; HRQoL: Health-related quality of life; ITT: Intention to treat; mITT:
modified ITT; KM curve: Kaplan Meier curve; KPS: Karnofsky performance status; MMSE: mini mental state examination; mMGMT: Methylated MGMT; umMGMT: unmethylated
MGMT; PFS: progression free survival; PP: per protocol; OS: overall survival.
 
 





















Green 1983 Age ≥ 65
KPS ≥ 70%
4 arms; see Table 1 - - - - - -
Supportive care 3.9 3.1 5.0 1.3 1.0 1.8Keime-Guibert 2007 Age ≥ 70
KPS ≥ 70% RT (50 Gy/28 fractions/5-6 weeks) +
supportive care
6.8 5.9 8.1 3.5 2.5 5.2
RT (40 Gy/15 fractions/3 weeks) 5.6 - - - - -Roa 2004 Age ≥ 60
KPS ≥ 50% RT (60 Gy/30 fractions/6 weeks) 5.1 - - - - -
RT (25 Gy/5 fractions/1 week) 6.8 4.5 9.1 4.3 2.6 5.9Roa 2015a (elderly
and/or frail)
Age ≥ 65
KPS 50-70% RT (40 Gy/15 fractions) 6.2 4.7 7.7 3.2 0.1 6.3
RT (25 Gy/5 fractions/1 week) 7.5 5.3 9.7 - - -Roa 2015 (elderly
and frail)
Age ≥ 65
KPS ≥ 50% RT (40 Gy/15 fractions) 6.7 4.5 8.9 - - -
RT (25 Gy/5 fractions/1 week) 8.0 5.9 10.0 - - -Roa 2015a(elderly
and non-frail)
Age ≥ 65
KPS ≥ 80% RT (40 Gy/15 fractions/3 weeks) 8.0 5.3 10.3 - - -
RT (60 Gy/30 fractions/6 weeks) 5.2 4.0 6.3 - - -
RT (34 Gy/10 fractions/2 weeks) 7.0 5.2 8.8 - - -
Malmstrom 2012 Age ≥ 70
WHO 0-2
TMZ 9.0 6.2 11.8      
























































































































































RT (any schedule) 7.0 5.8 8.3 - - -Malmstrom 2012 (un-
methylated)
Age ≥ 70
WHO 0-2 TMZ 6.8 5.9 7.7 - - -
RT (any schedule) 8.2 6.6 9.9 - - -Malmstrom 2012
(methylated)
Age ≥ 70
WHO 0-2 TMZ 9.7 8.0 11.4 - - -
RT (60Gy/30 fractions/6 weeks) 9.6 8.2 10.8 4.7 4.2 5.2Wick 2012b Age ≥ 65
KPS ≥ 60% TMZ 8.6 7.3 10.2 3.3 3.2 4.1
RT (60Gy/30 fractions/6 weeks) 10.4 8.0 11.6 4.6 3.7 6.3Wick 2012
(unmethylated)
Age ≥ 65
KPS ≥ 60% TMZ 7.0 5.7 8.7 3.3 3.0 3.5
RT (60Gy/30 fractions/6 weeks) 9.6 6.4 not
reached









RT (40 Gy/15 fractions/3 weeks) 7.6 7.0 8.4 3.9 3.5 4.3Perry 2017 Age ≥ 65
ECOG 0-2 RT (40 Gy/15 fractions/3 weeks) + TMZ
+ maintenance TMZ
9.3 8.3 10.3 5.3 4.6 6.2
RT (40 Gy/15 fractions/3 weeks) 7.9 - - - - -Perry 2017c
(unmethylated)
Age ≥ 65
ECOG 0-2 RT (40 Gy/15 fractions/ 3 weeks) + TMZ
+ maintenance TMZ
10 - - - - -
RT (40 Gy/15 fractions/3 weeks) 7.7 - - - - -Perry 2017c
(methylated)
Age ≥ 65
ECOG 0-2 RT (40 Gy/15 fractions/3 weeks) + TMZ
+ maintenance TMZ
13.5 - - - - -
RT (60 Gy/30 fractions) + TMZ + main-
tenance TMZ
- - - - - -AVAglio 2014 Age ≥ 70
WHO 0-2
RT (60 Gy/30 fractions) + TMZ + BEV +
maintenance
- - - - - -


























































































































































RT (±60 Gy/30 fractions/6 weeks) +
TMZ + maintenance TMZ
13.7 7.6 24.8 - - -Stupp 2017ad
Age ≥ 65
KPS ≥ 70%
RT (±60 Gy/30 fractions/6 weeks) +
TMZ + maintenance TMZ + TTFields
17.4 9.0 31.5 - - -
RT (40 Gy/15 fractions/3 weeks) 12.2 9.2 15.2 4.8 3.0 6.6ARTE 2018 Age ≥ 65
KPS ≥ 60% RT (40 Gy/15 fractions/3 weeks) + BEV 12.1 10.2 14.0 7.6 6.2 9.0
RT (60 Gy/30 fractions/6 weeks) + TMZ
+ maintenance




RT (60 Gy/30 fractions/6 weeks) + BEV
+ IRI + maintenance
13.4 - - - - -
RT (60 Gy/30 fractions/6 weeks) + TMZ
+ maintenance
- - - - - -Weller 2017 Age ≥ 65
KPS ≥ 60%
RT (60 Gy/30 fractions/6 weeks) + TMZ
+ maintenance + RIN
- - - - - -
Table 5.   Median survival associated with treatment options evaluated in included studies  (Continued)
BEV: bevacizumab; ECOG: Eastern Cooperative Oncology Group; Gy: Grays; IRI: irinotecan; KPS: Karnofsky performance score; OS: overall survival; PFS: progression free survival;
RIN: rindopepimut; RT: radiotherapy; TTF: tumour treating fields; TMZ: temozolomide; WHO: World Health Organization
aData from the Guedes de Castro et al 2017 substudy report on patients ≥ 65 years only
bThis study reported event free survival (EFS), not PFS. Findings by MGMT methylation status were reported by authors in the later (2017) publication.
cFrom Perry 2012 abstract
dMGMT promotor methylation status was not reported separately for the elderly subgroup. Median survival data were reported as time from randomisation not diagnosis.
Randomisation in this trial occurred aMer concomitant chemoradiotherapy.
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CHEC ITEM Ghosh et al (2018)
Is the study population clearly described? Y
Are competing alternatives clearly described? Y
Is a well-defined research question posed in answerable form? Y
Is the economic study design appropriate to the stated objective? Y
Is the chosen time horizon appropriate to include relevant costs and
consequences?
N
Is the actual perspective chosen appropriate? N
Are all important and relevant costs for each alternative identified N
Are all costs measured appropriately in physical units? Y
Are costs valued appropriately? N
Are all important and relevant outcomes for each alternative identified? N
Are all outcomes measured appropriately? N
Are outcomes valued appropriately? N
Is an incremental analysis of costs and outcomes of alternatives performed? Y
Are all future costs and outcomes discounted appropriately? N
Are all important variables, whose values are uncertain, appropriately subjected to sensitivity
analysis?
N
Do the conclusions follow from the data reported? N
Does the study discuss the generalizability of the results to other settings and patient/client
groups?
N
Does the article indicate that there is no potential conflict of interest of study researcher(s) and
funder(s)?
Y
Are ethical and distributional issues discussed appropriately? N





Section of paper Component Reported on Page
Number
Table 7.   CHEERS checklist* of included studies 
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Cochrane Database of Systematic Reviews
Ghosh et al (2018)
Identify the study as an economic evaluation or use more specific terms such as ‘‘cost-ef-
fectiveness analysis’’, and describe the interventions compared.
114Title and abstract
Provide a structured summary of objectives, perspective, setting, methods (including
study design and inputs), results (including base case and uncertainty analyses), and con-
clusions.
114
Describe characteristics of the base case population and subgroups analysed, including
why they were chosen.
Supplementary
material
State relevant aspects of the system(s) in which the decision(s) need(s) to be made. Not reported
Describe the perspective of the study and relate this to the costs being evaluated. Not reported
Describe the interventions or strategies being compared and state why they were chosen. 114-115




Report the choice of discount rate(s) used for costs and outcomes and say why appropri-
ate.
Not reported
Describe what outcomes were used as the measure(s) of benefit in the evaluation and
their relevance for the type of analysis performed.
115
Describe fully the design features of the single effectiveness study and why the single
study was a sufficient source of clinical effectiveness data.
115-116
Describe approaches used to estimate resource use associated with the alternative in-
terventions. Describe primary or secondary research methods for valuing each resource
item in terms of its unit cost. Describe any adjustments made to approximate to opportu-
nity costs.
Not reported
Report the dates of the estimated resource quantities and unit costs. Describe meth-
ods for adjusting estimated unit costs to the year of reported costs if necessary. Describe
methods for converting costs into a common currency base and the exchange rate.
115
Describe and give reasons for the specific type of decision-analytical model used. Provid-
ing a figure to show model structure is strongly recommended.
N/A
Describe all structural or other assumptions underpinning the decision-analytical model. N/A
Methods
Describe all analytical methods supporting the evaluation. This could include methods
for dealing with skewed, missing, or censored data; extrapolation methods; methods for
pooling data; approaches to validate or make adjustments (such as half cycle corrections)
to a model; and methods for handling population heterogeneity and uncertainty.
Partial, uncertain-
ty discussed.
Report the values, ranges, references, and, if used, probability distributions for all para-
meters. Report reasons or sources for distributions used to represent uncertainty where
appropriate. Providing a table to show the input values is strongly recommended.
Not reportedResults
For each intervention, report mean values for the main categories of estimated costs and
outcomes of interest, as well as mean differences between the comparator groups. If ap-
plicable, report incremental cost-effectiveness ratios.
116-118 & supple-
mentary material
Table 7.   CHEERS checklist* of included studies  (Continued)
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Describe the effects of sampling uncertainty for the estimated incremental cost and incre-
mental effectiveness parameters, together with the impact of methodological assump-
tions (such as discount rate, study perspective).
116
If applicable, report differences in costs, outcomes, or cost-effectiveness that can be ex-
plained by variations between subgroups of patients with different baseline characteris-
tics or other observed variability in effects that are not reducible by more
information.
N/A
Discussion Summarise key study findings and describe how they support the conclusions reached.
Discuss limitations and the generalisability of the findings and how the findings fit with
current knowledge.
118-119
Describe how the study was funded and the role of the funder in the identification, de-
sign, conduct, and reporting of the analysis. Describe other non-monetary sources of sup-
port.
119Other
Describe any potential for conflict of interest of study contributors in accordance with
journal policy. In the absence of a journal policy, we recommend authors comply with In-
ternational Committee of
Medical Journal Editors recommendations.
119




Direct Evidence Indirect Evidence Network EvidenceComparison
HR (95% CI) Certainty HR (95% CI) Certainty HR (95% CI) Certainty




Not estimable2 – 0.47 (0.29 to 0.76) Moderate
RT40 vs Supp Care – – 0.44 (0.25 to 0.77) Low3 0.44 (0.25 to 0.77) Low
CRT vs Supp Care – – – – 0.30 (0.17 to 0.53) Not grad-
ed4
TMZ vs Supp Care – – 0.42 (0.25 to 0.71) Low3 0.42 (0.25 to 0.71) Low
BEV_CRT vs Supp Care – – – – 0.25 (0.11 to 0.54) Not grad-
ed4
BEV_RT vs Supp Care – – – – 0.48 (0.23 to 1.00) Not grad-
ed4
             
CRT vs RT40 0.67 (0.56 to
0.80)
High – – 0.67 (0.56 to 0.80) High
BEV_CRT vs RT40 – – 0.56 (0.31 to 0.99) Moder-
ate5
0.56 (0.31 to 0.99) Moderate
Table 8.   Table of estimate e7ects and certainty ratings for overall survival 
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TMZ vs RT40** 0.72 (0.50 to
1.05)
Low6 – – 0.95 (0.71 to 1.26) Low
BEV_RT vs RT40 1.08 (0.65 to
1.78)
Low6 Not estimable2 – 1.08 (0.66 to 1.78) Low
             
RT40 vs RT60 0.74 (0.55 to
1.01)
Low6 Not estimable2 – 0.94 (0.72 to 1.23) Low
BEV_RT vs RT60 – – 1.01 (0.58 to 1.79) Very low7 1.01 (0.58 to 1.79) Very low
BEV_CRT vs RT60 – – – – 0.52 (0.28 to 0.98) Not grad-
ed4
CRT vs RT60 – – 0.63 (0.46 to 0.87) Low8 0.63 (0.46 to 0.87) Low
TMZ vs RT60 0.86 (0.68 to
1.09)
Very low9 – – 0.89 (0.71 to 1.11) Very low
             
BEV_RT vs CRT – – 1.61 (0.95 to 2.74) Low10 1.61 (0.95 to 2.74) Low
BEV_CRT vs CRT 0.83 (0.48 to
1.43)
Low6 Not estimable2 – 0.83 (0.48 to 1.44) Low
TMZ vs CRT – – 1.42 (1.01 to 1.98) Low10 1.42 (1.01 to 1.98) Low
             
BEV_RT vs TMZ – – 1.14 (0.64 to 2.02) Very
low10,11
1.14 (0.64 to 2.02) Very low
BEV_CRT vs TMZ – – – – 0.59 (0.31 to 1.12) Not grad-
ed4
             
BEV_CRT vs BEV_RT – – – – 0.52 (0.24 to 1.10) Not grad-
ed4
1 Evidence derived from a single small study
2 Could not be estimated because the intervention was not connected via a loop in the evidence network
3 Contributing direct evidence was of moderate or low certainty
4 There was no direct evidence for this comparison, which did not connect via a common comparator, therefore the certainty of evi-
dence was not graded.
5 Contributing direct evidence was of high or moderate certainty
6 Downgraded for study design limitations and imprecision
7 Contributing direct evidence was of low certainty; network estimate imprecise
Table 8.   Table of estimate e7ects and certainty ratings for overall survival  (Continued)
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8 Contributing direct evidence was of high or low certainty
9 Downgraded for imprecision, study design limitations and inconsistency
10 Contributing direct evidence was of high or low certainty
11Downgraded for imprecision
Table 8.   Table of estimate e7ects and certainty ratings for overall survival  (Continued)
*RT50 (Keime-Guibert 2007) coded as RT60.
**RT34 (Malmstrom 2012) coded as RT40.
Abbreviations: BEV_CRT = bevacizumab plus chemoradiotherapy; CI = confidence interval; ; CRT = chemoradiotherapy; RT40 =
radiotherapy (40Gy in 15 fractions); RT60 = radiotherapy (60Gy in 30 fractions); Supp Care = supportive care; TMZ = temozolomide; TTF_AC
= tumour treating fields with adjuvant chemotherapy (aMer concomitant chemotherapy)
 
 










BEV_CRT 1.4 1.4 1.4 – –
CRT 1.8 1.8 1.9 1.1* 1.1*
TMZ 3.8 3.8 3.7 2.8 2.8
RT40 4.3 4.3 4.2 3.3 3.3
BEV_RT 4.7 4.7 4.8 3.8 3.8
RT60 5.0 5.1 5.0 4.0 4.0
Supp_Care 7.0 7.0 7.0 6.0 6.0
Table 9.   Overview of SUCRA rankings 
*CRT40
BEV_CRT = chemoradiotherapy plus bevacizumab; CRT = chemoradiotherapy; RT40 = radiotherapy (40Gy in 15 fractions); RT60 =
radiotherapy (60Gy in 30 fractions); Supp_Care = supportive care; TMZ = temozolomide; TTF_AC = tumour treating fields with adjuvant
chemotherapy (aMer concomitant chemotherapy)
Sensitivity analysis A: Keime-Guibert 2007 study’s RT50 arm is coded as RT40; sensitivity analysis B: network without a loop due to exclusion
of the Malmstrom 2012 TMZ vs RT40 arm to avoid duplication of data; sensitivity analysis C.1 and C.2: disconnected networks due to non-
pooling of CRT40 and CRT60 arms from di$erent studies; sensitivity analysis D: disconnected network due to non-pooling of CRT40 and














































Outcomes presented were overall survival (OS) and pro-
gression free survival (PFS). The outcomes were also pre-
sented as QALYs. Preference values were taken from Eu-
ropean Organization for Research and Treatment of Can-
cer Quality of Life Questionnaire (EORTC QLQ-C30). The
scores were mapped onto the EQ-5D questionnaire from
which utility values were derived. The values were taken








Table 10.   Data extraction table for economic studies 
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McKenzie 2009. The QALY calculation based on the assump-




Table 10.   Data extraction table for economic studies  (Continued)
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Source Currency Average number of Re-
sources Used
Arm 1 / Arm 2
Source
Belarus 0.27 Not reported US Dollars (conversion not re-
ported)
44 16 Trial Dataset
Brazil (Porto
Alegre)
0.06 - Not reported US Dollars (conversion not re-
ported)
44 60 Trial Dataset
Georgia 0.3 Not reported US Dollars (conversion not re-
ported)
18 4 Trial Dataset
India 0.01 Not reported US Dollars (conversion not re-
ported)







Poland 1.36 Not reported US Dollars (conversion not re-
ported)
12 8 Trial Dataset
Belarus 269 Not reported US Dollars (conversion not re-
ported)
4 3 Trial Dataset
Brazil (Porto
Alegre)
119 Not reported US Dollars (conversion not re-
ported)
4 3 Trial Dataset
Georgia 130 Not reported US Dollars (conversion not re-
ported)
1 1 Trial Dataset
India 25 Not reported US Dollars (conversion not re-
ported)
1 1 Trial Dataset
CT Ghosh
2018
Poland 57 Not reported US Dollars (conversion not re-
ported)
4 1.5 Trial Dataset
Belarus 330 Not reported US Dollars (conversion not re-
ported)
5 - Trial Dataset
Brazil (Porto
Alegre)
293 Not reported US Dollars (conversion not re-
ported)
4 - Trial Dataset
MRI Ghosh
2018
Georgia 230 Not reported US Dollars (conversion not re-
ported)
1 3 Trial Dataset
























































































































































India 58.3 Not reported US Dollars (conversion not re-
ported)
3 1 Trial Dataset
Poland 130 Not reported US Dollars (conversion not re-
ported)
3 3 Trial Dataset
Belarus 600 Not reported US Dollars (conversion not re-
ported)
- - Trial Dataset
Brazil (Porto
Alegre)
1046 Not reported US Dollars (conversion not re-
ported)
- - Trial Dataset
Georgia 2900 Not reported US Dollars (conversion not re-
ported)
- - Trial Dataset
India 25 Not reported US Dollars (conversion not re-
ported)





Poland 3472 Not reported US Dollars (conversion not re-
ported)
- - Trial Dataset
Belarus 1800 Not reported US Dollars (conversion not re-
ported)
- - Trial Dataset
Brazil (Porto
Alegre)
1985 Not reported US Dollars (conversion not re-
ported)
- - Trial Dataset
Georgia 3800 Not reported US Dollars (conversion not re-
ported)
- - Trial Dataset
India 42 Not reported US Dollars (conversion not re-
ported)





Poland 3472 Not reported US Dollars (conversion not re-
ported)
- - Trial Dataset
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A P P E N D I C E S
Appendix 1. Search strategies
CENTRAL search strategy
#1 MeSH descriptor: [Glioblastoma] this term only
#2 glioblastoma* or GBM* or GB* or astrocyt*
#3 #1 or #2
#4 MeSH descriptor: [Aged] explode all trees
#5 aged* or old* or ageing* or geriatric*
#6 elder* or "over 60" or "over 65" or "over 70" or "over 80" or "60 year*" or "65 year*" or "70 year*" or "85 year*"
#7 #4 or #5 or #6
#8 #3 and #7
#9 MeSH descriptor: [Neurosurgery] this term only
#10 Any MeSH descriptor with qualifier(s): [Surgery - SU]
#11. surg* or neurosurg* or craniotomy* or resect* or EOR* or intraoperative*)
#12. MeSH descriptor: [Radiotherapy] explode all trees
#13. radiotherap* or RT or radiat* or irradiat*
#14 Any MeSH descriptor with qualifier(s): [Radiotherapy - RT]
#15 MeSH descriptor: [Antineoplastic Agents] explode all trees
#16 MeSH descriptor: [Antineoplastic Combined Chemotherapy Protocols] this term only
#17 temozolomide or TMZ or Temodal or Temodar or Temodal or Temcad* or chemotherap* or procarbazine or Lomustine or CCNU or
vincristine or PCV or cisplatinum or carboplatinum
#18 MeSH descriptor: [Chemoradiotherapy] explode all trees
#19 radiochemo* or chemoradio*
#20 MeSH descriptor: [Immunotherapy] explode all trees
#21 immunotherap*
#22 MeSH descriptor: [Steroids] explode all trees
#23 dexamethasone or prednisolone or methylprednisolone
#24 #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20 or #21 or #22 or #23
#25 #8 and #24
MEDLINE search strategy for eectiveness evidence
1. Glioblastoma/
2. (glioblastoma* or Glioblastoma* or GB* or astrocyt*).ti,ab.
3. 1 or 2
4. exp Aged/
5. (aged* or old* or ageing* or geriatric*).ti,ab.
6. (elder* or "over 60" or "over 65" or "over 70" or "over 80" or "over 85" or "60 year*" or "65 year*" or "70 year*" or "80 year" or "85
year*").ti,ab.
7. 4 or 5 or 6
8. 3 and 7
9. Neurosurgery/
10. surgery.fs.
11. (surg* or neurosurg* or craniotomy* or resect* or EOR* or intraoperative*).mp.
12. exp Radiotherapy/
13. radiotherapy.fs.
14. (radiotherap* or RT or radiat* or irradiat*).ti,ab.
15. exp Antineoplastic Agents/
16. Antineoplastic Combined Chemotherapy Protocols/
17. (temozolomide or TMZ or Temodal or Temodar or Temodal or Temcad* or chemotherap* or procarbazine or Lomustine or CCNU or
vincristine or PCV or cisplatinum or carboplatinum).mp.
18. exp Chemoradiotherapy/




23. (dexamethasone or prednisolone or methylprednisolone).mp.
24. 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23
25. 8 and 24
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26. randomized controlled trial.pt.
27. controlled clinical trial.pt.
28. randomized.ab.
29. placebo.ab.
30. clinical trials as topic.sh.
31. randomly.ab.
32. trial.ti
33. 26 or 27 or 28 or 29 or 30 or 31 or 32
34. (animals not (humans and animals)).sh.
35. 33 not 34
36. 25 and 35
key:





MEDLINE search strategy for economic evidence
1. Glioblastoma/
2. (glioblastoma* or Glioblastoma* or GB* or astrocyt*).ti,ab.
3. 1 or 2
4. exp Aged/
5. (aged* or old* or ageing* or geriatric*).ti,ab.
6. (elder* or "over 60" or "over 65" or "over 70" or "over 80" or "60 year*" or "65 year*" or "70 year*" or "85 year*").ti,ab.
7. 4 or 5 or 6
8. 3 and 7
9. Neurosurgery/
10. surgery.fs.
11. (surg* or neurosurg* or craniotomy* or resect* or EOR* or intraoperative*).mp.
12. exp Radiotherapy/
13. radiotherapy.fs.
14. (radiotherap* or RT or radiat* or irradiat*).ti,ab
15. exp Antineoplastic Agents/
16. Antineoplastic Combined Chemotherapy Protocols/
17. (temozolomide or TMZ or Temodal or Temodar or Temodal or Temcad* or chemotherap* or procarbazine or Lomustine or CCNU or
vincristine or PCV or cisplatinum or carboplatinum).mp.
18. exp Chemoradiotherapy/




23. (dexamethasone or prednisolone or methylprednisolone).mp.
24. 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23
25. 8 and 24
26. Economics/
27. exp "costs and cost analysis"/
28. Economics, Dental/




33. (economic$ or cost or costs or costly or costing or price or prices or pricing or pharmacoeconomic$).ti,ab.
34. (expenditure$ not energy).ti,ab.
35. value for money.ti,ab.
36. budget$.ti,ab.
37. 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36
38. ((energy or oxygen) adj cost).ti,ab.
39. (metabolic adj cost).ti,ab.
40. ((energy or oxygen) adj expenditure).ti,ab.
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41. 38 or 39 or 40




46. 43 or 44 or 45
47. 42 not 46
48. 25 and 47
key:





Embase search strategy for eectiveness evidence
1. glioblastoma/
2. (glioblastoma* or GBM* or GB* or astrocyt*).ti,ab.
3. 1 or 2
4. exp Aged/
5. (aged* or old* or ageing* or geriatric*).ti,ab.
6. (elder* or "over 60" or "over 65" or "over 70" or "over 80" or "over 85" or "60 year*" or "65 year*" or "70 year*" or "80 year" or "85
year*").ti,ab.
7. 4 or 5 or 6
8. 3 and 7
9. neurosurgery/
10. surgery.fs.
11. (surg* or neurosurg* or craniotomy* or resect* or EOR* or intraoperative*).mp.
12. exp radiotherapy/
13. radiotherapy.fs.
14. (radiotherap* or RT or radiat* or irradiat*).ti,ab.
15. exp chemotherapy/
16. exp antineoplastic agent/
17. (temozolomide or TMZ or Temodal or Temodar or Temodal or Temcad* or chemotherap* or procarbazine or Lomustine or CCNU or
vincristine or PCV or cisplatinum or carboplatinum).mp.
18. exp chemoradiotherapy/




23. (dexamethasone or prednisolone or methylprednisolone).mp.
24. 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23
25. 8 and 24
26. crossover procedure/
27. double-blind procedure/




32. (crossover* or cross over* or cross-over*).mp.
33. placebo*.mp.
34. (double* adj blind*).mp.




39. 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36 or 37 or 38
40. 25 and 39
key:
Treatment of newly diagnosed glioblastoma in the elderly: a network meta-analysis (Review)









Cochrane Database of Systematic Reviews





Embase search strategy for economic evidence
1. glioblastoma/
2. (glioblastoma* or GBM* or GB* or astrocyt*).ti,ab.
3. 1 or 2
4. exp Aged/
5. (aged* or old* or ageing* or geriatric*).ti,ab.
6. (elder* or "over 60" or "over 65" or "over 70" or "over 80" or "over 85" or "60 year*" or "65 year*" or "70 year*" or "80 year" or "85
year*").ti,ab.
7. 4 or 5 or 6
8. 3 and 7
9. neurosurgery/
10. surgery.fs.
11. (surg* or neurosurg* or craniotomy* or resect* or EOR* or intraoperative*).mp.
12. exp radiotherapy/
13. radiotherapy.fs.
14. (radiotherap* or RT or radiat* or irradiat*).ti,ab.
15. exp chemotherapy/
16. exp antineoplastic agent/
17. (temozolomide or TMZ or Temodal or Temodar or Temodal or Temcad* or chemotherap* or procarbazine or Lomustine or CCNU or
vincristine or PCV or cisplatinum or carboplatinum).mp.
18. exp chemoradiotherapy/




23. (dexamethasone or prednisolone or methylprednisolone).mp.
24. 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23
25. 8 and 24
26. Health Economics/
27. exp Economic Evaluation/
28. exp Health Care Cost/
29. pharmacoeconomics/
30. 26 or 27 or 28 or 29
31. (econom$ or cost or costs or costly or costing or price or prices or pricing or pharmacoeconomic$).ti,ab.
32. (expenditure$ not energy).ti,ab.
33. (value adj2 money).ti,ab.
34. budget$.ti,ab.
35. 31 or 32 or 33 or 34




40. 37 or 38 or 39
41. 36 not 40
42. (metabolic adj cost).ti,ab.
43. ((energy or oxygen) adj cost).ti,ab.
44. ((energy or oxygen) adj expenditure).ti,ab.
45. 42 or 43 or 44
46. 41 not 45
47. 25 and 46
48. (exp animal/ or nonhuman/ or exp animal experiment/) not human/
49. 47 not 48
key:
mp=title, original title, abstract, name of substance word, subject heading word
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Appendix 2. ‘Risk of bias' assessment
We will assess the risk of bias according to the following criteria.
1. Random sequence generation
• Low risk of bias e.g. participants assigned to treatments on basis of a computer-generated random sequence or a table of random
numbers
• High risk of bias e.g. participants assigned to treatments on basis of date of birth, clinic identification-number or surname, or no attempt
to randomise participants
• Unclear risk of bias e.g. not reported, information not available
2. Allocation concealment
• Low risk of bias e.g. where the allocation sequence could not be foretold
• High risk of bias e.g. allocation sequence could be foretold by patients, investigators or treatment providers
• Unclear risk of bias e.g. not reported
3. Blinding of participants and personnel
• Low risk of bias if participants and personnel were adequately blinded
• High risk of bias if participants or personnel, or both, were not blinded to the intervention that the participant received
• Unclear risk of bias if this was not reported or unclear
4. Blinding of outcomes assessors
• Low risk of bias if outcome assessors were adequately blinded to the intervention that the participant received
• High risk of bias if outcome assessors were not blinded to the intervention that the participant received
• Unclear risk of bias if this was not reported or unclear
5. Incomplete outcome data
We will record the proportion of participants whose outcomes were not reported at the end of the study. We will code a satisfactory level
of loss to follow-up for each outcome as follows.
• Low risk of bias, if fewer than 20% of patients were lost to follow-up and reasons for loss to follow-up were similar in both treatment arms
• High risk of bias, if more than 20% of patients were lost to follow-up or reasons for loss to follow-up di$ered between treatment arms
• Unclear risk of bias if loss to follow-up was not reported
6. Selective reporting of outcomes
• Low risk of bias e.g. review reports all outcomes specified in the protocol
• High risk of bias e.g. it is suspected that outcomes have been selectively reported
• Unclear risk of bias e.g. it is unclear whether outcomes had been selectively reported
7. Other bias
• Low risk of bias, i.e. no other source of bias suspected and the trial appears to be methodologically sound
• High risk of bias, if we suspect that the trial was prone to an additional bias
• Unclear risk of bias, if we are uncertain whether an additional bias may have been present
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